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This research aims to investigate four novel approaches to the detection and prevention of 
catheter encrustation and blockage following infection by the Gram-negative, motile bacterium 
Proteus mirabilis (P. mirabilis). Expression of a potent bacterial urease elevates urinary pH, 
leading to the local supersaturation and precipitation of mineral deposits from the urine that 
occludes urine-flow through the catheter. Vesico-ureteric reflux following blockage by 
crystalline biofilms may result in serious symptomatic episodes such as pyelonephritis, 
endotoxic shock and septicaemia.  
Three of the four described approaches for the management of catheter-associated urinary 
tract infection employ a dual-layered polymeric delivery system, in which a lower poly(vinyl 
alcohol) reservoir layer contains either a diagnostic (5(6)-carboxyfluorescein) or therapeutic 
(lytic bacteriophage) cargo. The hydrogel layer is capped and sealed by an upper layer of the 
pH-responsive polymer poly(methyl methacrylate-co-methacrylic acid) (Eudragit S100®). 
Alkalinisation of local urine media (pH >7) induces degradation of the Eudragit layer, thus 
releasing the contained cargo. Release of 5(6)-carboxyfluorescein results in a clear and 
unambiguous colour change to give advance warning (up to 14.5 hours) of impending catheter 
blockage, whilst bacteriophage release increased time to catheter blockage by 100% (13 hours 
to 26 hours).  
The final approach describes the formulation and development of a novel small-molecule 
urease inhibitor, 2-mercaptoacetamide (2-MA), for the prevention of crystalline biofilm 
formation. Inhibition of bacterial urease without inducing bacterial cell death allows for the 
‘disarming’ of P. mirabilis without directing population evolution via initiation of a selective 
pressure. Comparison of 2-MA with the approved drug acetohydroxamic acid (AHA) allows for 
direct evaluation against the current ‘gold standard’ in treatment of chronic urea-splitting 
infection.  
All approaches were evaluated for clinical efficacy within a physiologically representative 
model of the catheterised tract. In vitro bladder models were formulated to emulate late-stage 
infection by uropathogenic clinical isolates (initial inoculum 108 CFU/mL), such that 
preventative strategies were evaluated under ‘worst-case scenario’ conditions. Performance 
within in vitro systems inoculated with P. mirabilis was directly compared to urease-negative 
Escherichia coli (E. coli), to assess uropathogenic specificity. Translation of these approaches 
into a clinical environment may allow a multifaceted approach to the detection and prevention 
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Chapter 1: The Clinical Problem: Catheter-Associated 
Urinary Tract Infection  
Since its initial inception into human medicine more than 3,500 years ago, the urinary catheter 
has become arguably the most venerable medical device used in modern medical practice, used 
on an intermittent or indwelling basis as a common management technique for urinary 
incontinence or retention.1 The most commonly employed catheter design is the Foley 
catheter, whose design constitutes a flexible silicone or latex tube inserted into the bladder via 











Figure 1.1: The catheterised bladder: A) The catheter is held in place by a reservoir balloon 
routinely inflated with sterile water/saline. Drainage is facilitated by an eyehole at the 
proximal end of the catheter. B) Cross-section of the Foley catheter double-lumen system. 
The large lumen facilitates urinary drainage; the small enables retention balloon inflation. C) 
The junction of catheter and sterile drainage system is preconnected and remains unbroken 
throughout the course of treatment. D) Valve for the inflation lumen. E) One-way sampling 
port, through which urine specimens for microbiological examination may be obtained. F) 
Accumulation of urine within the urinary drainage bag. G) Urine is emptied into the external 
environment via the outlet valve, such that the ‘closed drainage system’ remains intact and 
the sterility of the system is uncompromised. Reprinted with permission from Siddiq et al.2 © 
Springer Nature 2012 




It is estimated that approximately 100 million indwelling urinary catheters are sold worldwide 
annually.3 Indeed, the Foley catheter is the most commonly deployed medical device, with 
numbers far outstripping other common devices such as central venous catheters or fracture 
fixation devices.4 Consequently, catheter-associated urinary tract infection (CAUTI) constitutes 
80% of all nosocomial infections worldwide.5,6 In the UK, complications arising from the use of 
urinary catheters costs the National Health Service (NHS) between £1-2.5 billion, and accounts 
for ~2,100 deaths annually.1 Approximately 15-25% of patients admitted to NHS hospitals each 
year will require urethral catheterisation, with the risk of developing bacteriuria increasing by 
roughly 5% each day.7 Subsequent development of CAUTI is likely to prolong a patient’s stay 
in hospital by 6 days and can be fatal, owing to the development of serious clinical sequelae 
such as pyelonephritis, endotoxic shock and septicaemia (13-30% mortality rate for CAUTI 
bacteraemia).8,9 
 Long-Term Indwelling Catheters 
Catheter-associated bacteriuria (CAB) is defined as the presence of ≥105 colony-forming units 
per millilitre (CFU/ml) of one or more bacterial species in a single catheter urine sample, and 
is universal in patients undergoing long-term indwelling catheterisation.2 Indeed, more than 
50% of catheters become colonised within 10-14 days of insertion. Fortunately, most cases of 
CAB are asymptomatic, and thus antibiotic prophylaxis is not recommended (owing to 
concerns about superinfection by multiresistant strains).10 A recent survey of antimicrobial 
resistance by the European Centre for Disease Prevention and Control reported that the most 
commonly isolated uropathogens from CAB are resistant to at least one of the antimicrobial 
agents commonly used in clinical practice. Notably, 58.6% of Escherichia coli (E. coli) isolates 
were found to be at least one antimicrobial groups under regular surveillance 
(aminopenicillins, fluoroquinolones, third-generation cephalosporins, aminoglycosides and 
carbapenems).11 
In contrast, the term CAUTI is used to refer to patients suffering from symptomatic infection. 
That is, significant bacteriuria as well as symptoms of clinical infection in the absence of any 
other identifiable sources. Although fewer than 3% of patients with asymptomatic infection 
develop complicate bacteraemia, given the ubiquitous and nature of these infections, CAUTI is 
one of the most frequent causes of secondary bloodstream infection found within the long-
term care setting.12 
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 History and Development of the Foley Catheter 
Derived from the ancient Greek kathiénai, the word catheter can be literally translated as “to 
thrust into”, or “to send down”, and describes an instrument used to drain fluid from a body 
cavity. The chronology of the recorded development of the urinary catheter is decorated with 
a variety of different materials, including metals such as copper, tin and bronze in the 3rd 
century BCE, lead and papyrus utilised by the Egyptians, and organic materials such as 
lacquered palm leaves or hollow onion stems by the Chinese is 100 BCE.1 However, the first 
example of a flexible catheter made from malleable gum-elastic did not emerge until the late 
18th century, after its creation by Bernard (a French jeweller and goldsmith) following the 
development of natural rubber in 1735. Difficulties in achieving a compromise between rigidity 
and flexibility were not overcome until the vulcanisation of rubber was discovered by Charles 
Goodyear in 1839.13 The modern-day Foley catheter was first introduced in the mid-1930s by 
Dr Frederick B. Foley14 and, despite becoming the cornerstone for the management of the 
dysfunctional bladder within modern medicine, has revealed a plethora of medical 
complications, owing to its inherent design flaws and vulnerability to rapid-onset bacteriuria. 
Teflon-coated and silicone catheters were introduced in the 1960s and 1970s, respectively, 
with the goal of reducing patient discomfort and catheter encrustation. Attention was finally 
focused on reduction of bacterial biomass and subsequent infection in the 1980s and 1990s 
with the development of various antimicrobial catheter iterations, including chlorhexidine, 
silver oxide, colloidal silver and hydrogel, and nitrofurazone-impregnated catheters.15 
 Pathogenesis of CAUTI  
Despite innate mechanical safeguards against microbial invasion of the urinary tract, long-term 
indwelling catheters are universally complicated by polymicrobial or dynamic bacteriuria.6 
Within the healthy, uncatheterised urinary tract, regular flushing of the urethra as a result of 
bladder emptying impedes ascending infection via mechanical means. Further intrinsic 
defences such as the lining of the bladder with glycosaminoglycan-coated urothelial cells also 
help to mitigate infection via the activation of microbial sensing proteins, thus triggering host 
defences with a cascade of cellular and molecular effectors.1 Catheterisation of the urinary tract 
allows uropathogenic species opportunities to exploit the absence of such safeguards, resulting 
in successful colonisation and subsequent infection. Since catheterisation introduces a 
continuous drainage system, the resultant steady trickle of urine through the catheter is unable 
to impede the migration of bacterial cells. Furthermore, the retention balloon ensures that a 
reservoir of stagnant urine is maintained below the level of the eyeholes at the catheter tip. 
Consequently, a continuous culture system is initiated, whereby the urine is unceasingly 
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replenished form the kidneys, resulting in the rapid accumulation of staggeringly large 
bacterial populations, generally in the region of 108 cells per millilitre of urine.16 
The majority of endemic CAUTI-causing microorganisms originate from the patient’s own 
colonic and perineal flora. Bacterial entry into the catheterised bladder may occur via several 
routes. Organisms that colonise the periurethral skin may migrate into the bladder via the 
mucoid film that forms between the epithelial surface of the urethra and the catheter. 
Additionally, contamination of the junction between the catheter and drainage bag, or indeed 
of the urine within the drainage bag itself may allow transitory microflora access to the bladder 
via the intraluminal catheter surfaces during insertion or manipulation of the closed-collection 
system.12 
 Biofilms  
Bacterial growth is generally characterised by two major phenotypes: single (planktonic) cells, 
and sessile aggregates, known as biofilms. The biofilm mode of growth enables single cells to 
assume a temporary multicellular lifestyle, within which cells may partake in “group 
behaviour”, thus facilitating survival in adverse environments. The formation of a community 
of microorganisms attached to a surface has come to be recognised as a complex and 
multifaceted developmental process that is inherently dynamic and biologically 
responsive.17,18 Biofilm formation on the surface of urinary catheters is particularly favoured 
as, upon insertion of the catheter, a host of urinary components (including proteins, 
electrolytes and other organic molecules) deposit on the surface, resulting in the formation of 
a conditioning film to which bacterial cells may adhere at an exacerbated rate. 
A biofilm is a consortium of cells irreversibly attached to a surface via a self-excreted 
extracellular matrix, which accounts for approximately 90% of biofilm biomass.19 The matrix 
is composed of extracellular polymeric substances (EPS), which, along with carbohydrate-
binding proteins, pili, flagella, adhesive fibers and extracellular DNA, act as a stabilising scaffold 
for the three-dimensional biofilm structure.20 Within the matrix, nutrients are trapped for 
metabolic use by the resident bacterial cells, and water is retained via hydrogen-bonding 
interactions with the hydrophilic polysaccharides.19 Secreted enzymes may modify the 
composition of the EPS in response to changes in nutrient acquisition, thereby effectively 
tailoring the biofilm composition to the specific environmental niche. 
 Biofilms may form on biotic or abiotic surfaces and are prevalent in natural, industrial and 
hospital settings. Once a cell differentiates to the biofilm mode of growth, it undergoes a 
phenotypic shift in behaviour, in which large suites of genes are differentially regulated.17 
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1.4.1. Stages of Biofilm Development  
Biofilm formation occurs via a series of five sequential steps, involving numerous conserved 
and/or species-specific factors (Figure 1.2). 
The first step involves the introduction of bacteria to a surface, a process which is largely 
stochastic, driven by Brownian motion and gravitational forces, and influenced by surrounding 
hydrodynamic forces. Velocity and direction toward or away from the contact surface are 
influenced greatly by nutrient properties, pH, ionic strength, temperature and bacterial cell-
surface composition.22 Upon intercepting the surface, adherence is mediated by extracellular 
adhesive appendages and secreted adhesins. However, this initial attachment is dynamic and 
reversible. Colonising bacteria may be perturbed by hydrodynamic or shear forces, as well as 
limitations on nutrient availability, thus leaving and re-joining the planktonic population 
according to external factors.23 
Irreversible attachment is achieved by bacteria able to weather the shear forces and maintain 
contact with the surface. Multiplication of adherent cells form microbial aggregates of the same 
or different species. Subsequent secretion of the EPS forms a barrier between the bacterial 
community and the extracellular environment, the composition of which is largely species and 
condition-dependent.24  
Maturation of the established community involves changes in gene expression and up-
regulation of factors favouring sessility, such as those implicated in the formation of the EPS.  
Figure 1.2: The five stages of biofilm development. A) Reversible attachment to a solid 
support. B) Irreversible attachment and aggregation. C) Biofilm maturation. Bacterial cells 
become layered and quorum sensing is initiated. D) Clusters reach maximum density. E) 
Matrix dispersion to facilitate colonisation of new environmental niches. Reprinted with 
permission from Davies et al.21 © Springer Nature 2003 
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Proximity of cells within the biofilm community provides ideal conditions for the formation of 
nutrient gradients, gene transfer (Section 1.4.3) and quorum sensing (Section 1.4.2). 
Continuous replication and accumulation of EPS enables the formation of a three-dimensional 
structure which is able to resist mechanical stress and detachment of the community from the 
surface of the substrate.  
Within the mature biofilm resides a bustling community of cells, actively exchanging products 
that play a pivotal role in maintaining a stable biofilm architecture and living environment for 
the resident cells. Once a critical concentration of cells is reached, biofilm dispersal may occur, 
as cells move back into the planktonic state in order to adsorb to previously uncontaminated 
surfaces, thus forming new biofilm micro-colonies in new environmental niches. Biofilm 
dispersal can be the result of several cues, such as alternations in nutrient availability, oxygen 
fluctuations and the accumulation of toxic products. This step is essential for the propagation 
and self-renewal of the community, avoiding overcrowded biofilms and thus the gradual 
decline of the community’s health by size-limiting factors.17,25 
1.4.2. Quorum Sensing 
Quorum sensing in bacteria is a regulatory mechanism, which controls gene expression in a 
manner dependent on cell density. Bacteria within the biofilm engage in a coordinated 
‘decision-making’ process via a chemical vocabulary. A single bacterium may perceive the 
bacterial cell density in the surrounding area, making it more likely to join and contribute 
towards biofilm formation. Bacterial colonies utilise quorum sensing to modulate a variety of 
chemical and cellular functions, including virulence, nutrient acquisition, conjugation, motility 
and secondary metabolite/toxin production.26 
Both Gram-positive and Gram-negative bacteria utilise quorum sensing via the production, 
release and group detection of extracellular signalling molecules called autoinducers. 
Accumulation of autoinducers as cell density increases allows individual cells to monitor 
changes in population numbers and collectively alter global patterns of gene expression.27 
Gram-positive systems typically use secreted oligopeptides and two-component systems, 
consisting of membrane-bound sensor kinase receptors and cytoplasmic transcription factors 
that direct alterations in gene expression. The process and biological role of quorum sensing 
in Gram-positive bacteria have been extensively reviewed elsewhere.28,29  
N-Acyl homoserine lactones (AHLs) are the most commonly used molecules used by Gram-
negative bacteria as quorum sensing autoinducers. These molecules are comprised of an 
invariant homoserine lactone ring, attached to an acyl chain that may vary in length between 
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4-18 carbon atoms. Variation in length of the acyl chain may affect stability, thus having 
potential consequences for signalling dynamics.27 Autoinducers are produced within the 
bacterial cell and freely diffuse across the inner and outer membranes. At levels of high cell 
density, when autoinducer concentration is sufficiently high, they bind to cytoplasmic 
receptors that operate as transcription factors. In many cases, autoinducers participate in 
forward feedback loops, whereby a low initial concentration of an autoinducer amplifies the 
production of a chemical signal involved in gene expression.   
Quorum sensing has proved a promising therapeutic target in recent years, since the 
mechanistic understanding of quorum sensing systems and appreciation for their importance 
in bacterial pathogenesis has improved. As additional systems and signal molecules have been 
identified, so have examples of quorum sensing inhibition, by both signal-targeting 
enzymes30,31 and small molecule inhibitors32,33 of signal synthases and receptors. The 
possibility of targeting quorum sensing as a means to alleviate or prevent infection has been 
met with strong optimism in the wake of the antibiotic resistance crisis that currently impedes 
the treatment of many pathogenic infections.29 
1.4.3. Gene Transfer and Antibiotic Resistance 
Perhaps the most salient difference between biofilm-bound and free-living cells is their greater 
tolerance to antimicrobial agents and host defences. Owing to the dense and compact nature 
of a biofilm structure, the reduced rates of cellular growth and the diffusion limitations 
conferred by the EPS, bacteria within a biofilm are considerably protected from natural and 
chemical agents, rendering biofilm cells 10-1,000-fold less susceptible to antimicrobial therapy 
than their planktonic counterparts.21 For instance, the antibiotic tobramycin requires a 1000-
fold increase in concentration to kill biofilm cells of Pseudomonas aeruginosa (P. aeruginosa) 
growing on a urinary catheter, compared with planktonic cells of the same species.34 
It is generally accepted that the basis for biofilm-specific antibiotic resistance is multifactorial, 
and depends on the agent, the bacterial strain and species, the developmental stage of the 
biofilm and the biofilm growth conditions.35 Indeed, the biofilm EPS may act as an adsorbent 
or reactant, thereby reducing the concentration of agent able to interact with resident cells, 
which may themselves be physiologically different from planktonic cells (expressing 
protective factors such as multidrug efflux pumps and stress-response regulons).36 
Even successful penetration of the biofilm by antimicrobial agents may be insufficient to 
completely eliminate the colony, owing to the presence of so called ‘persister cells’. These cells 
constitute approximately 1% of the biofilm population, and exist in a state of metabolic 
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dormancy. Persister cells survive antibiotic treatment without undergoing a phenotypic 
change, hence they are not referred to as resistant, but rather tolerant to antibiotic treatment. 
Metabolic quiescence appears to be responsible for the recalcitrance of chronic infection even 
after repeated antibiotic treatments, as these cells remain viable, thus repopulating biofilms 
when the concentration of antibiotic diminishes.37 
Biofilms provide an ideal niche for the exchange of extrachromosomal DNA in the form of 
plasmids. Conjugation (the mechanism of plasmid transfer) has been found to occur at a 
greater rate between sessile cells.38 Horizontal gene transfer has been proven to be of 
particular importance within multispecies biofilms, as resistance genes may be transferred 
between apathogenic and highly virulent strains both within and beyond species borders. The 
rate of genetic exchange occurring within the biofilm has the potential to allow significant 
spread of antibiotic resistance genes, allowing bacterial to rapidly adapt to changing 
environments.39 
 The CAUTI Microbiota 
The microbiome of the colonized catheter is highly time dependent. Bacteriuria as a result of 
short-term intermittent catheterisation is generally resultant from a single species of 
uropathogen (the most common responsible organisms are E. coli, Enterococcus faecalis and 
Staphylococcus aureus/ epidermidis.40 For long-term indwelling catheterisation, multispecies 
biofilms occur more frequently, consisting of organisms such as P. aeruginosa, Providencia 
stuartii and Proteus mirabilis (P. mirabilis) (Table 1.1). 
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Table 1.1: The incidence of uropathogens isolated from 106 catheter biofilms, from patients 
undergoing long-term indwelling catheterisation. Reproduced with permission from Macleod 
et al.40 © Microbiology Society 2007 
Species 











36 41 23 
Enterococcus faecalis 34 45 7 
Escherichia coli 31 41 7 
Proteus mirabilis* 30 34 20 
Klebsiella pneumoniae* 18 24 3 
Morganella morganaii* 13 15 10 
Providencia stuartii  10 12 7 
Staphylococcus aureus* 10 13 3 
Enterobacter cloacae 9 9 7 
Klebsiella oxytoca* 9 11 3 
Providencia rettgeri* 5 5 3 
Coagulase-negative 
staphylococci* 
5 5 3 
Citrobacter spp 4 5 3 
Proteus vulgaris* 3 3 3 
* Indicates species capable of producing urease 
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 The Role of Proteus mirabilis  
P. mirabilis is an organism of unique importance for patients undergoing long-term indwelling 
catheterisation. Since the CAUTI microbiome is highly time dependent, this species is seldom 
isolated following initial colonisation of the catheterised urinary tract. The longer the catheter 
is in place, the more likely it is to become colonised by P. mirabilis, hence this organism is 
isolated from approximately 40% of urine samples collected from patients with long-term 
indwelling catheters.12  
P. mirabilis is a Gram-negative, dimorphic, motile member of the family Enterobacteriaceae, 
and readily colonises the lumen and external surfaces of all catheter types. It was observed by 
Roberts et al.41 that P. mirabilis has the greatest ability to attach to catheters out of all Gram-
negative organisms. This is achieved by the expression of 17 putative fimbrial operons, the 
most encoded by any sequenced bacterial species.42 
1.6.1. The Swarming Motility 
Merging mythology and morphology, P. mirabilis is named after the early sea god from Greek 
mythology, noted for being versatile and capable of assuming many forms.43 Proteus appears 
in Homer’s Odyssey, and is able to shift shape to avoid capture. Likewise, P. mirabilis is able to 
differentiate from short rods into elongated, multinucleate cells that express thousands of 
flagella. Ergo, Proteus species are distinguishable from almost any other genera by their ability 
to swarm across a solid surface.44 
Microscopic examination of samples of infected urine reveals peritrichous planktonic P. 
mirabilis approximately 2 μm in length. The flagella of the vegetative bacteria are engaged in 
what is known as the swimming motility, where they may be likened to a rotating motor, 
coupled to allow the flow of protons across the membrane to provide rotational energy. In 
liquid planktonic culture, the swimming motility is the primary locomotive method employed 
by P. mirabilis, the direction of which is determined by the direction of flagella rotation, and is 
controlled by external sensory input linked to environmental influences.45 
The presence of a solid or highly viscous surface provides the conditions required for the 
swarming motility to dominate. After adherence to the surface, cells undergo a rapid 
differentiation into multinucleate, 20-50-fold elongated swarmer cells with thousands of 
expressed flagella. Swarmer cells may then arrange themselves into parallel groups, entwined 
by the helical binding of their flagella around adjacent cells, forming raft-like structures that 
are capable of moving off rapidly in unison (Figure 1.3). By this mechanism, large populations 
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of P. mirabilis are able to effectively and efficiently colonise surfaces such as the luminal 
surfaces of the urinary catheter.43 
 
P. mirabilis provides the most well-documented irregular swarming pattern of all motile 
bacteria. The characteristic bullseye pattern formed on the solid substrate occurs as a result of 
cyclic and synchronous waves of motility, followed by regular periods of swarming cessation. 
Each cycle of swarming produces one annulus of the pattern, and consists of a macroscopic 
‘zone of consolidation’, or ‘terrace’. The development of the concentric rings may be separated 
into three distinct phases: lag phase (the growth of the initial inoculum), swarming phase 
(independent movement of the swarming raft structures), and consolidation phase (uniform 
thickening of the newly formed terrace).46 
Another fascinating aspect of the P. mirabilis swarming motility (and an example of the 
complexity of the interbacterial communications required to achieve it) is the Dienes 
phenomenon. Two swarming colonies of a single strain of P. mirabilis may merge with each 
other, whereas swarms of different strains form a distinct boundary where they meet, known 
as the Dienes line.47 Formation of the Dienes line requires direct cell-cell contact and is thought 
to involve the killing of one strain at the boundary, for example by the production of the 
bacteriocin proticine.48 
P. mirabilis’ employment of the swarming motility facilitates colonisation of the urinary 
catheter by coordinating the rapid movement of bacteria from the site of contamination to the 
bladder via the luminal surface. Additionally, swarming cells of P. mirabilis have been  shown 
to be capable of transporting other, non-motile organisms over the surface of the catheter, thus 
confirming the role that swarming plays in the initiation and pathogenesis of CAUTI.49 
Figure 1.3: Locomotive mechanisms of P. mirabilis. A) The swimming motility, powered by 
rotating flagella in planktonic culture. B) The swarming motility, engaged on contact with a 
solid substrate, and powered by the multicellular movement of elongated cells with 
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1.6.2. Toxin Production 
P. mirabilis is capable of producing an arsenal of bacterial toxins. Haemolysin was originally 
proposed as a virulence factor, as cytotoxicity towards human renal epithelial cells is largely 
due to haemolysin, and strains with high haemolysin production are significantly more lethal 
than those with low production.50,51 Haemolysin is also thought to facilitate bacterial spread 
within the kidney and pyelonephritis development during ascending CAUTI.52 However, 
mutation of hpmA, the gene encoding this toxin, did not appear to affect kidney colonisation or 
tissue damage during colonisation. Hence, either haemolysin is not as active during infection 
as the in vitro data suggests, or the activity of other virulence factors masks its contribution.43,53 
Proteus toxic agglutinin (Pta), encoded by the mosaic pathogenicity island ICEPm1, is a 
bifunctional outer-membrane autotransporter that mediates cell-cell aggregation. It achieves 
bladder and kidney damage via damage to the structural integrity of the native cells.54 In the 
proposed mechanism of action, Pta punctures the host cell membrane, inducing cytosol 
leakage, osmotic stress and depolymerisation of actin filaments.9  Notably, simultaneous 
inactivation of Pta and hpmA facilitates a greater reduction in cytotoxicity than each mutation 
individually, indicating that the toxins act additively.53 Indeed, Pta production by the hpmA 
mutant may explain why no difference in pathogenicity was observed between the haemolysin 
mutant and the parent strain. 
1.6.3. Persistence and Immune Evasion 
Infections by P. mirabilis in the catheterised urinary tract are notoriously difficult to treat, 
owing to the remarkable ability of this bacteria to persist despite antibiotic treatment and 
catheter change. Successful persistence within the host relies on the evasion of innate and 
adaptive immune responses. Once such mechanism of immune evasion employed by P. 
mirabilis is the variation in expression or composition of antigenic structures, such as outer-
membrane proteins or fimbriae. The best-studied fimbrial type of P. mirabilis, MRP fimbriae, 
are known to be phase variable.55 It is not yet known whether the other 16 types of fimbriae 
undergo phase variation, although any range of expression within such an extensive fimbriae 
library would contribute significantly to fitness.43 
Furthermore, P. mirabilis encodes a metalloproteinase, ZapA, able to cleave serum and 
secretory immunoglobulins, thereby providing protection from the mucosal immune 
response.56 ZapA may also be capable of cleaving cell matrix components such as collagen, 
fibronectin and laminin, as well as cytoskeletal proteins such as actin and tubulin.57 The 
importance of ZapA in the bacteria’s evasive procedures is emphasised by the finding that the 
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mutation of ZapA results in a significant decrease in bacterial cell recovery from the urine, 
bladder and kidneys.58 
1.6.4. Horizontal Gene Transfer 
The 94 kilobase mobile pathogenicity island, ICEPm1, of P. mirabilis has been found to be 
present in several isolates of Providencia stuartii and Morganella morganii, suggestive of DNA 
transfer between bladder pathogens.59 ICEPm1 is more prevalent in P. mirabilis clinical isolates 
taken from the urine of catheterised individuals than from other body sites, indicating that this 
mobile genetic element contributes to colonisation and pathogenicity within the catheterised 
urinary tract. As CAUTI is often initiated by the patient’s own resident gut flora, the acquisition 
of ICEPm1 may give some insight as to why these organisms (which are normally commensal) 
become pathogenic when they reach this site.43 Additionally, it has been shown that ICEPm1 
can excise from the P. mirabilis chromosome and integrate into ICEPm1-deficient strains, 
provided that the integrase, chromosome-partitioning protein A, and the type IV secretion 
system remain intact.60 These studies support the concept of horizontal gene transfer within 
the clinical setting, a phenomenon which may also allow for the transfer of antimicrobial 
resistance. 
1.6.5. Cell-Cell Communication 
Interbacterial communication and quorum sensing between cells of P. mirabilis is both elusive 
and complex. P. mirabilis lacks a clear AHL synthase homologue (LuxI), capable of producing 
N-acyl homoserine lactone signalling molecules typically used by Gram-negative species to 
sense population density and coordinate gene expression. However, P. mirabilis instead 
encodes a LuxR family transcriptional regulator, and seems to produce compounds with AHL-
like activity.44,61 However, AHLs secreted by other species present on the catheter may be able 
to modulate P. mirabilis swarming or virulence, since it has been found that the exogenous 
addition of AHL to a population of P. mirabilis has a strain-specific impact on virulence factor 
expression, swarming and biofilm formation.62,63 
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1.6.6. Urease and Catheter Encrustation 
Arguably the most important aspect of P. mirabilis pathogenesis from a clinical perspective is 
the expression of bacterial urease and the subsequent catheter encrustation. Once colonised 
onto the catheter and uroepithelial surfaces, P. mirabilis must adapt and obtain nutrients from 
the urinary tract environment in which it thrives. The expression of a potent cytoplasmic nickel 
metalloenzyme, urease, allows P. mirabilis to exploit urea as a nitrogen source (Scheme 1.1). 
Nitrogen, in the form of ammonia, may then be assimilated into biomolecules via glutamine 
synthesis or glutamate dehydrogenase.64 
A full discussion into the structure and mechanistic action of bacterial urease can be found in 
Chapter 5. Briefly, urea hydrolysis results in the production of carbonic acid and two molecules 
of ammonia. The physical manifestation of this enzymatic process within the catheterised 
bladder is the substantial and rapid rise in urinary pH, owing to the net production of ammonia 
which gradually accumulates within the urine reservoir. The alkalinised local environment 
may cause the urinary pH to rise to pH 7.5-9, compared to healthy, acidic urine pH of 5.5-6.5.65 
Consequently, local supersaturation and precipitation of polyvalent ions (primarily struvite, 
MgNH4PO4.6H2O and carbon apatite, Ca10(PO4CO3OH)6(OH)2) into the catheter lumen may 
cause abrasive crystalline deposits to become incorporated into the catheter biofilms. Total 
occlusion of the catheter lumen may follow, in addition to severe bladder and urethral trauma 
upon removal.44 
1.6.7. Structure and Formation of Crystalline Biofilms  
For patients with long-term indwelling catheters, catheter changes are generally scheduled at 
approximately 10-12 week intervals, allowing contaminated urine to flow through an 
individual catheter for long periods of time. Consequently, thriving bacterial biofilm 
communities are formed, with the gentle flow of warm nutritious urine facilitating a 
continuous culture system, which prevents the community from becoming nutrient-limited.66 
All types of Foley catheter, including silver-coated and nitrofurazone-impregnated catheters, 
are susceptible to colonisation by crystalline biofilms. Motile bacteria such as P. mirabilis have 
Scheme 1.1: Urease-catalysed hydrolysis of urea  
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a competitive advantage when forming a biofilm, utilising flagella to overcome hydrodynamic 
and repulsive forces.17 
In addition to biological factors, physical effects can prove powerful in the initiation of biofilm 
development. A study utilising episcopic differential interference contrast (EDIC) microscopy 
to compare the surface morphologies of different catheter types revealed that all catheter types 
display a rough, irregular surface, able to provide a nucleation site for the adhesion of bacterial 
cells in the early stages of biofilm formation.67 The manufacturing techniques used to produce 
the eyeholes tear through the material, resulting in surfaces covered in microscale craters and 
crevices. All-silicone catheters have smoother surfaces than latex catheters, although 
irregularities are still commonplace around the eyeholes and in areas where extrusion 
manufacturing techniques produce striations on the luminal surfaces (Figure 1.4).66,67 
1.6.8. Recurrent Crystalline Biofilms  
Recurrent catheter blockage is a major issue within the healthcare setting, causing distress to 
both patients and caregivers, as well as proving costly to the health service. The usual 
management technique recommended for recurring blockage is simply the replacement of the 
blocked catheter with a new one.68 Fresh catheters are thus placed directly into urine cultures 
of P. mirabilis at alkaline pHs, often containing microcrystals of calcium and magnesium 
phosphates. Examination of crystalline biofilm formation under these conditions in a 
laboratory model, revealed that catheter surfaces were covered in a microcrystalline layer 
Figure 1.4: EDIC microscopy images of unused catheter surfaces, showing surface 
topography. A) All silicone catheter, showing luminal striations. B) Hydrogel latex catheter. 
(Magnification x1000, scale bar = 10 μm). © 2015 Wilks et al.67 
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after just 1 hour. After 18 hours, the eyelets and luminal surfaces of all catheters were 
comprehensively covered by densely populated crystalline biofilms of P. mirabilis.69 
Approximately 50% of patients who undergo long-term indwelling catheterisation will 
experience encrustation and blockage owing to P. mirabilis biofilms.16 The consequences of 
blockage may vary greatly in terms of medical severity. Leakage around the outside of the 
catheter may cause patient incontinence, thus increasing need for nursing care. Complete 
blockage of the catheter lumen may cause retention of urine in the bladder and subsequent 
vesicoureteric reflux of urine to the kidneys. If the blockage is left untreated or unnoticed at 
this stage, patients are likely to suffer serious symptomatic episodes of pyelonephritis, 
bacteraemia and peri-urethral purulent infection, ultimately leading to chronic renal failure 
and death.70 
 Treatment and Prevention of CAUTI 
Even with meticulous care, patients undergoing long-term catheterisation will experience 
bacteriuria owing to cross-contamination.44 Since the majority of cases are asymptomatic in 
their early stages, treatment is not recommended, as a balance must be struck between the 
reduction in CAUTI morbidity and the forestalling of the emergence of antibiotic resistance. In 
long-term catheterisation, antibiotic therapy has little benefit, owing to the re-emergence of 
infection upon the changing of the catheter.71 Indeed, bacteriuria is such a common occurrence, 
that treatment with prophylactic antibiotics inevitably leads to the emergence and selection of 
antibiotic-resistant strains of P. mirabilis, as well as the development of other multiresistant 
nosocomial strains. Consequently, patients are only treated in this manner if 
immunosuppressed (e.g. post-organ transplantation), at significant risk of bacterial 
endocarditis, about to undergo urinary tract instrumentation, or pregnant.72 
Many efforts have been made to design catheters that are resistant to bacterial colonisation, 
with the overall aim or preventing CAUTI incidence and subsequent catheter blockage. Despite 
the large number of reported approaches appearing within the literature in recent years, few 
platforms have progressed to clinical studies, and even fewer to clinical practice. This lack of 
translational success can be attributed, in part, to the inherent complexity of the clinical 
problem, as well as the necessary interdisciplinary nature of the research required to   
overcome it. 
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1.7.1. Engineering Approaches 
Despite its innate design flaws, the Foley catheter remains the fundamental linchpin in the 
management of the dysfunctional bladder. Variations on Foley’s original design,73,74 as well as 
additive devices75 to be used with the current clinical setup have been explored. Recently, a 
novel catheter design has been described by Levering et al.76 which aims to provide on-demand 
biofilm removal in situ. Active surface deformation via the utilisation of multi-inflation lumens 
facilitates the debridement of approximately 80% of a mixed community biofilm of P. mirabilis 
and E. coli. (Figure 1.5). Inflation of the four intra-wall inflation lumens simultaneously is able 
to supply sufficient strain around the intra-luminal perimeter to debond biofilms from the 
otherwise largely inaccessible main drainage lumen. 
Other attempts to redesign aspects of the urinary catheter include the trefoil design described 
by Sun et al.,77whose profile proved successful in delaying the appearance of culturable 
organisms when tested in an in vivo rabbit model.  
A 2018 commissioning brief by the National Institute for Health Research78 outlines several 
modified catheter designs, including the Duette dual balloon urinary catheter (Poiesis Medical, 
Florida),79 the CymActive™ bladder management system (Ingenion Medical Limited, 
London),80 and the OPTION-vf and OPTION-vm gender specific valved catheters (Practica 
Medical Manufacturing Inc., Florida),81 which allow urine storage within the bladder rather 
than in the collection bag. The valve design permits urine drainage in a manner similar to 
normal uncatheterised voiding, therefore avoiding the accumulation of stagnant urine beneath 
the eyehole level of a standard Foley catheter. 
Such variation in catheter design may prove promising in the prevention of CAUTI. As well as 
the inherent advantages offered by the novel design of the catheter itself, catheters such as the 
trefoil and multi-inflation lumen design may also be coated with passive or stimuli-responsive 
coatings, thus providing a multifaceted approach to the prevention of encrustation and 
blockage. 




Figure 1.5: (Top) Cross-section of a silicone urinary catheter shaft with four inflation 
lumens. Strain contour plot shows model subjected to an inflation pressure of 80 kPa. 
(Bottom) Multi-inflation lumens capable of debridement of multispecies P. mirabilis and E. 
coli biofilms. Cross sectional images of A) control catheter (no inflation). B) First inflation 
after 30 hours of biofilm growth. C) Second inflation after 24 hours biofilm regrowth. D) 
Sections from which the cross-sections were obtained. i) bottom, ii) middle, iii) top, and iv) 
distal tip. Scale bars indicate 1 mm. Reprinted from Levering et al.76 © 2016, with 
permission from Elsevier. 
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1.7.2. Medical Approaches  
Over the past decade, imbibing or coating medical implants with antimicrobial solutions has 
been commonly used to control infection. A range of passive release-based systems have been 
investigated for the prevention or delay of catheter blockage, the most common of which is 
simple impregnation, where the agent is held within a reservoir and released via passive 
diffusion. In contrast to oral or systemic delivery of administration, release coatings provide 
the ability to deliver agents at a high local concentration, whilst limiting systemic exposure and 
potential toxicity. Though passive release coatings endeavour to achieve effective prophylaxis 
and/or treatment of established bacteriuria, the reservoirs of antimicrobial cargos are limited, 
thus their action is ultimately temporary. Passive release kinetic profiles generally follow first- 
or second-order kinetics (where an initial burst release is followed by a decreasing tail 
distribution).82 The timeframe of release and subsequent decline in active concentration is 
highly application- and location-dependent, although generally lies within the region of hours 
or days. This provides a significant challenge in coating design, forcing a compromise between 
device function and reservoir capacity. As such, the design of coatings able to maintain 
antimicrobial concentrations throughout the therapeutic window sufficient to cause bacterial 
cell death, but without causing eukaryotic cytotoxicity, remains a significant challenge.83 
 Antibiotics 
A number of antibiotics have been approved for used in medical impregnated catheters, for the 
prophylaxis of CAUTI. These include the nitrofurans nitrofurazone and nitrofurantoin, which 
are known to have a broad spectrum of activity against both Gram-negative and –positive 
pathogens, and are less prone to inducing antimicrobial resistance.84 Nevertheless, these 
commercially-available antimicrobial catheters still lack strong evidence to support their 
routine use in CAUTI management.85 
Though nitrofuran-coated catheters are well studied, a recent Cochrane review reported that 
whilst nitrofurazone-coated catheters did achieve a reduction in symptomatic CAUTI, the 
impact was of borderline statistical significance. Furthermore, patients treated with catheters 
of this type complained of greater pain compared with a standard unmedicated catheter, both 
while the catheter was in situ, and upon removal.85 Owing to its poor clinical performance in 
large-scale trials, these catheters have been discontinued in the USA. 
Whilst antibiotic-impregnated catheters may seem the obvious choice for CAUTI prevention, 
the inherent issue of antibiotic resistance can render these systems useless after the second or 
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third application. Antibiotic resistance within the catheterised urinary tract is particularly 
problematic, since biofilms required a high doses of antibiotics. A better understanding of 
resistance towards these agents is therefore required in order to develop coatings with a 
potent dose of antibiotics without promoting the development of resistant bacterial strains. An 
in-depth discussion of antibiotic resistance within the catheterised urinary tract, as well as 
potential alternatives, can be found in Chapter 4.   
 Silver 
Silver has been used for centuries in the treatment of various maladies, or to prevent the 
transmission of infection. Since silver is one of the few antimicrobial agents for urinary catheter 
coatings that is approved by the Food and Drug Administration (FDA), commercially-available 
silver-coated catheters have been extensively studied clinically. For medical device coatings, 
silver ion release coatings can be designed in the form of silver alloy (often with gold or 
palladium), silver-containing polymers and silver nanoparticles. Silver is susceptible to 
oxidation in aqueous environments, releasing ions which are highly biocidal in nature. 
However, this influx of ions must be controlled and sustained, not least because fast and 
excessive release of ions may prove cytotoxic.5 
In a major study conducted over a 40-month period (2007-10) on 7102 patients in the UK, 
silver alloy-coated latex catheters (Bardex IC, Bard Medical, Crawley, UK), were found to be 
less effective in reducing infection or cost of urethral catheterisation in comparison to 
antibiotic coatings. However, catheters of this type were not met with the same level of patient 
discomfort when compared to their antibiotic-impregnated counterparts.86 
Further to its limited success in clinical trials, silver alloy has been combined with other 
materials to improve its antimicrobial efficacy. An epidemiological screening  conducted by 
Rupp et al.87 found that silver alloy hydrogel-coated catheters reduced the occurrence of CAUTI 
from 6.13/1000 catheters, to 2.62/1000 catheters in 2001-2002 (p = 0.002). In 2014, another 
study was conducted with silver alloy hydrogel catheters, with patients from 7 acute care 
hospitals.88 According to the criteria of the National Healthcare Safety Network, a 58% relative 
reduction occurred in the incidence of CAUTI when silver alloy hydrogel catheters were 
employed, compared to standard catheters.  
The exhaustive list of studies performed on silver coatings proves that research into finding 
the ideal antimicrobial coating for urinary catheters is both complex, and may require a 
combination of both novel and existing compounds. Despite the abundance of reports 
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suggesting silver to be a safe and effective antimicrobial agent, its efficacy in urinary catheters 
has proven limited. Thus, research on the use of silver for this application will likely continue 
through the advent of new combinations that endeavour to substantially increase its 
antimicrobial efficacy and decrease cytotoxicity. 
1.7.3. Chemical Approaches  
Many efforts have been made to design catheters that are resistant to bacterial colonisation. 
Approaches designed to prevent adhesion of bacteria generally aim to impede biofilm 
formation in its infancy by utilising unfavourable surface topography or surface chemistry. 
Since the host-derived conditioning film of urinary components begins at the point of catheter 
insertion, any existing surface properties of the material are often concealed, and pathogen 
attachment promoted. Thus, development of chemical modification approaches for prevention 
of CAUTI must not only target uropathogen attachment, but also urinary constituents.83 
 Anti-Adhesion/Antifouling Surfaces 
Whilst the conceptual simplicity and potential biocompatibility of anti-adhesion coatings 
makes them an appealing approach, their antibacterial action requires extremely close 
proximity with bacterial cells. Catheter surfaces within such a complex biological matrix may 
become rapidly contaminated with non-specifically attached materials, thus compromising the 
defect-free surface. Nevertheless, the field of anti-fouling polymers is fast growing and showing 
significant promise. Poly(ethylene glycol) (PEG) is the most widely used polymer for 
antifouling in recent years,89 although its efficacy largely depends on the surface grafting 
technique and the polymeric architecture.90 Polymers such as PEG form a tightly-bound and 
structured hydration shell via hydrogen bonding, which creates a thermodynamically 
unfavourable surface for the adsorption of organic substances or particle adhesion. However, 
it has been demonstrated that PEG is susceptible to oxidative damage in the presence of oxygen 
and transition metal ions, thereby significantly worsening its antifouling properties. 91 
Zwitterionic materials, containing equal positive and negative charge functionalities are able 
to maintain electric neutrality and are well-known for their antifouling properties. Zwitterionic 
materials have recently been introduced on to polydimethylsiloxane (PDMS) (the material 
most commonly used for the production of Foley catheters).91,92 much like PEG-based systems, 
the introduction of hydrophilic zwitterionic moieties leads to the formation of a bound water 
layer, thus rendering the surface thermodynamically unfavourable for the adhesion of fouling 
species.92 Unlike PEG-based systems, however, formation of the hydration shell is via 
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electrostatic interactions which, as they are stronger than hydrogen bonding, result in denser 
and more tightly adsorbed water.93 
 Nanostructured Materials  
The material and resulting surface topography from which a urinary catheter is formed can 
significantly impact the rate of biofilm formation. Recent studies have aimed to investigate and 
exploit the abilities of a material’s surface topography in order to modulate cellular adhesion. 
Nature-inspired patterned surfaces, such as Sharklet™ have shown promise in the 
development of a benign surface treatment for the prevention of bacterial attachment.94,95 The 
Sharklet micropatterned surface has been shown to inhibit colonisation and migration of 
uropathogenic E. coli under growth conditions in vitro.96 The ability of the uropathogenic E. coli 
to colonise three variations of the Sharklet micropattern was assessed, all of which 
outperformed a standard PDMS control. An average of 47% reduction in CFU and bacterial area 
coverage was observed, in addition to 77% reduction in colony size, both in growth media and 
artificial urine.  
Surface topographies such as Sharklet create mechanical stress on a settling bacterium, a 
phenomenon known as mechanotransduction. Nanoforce gradients caused by surface 
variations induce stress gradients within the lateral plane of the surface membrane of a settling 
microorganism during initial contact. The stress gradient disrupts normal cell function, forcing 
the cell to provide energy to adjust its contact area on each topographical feature in order to 
equalise the stresses. The expenditure of this energy is thermodynamically unfavourable, thus 
inducing its detachment and subsequent search for an alternative attachment site (Figure 
1.6).97  
The employment of inert nanostructured materials as anti-adhesive surfaces represents a 
paradigm shift in the current considerations of using chemical modifications to alter the 
surfaces of medical devices, by relying on a microscopic texture to provide an inhospitable 
surface for microorganism colonisation. 
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1.7.4. Stimuli-Responsive Approaches  
Current research into stimuli-responsive systems has provided a potential solution to many of 
the issues encountered with standard passive-release strategies. Such systems rely on an 
external stimulus (either directly or indirectly associated with the onset of infection), in order 
to facilitate diagnosis or treatment. Direct stimuli caused by successful colonisation include 
specific biomarkers produced by pathogenic bacteria (e.g. enzymes and toxins), whilst a 
change in the physical conditions (e.g. pH or temperature) may provide indirect indication of 
infection. Crucially, stimuli-responsive materials are able to retain their diagnostic or 
Figure 1.6: (Top) Scanning electron micrographs of force-gradient engineered topography 
Sharklet™ (SK) fabricated in PDMS, in comparison to a smooth PDMS surface (SM). (Bottom) 
Schematic of a settling cell/organism contacting two dissimilar topographical features, 
creating an effective stress gradient within the lateral plane. The separation distance between 
each feature induces strain on the cell membrane. Adapted with permission from Schumacher 
et al.97 ©2008 American Chemical Society. 
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therapeutic capabilities until an endogenous factor initiates a burst response of the cargo 
contained within. This may manifest as a change in volume or structure of the cargo’s reservoir 
material, or a bond cleavage of anchored moieties.98 
The ability to control both the release kinetics and delivery location of a diagnostic or 
therapeutic cargo offers significant advantages over conventional passive release systems. 
Since the cargo is held within a reservoir until its release is initiated, sub-lethal exposure of 
antimicrobial agents to pathogenic bacteria, and subsequent development of resistance is 
circumvented. Furthermore, the cargo itself, which may be sensitive to external conditions 
with prolonged exposure, is protected. The concept of controlled release is particularly 
attractive for the treatment of CAUTI, owing to the time-dependent release of the cargo, since 
premature administration of a therapeutic agent will inevitably result in elution from the 
bladder, rendering the system ineffective before the progression of infection.  
A recent study by Francesko et al.99 utilises specific biomarkers to induce the release of 
antibacterial agents, via the disassembly of polycationic nanospheres. Catheter coatings were 
composed of intact, highly antibacterial polycationic nanospheres, processed from aminated 
cellulose (able to disrupt bacterial membranes) and bacteria-degrading hyaluronic acid. 
Coatings were found to be stable in the absence of bacteria, but disassembled gradually upon 
incubation with P. aeruginosa, thereby preventing biofilm formation under dynamic conditions 
using a model of the catheterised bladder. The outer, bacteria-responsive layer of hyaluronic 
acid was found to be degraded by pyocyanin (a redox-active virulence factor produced by P. 
aeruginosa), resulting in a 70% reduction in bacterial growth after 2 hours (p < 0.001). 
The urease-catalysed hydrolysis of urea to ammonia by P. mirabilis, and the subsequent 
increase in urinary pH has been exploited in the development of pH-responsive systems for the 
prevention of CAUTI. These approaches will be discussed in Chapters 4 and 5. The urinary pH 
elevation provided by P. mirabilis infection is the obvious choice of stimulus to form the basis 
of a triggered-release system, since it is both rapid and significant within the catheterised 
urinary tract. 
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 Conclusion and Project Aims 
In summary, catheterisation of the urinary tract provides a significant risk to those undergoing 
long-term indwelling catheterisation, owing to the formation of crystalline biofilms following 
colonisation by P. mirabilis. Whilst many attempts have been made to render the current Foley 
catheter system less susceptible to infection, resistance to change of the current design by both 
care-givers and patients has rendered many of these approaches largely redundant. In 
particular, engineering-based approaches that encompass a completely redesigned catheter 
system have thus far proved unsuccessful in clinical translation. Furthermore, medicated 
catheters containing antibiotics (e.g. nitrofurans) and or silver derivatives have shown limited 
efficacy in clinical trials, owing to the masking of antimicrobial effects upon the initiation of a 
conditioning biofilm layer, or increased patient discomfort. Whilst it is widely acknowledged 
that the clinical, social, and economic burdens associated with the use of the Foley catheter 
have gained notoriety in recent years, it is also true to say that regulatory authorities, relevant 
industrial and commercial companies, as well as the scientific community have thus far failed 
to find a comprehensive solution. Thus, there exists a need for novel approaches to the 
prevention and detection of catheter encrustation and blockage that are sympathetic to the 
currently accepted Foley catheter design and closed drainage system, which has remained 
unchanged since its ubiquitary clinical introduction in the 1930s. 
The aim of this thesis is to develop novel strategies for the detection and prevention of catheter 
encrustation and blockage. The research agenda for the following chapters will endeavour to 
design supplementary systems to the current Foley design, able to either detect P. mirabilis 
infection in advance of catheter blockage, or to delay blockage and extend the catheter lifetime. 
The diagnostic approaches (Chapters 2 and 3) will endeavour to facilitate advance warning of 
impending catheter blockage, in order to permit clinical intervention prior to the onset of 
serious symptomatic episodes. The therapeutic approaches (Chapters 4 and 5) will aim to 
utilise alternatives to antibiotics in order to delay biofilm formation and subsequent 
encrustation of the urinary catheter. The use of conventional antibiotics is deliberately 
avoided, since the overuse and exposure of sub-lethal concentrations of chemical antibiotics 
may rapidly induce the dawn of a post-antibiotic era.  
Given the nature and complexity of the clinical problem, research which endeavours to extend 
catheter lifetime is inherently multidisciplinary. Hence, the strategies presented in this thesis 
aim to combine chemical, biological and engineering advances, whilst still maintaining aspects 
of the original design. 
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Chapter 2: Development of an Infection-Detection 
Sensor Coating for Urinary Catheters 
2.1. Abstract 
The research presented in this chapter describes the development and in vitro testing of an 
infection-responsive coating for urinary catheters, that provides a clear visual early warning 
of infection and subsequent catheter blockage. The system utilises pH as an indirect external 
marker of infection, thus rendering it sensitive to infections by P. mirabilis. The coating is 
comprised of a dual-layered system, in which the lower poly(vinyl alcohol) (PVA) reservoir 
layer contains the self-quenching dye 5(6)-carboxyfluorescein. This is capped by an upper 
layer of the pH-responsive polymer poly(methyl methacrylate-co-methacrylic acid) (Eudragit 
S100®). Elevation of the urinary pH (pH >7) as a consenquence of infection by P. mirabilis 
causes a significant morphological change in the Eudragit layer, thus releasing the dye to 
provide clear visual warning of impending blockage (Figure 2.1). Prototype coatings were 
evaluated in a clinically relevant in vitro bladder model, which provides a physiologically 
accurate representation of the catheterised urinary tract.  
This system aims to provide a proof-of-concept catheter coating, in order to investigate the 
delivery of small molecules directly into the bladder in response to infection. 5(6)-
carboxyfluorescein acts as a ‘model drug’ for the release of therapeutic species into the bladder. 
The use of a diagnostic agent aims to reduce the administration of unnecessary antibiotics for 
infections of this nature, whilst reducing patient discomfort and clinical intervention.  
Figure 2.1: Schematic representation of the dual-layered polymeric architecture for the pH-
responsive release of 5(6)-carboxyfluorescein from a urinary catheter coating. 




2.2.1. Point-of-Care Diagnostic Systems: The Clinical Need 
In a medical sense, a diagnosis can be regarded as an attempt at classification of an individual’s 
condition into separate and distinctive categories, to allow medical decisions regarding 
treatment and prognosis to be made. Recent technological advances have markedly improved 
the way in which infection and disease are clinically diagnosed, and are now beginning to make 
the transition from laboratory to clinic.  
Point-of-care (POC) diagnosis is defined as medical diagnostic testing at or near the point of 
care. That is, at the time and place of patient care. This contrasts with the historical pattern, in 
which testing is wholly or mostly confined to the medical laboratory, and specimens from the 
POC are sent for analysis by trained personell. Results are generally obtained within hours or 
days, during which care must continue without the desired information. POC testing systems 
provide rapid results, facilitating actionable information that can lead to a change in patient 
management. Such results reduce the need for multiple patient visits, enable timely treatment, 
and aid the containment of infectious disease outbreaks. Crucially, POC disgnostics reduce 
reliance on presumptive treatment, thereby increasing antimicrobial stewardship.1 
A 2015 interdisciplinary workshop organised by the Wellcome Trust examined the use of 
diagnostic tools to guide antibiotic usage in a range of common clinical scenarios. Rapid 
diagnostics were thought to play a vital role in the battle against drug-resistant infections by 
indentifying specific pathogens and allowing timely intervention. Increasing the availability of 
novel diagnostic technology allows for less indiscrimante use of antibiotics, a major driving 
factor in the emergence and spread of resistance. Specific goals outlined by the Wellcome Trust 
include the ability to identify high-risk patients; tools able to identify precise biomarkers 
indicative of location-specific infection may prove crucial for the prognosis of likely poor 
clinical outcomes.2 
2.2.1.1. Prevention of Catheter Blockage: Current Strategies  
The diagnostic challenge for CAUTI is inherently multifactorial. Uncomplicated cases of 
bacteriuria as a result of short-term, intermittent catheterisation do not generally lead to 
serious symptomatic episodes, and often self-resolve upon removal of the catheter. Patients 
suffering from CAUTI are likely to be elderly and residing in a care-home environment. 
Consequently, a range of undifferentiated symtoms (confusion, fever, incontinence) may be 
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indicative of unrelated conditions. Patients must hence be rapidly diagnosed as either 
requiring antibiotic intervention or not, often by unqualified personell, by determining 
whether or not they are progressing towards sepsis. In this scenario, overtreatment is 
common, thus there exists an urgent need for a diagnostic tool able to identify colonising 
bacteria. Further challenges lie in the ability to distinguish true infection from colonisaiton via 
an easily identifiable sensor system, which may alert even an untrained patient or caregiver to 
the type of intervention required.2,3 
Current clinical guidelines for preventing catheter blockage as a result of CAUTI are simply to 
remove the catheter and avoid their use where possible.4 There is currently no objective 
method of predicting catheter blockage. Where catheters must remain in place on a long-term 
indwelling basis, preventative measures for catheter encrustation and blockage include 
ensuring a consistent fluid intake, regular emptying of the drainage bag, maintaining good 
general hygiene, and performing regular catheter changes of 4-6 weeks post-insertion.5 
In 2017, the Royal United Hospital (Bath, UK) introduced a novel ‘catheter passport’ for urology 
and community care outpatients, to improve catheter management and reduce recurrent 
blockage outside of the acute care setting.6,7 One aspect of this newly implemented 
documentation is a ‘catheter diary’, whereby the catheterised patient may record the dates of 
catheter changes, as well as any adverse events such as blockage or bladder spasms. Despite 
being primitive and puerile, catheter diaries remain the primary method of predicting long-
term indwelling catheter blockage. Indeed, guidelines recommended by the Centre for Disease 
Control are designed only for short-term urinary catheter use, thus often do not cover the 
frequency that indwelling catheters should be changed. Emphasis is therefore placed on 
evidence-based recommendations, driven by reimbursement and tradition.8 
Given the sparce and nebulous nature of the clinical guidelines regarding the prevention of 
CAUTI in indwelling catheters, there exists a need for a rapid and accurate point-of-care 
diagnostic, able to identify the progression of CAB to CAUTI. Specifically, a diagnostic system 
able to give prior warning of explicit symptomatic epsiodes, namely catheter blockage, would 
be valuable to provide reliable and objective notification of blockage. Crucially, the diagnostic 
output must be easily interpretable, and not requiring specialist equipment or training, to 
render the technology accessible to patients outside the acute care setting.  
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2.2.2. Novel Diagnostic Systems for CAUTI 
The design constraints of the current Foley catheter system are important considerations in 
the formulation of a novel sensor for infection by P. mirabilis, and subsequent catheter 
blockage.  The concept of utilising urinary pH elevation to provide ‘early warning’ of blockage 
via creation of a sensor system compatible with the current design has been explored 
previously by Stickler et al.9,10 The first iteration of these sensors involved the covalent linkage 
of the pH indicator bromothymol blue to cellulose acetate polymer. Despite successful in vitro9 
and clinical assessments11 of this system, the sensor was deemed unsuitable for commercial 
development. Hence, the system was modified to improve commercial viability via the 
manufacture of a silicone-based formulation with the incoporated indicator and a hydrophilic 
filler. The sensor was housed within a small polyvinyl chloride connector, located in the 
junction between catheter and drainage bag. Despite its initial promise, the ‘early warning’ of 
catheter blockage in human trials was >18 days, thus calling into question whether this system 
can be considered an indicator of imminent blockage. Additionally, some participants in the 
trial reported leakage around the sensor, or expressed concerns over the additional length,12 
thereby highlighting the need for any novel sensor to be compatible with the existing closed-
drainage system. 
Other diagnostic urinary catheter accessories described in the literature include the 
development of a pH-sensitive, reversible colourimetric porous membrane as part of a 
multimodal system involving a nitrite sensor, embedded within a hydrogel matrix and coated 
onto the internal surface of the drainage tubing. Since nitrite (NO2-) is a metabolite of the 
biological nitrogen cycle,13 but not a natural component of human urine, this system provides  
dual-aspect sensing technology to both alert to the presence of bacteriuria, and distinguish the 
presence of urease-producing species.14 
Diagnostic accessories that do not rely on pH, but instead on electrochemical detection of 
urinary catheter biofilm formation, have also been described. Investigation into a sensor 
module employing electrical impedence utilising two or more substrate-integrated electrodes, 
allows for a rapid output signal for the presence of a bacterial biofilm as well as biofilm 
thickness and possible encrustation. This sensor may be combined with additional modules 
such as those detecting changes in pH/ body temperature to provide multifaceted feedback 
regarding the development of infection in situ.15 
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2.2.3. Carboxyfluorescein  
Fluorescence spectroscopy is frequently used in aspects of biochemistry, cell biology, 
molecular biology and biophysics, owing to its sensitivity and rapid response times. 
Spectroscopic systems utilising fluorescent signals can be 100-fold more sensitive than 
absorption spectrophotometry, thus micromolar concentrations are sufficient to give a strong 
signal.16 In particular, carboxy derivatives of fluorescein (Scheme 2.1) are widely used within 
bioconjugate chemistry, for example the synthesis of labelled oligonucleotides.17,18 
Carboxyfluorescein is a particulary valuable fluorescent agent in biochemical and medical 
diagnostic applications, owing to its combination of useful properties, including fluorescence, 
pH-sensitivity, biocompatibility and concentration-quenching.19  
Fluorecence quenching can be defined as a bimolecular process that reduces the fluorescence 
quantum yield, whilst leaving the fluorescence emission spectrum unchanged. Concentration-
quenching, also known as self-quenching, refers to the quenching of a fluorophore by another 
of the same. Concentration quenching is a highly distance-depedent excited-state interaction 
between two fluorophores, via the formation of non-fluorescent dimers. It is widely accepted 
that concentration-quenching occurs as a result of internal conversion and intersystem 
crossing in the excited states of dimers in solution.20 The fluorescence quantum yield can be 
strongly affected by dimerisation, since the intersystem crossing between the singlet and 
Scheme 2.1: Fluorescein (A) and its carboxy derivatives. (B) 6-carboxyfluorescein. (C) 5(6)-
carboxyfluorescein. 
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triplet excited states may lead to a radiationless decay channel that cannot be realised in the 
monomeric species.21 Concentration-quenching in carboxyfluorescein arises owing to the 
overlap of the absorption and emission spectrum, thus facilitating a reduction in fluorescence 
signal upon formation of non-fluorescent dimers.22  
2.2.3.1. Carboxyfluorescein as a Model Drug 
Carboxyfluorescein is frequently used as a hydrophilic model drug system in novel targeted 
drug delivery formulations. Such systems often include the encapsulation of a hydrophilic drug 
within the internal aqueous core of lipid vesicle systems (such as conventional liposomes,23 
transfersomes,24 and ethosomes,25 as well as biopolymer-based multilayers).26 Release of 
carboxyfluorescein from the highly-concentrated aqueous core results in an increase in 
detectable fluorescence output. 
A recent study by De Leo et al.27 describes the formulation of a liposome-modified titanium 
surface as a strategy to locally deliver bioactive molecules from orthopaedic or dental implants. 
Titanium and its alloys are widely employed in medical implants owing to their mechanical 
properties, resistance to corrosion, and osseointegration capability. However, adverse 
reactions may occur at the tissue/implant interface, thereby limiting the success of 
biointegration. Carboxyfluorescein was used as a model biomolecule for delivery from 
liposome-based coatings for titanium implants, employing fluorescence microscopy for real-
time imaging of cargo delivery to adherent cells, and subsequent cellular uptake.  
Carboxyfluorescein was detectable within MG63 human osteoblast-like cells after 1 hour 
incubation at 37 °C (Figure 2.2). 
Figure 2.2: The use of carboxyfluorescein as a model drug. Fluorescence micrographs of 
MG63 human osteoblast cells cultured in the presence of carboxyfluorescein-loaded 
liposomes, anchored to titanium sheets. Fluorescence response detected in the cytoplasm 
after 15 minutes (A), 1 hour (B), and 2 hours (C) after incubation at 37 °C. Dotted green 
fluorescence (white arrows) shows cellular uptake of liposomes (scale bars 10 μm). Modified 
with permission from De Leo et al.27 © 2017, with permission from Elsevier. 
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2.2.3.2. Carboxyfluorescein as a Diagnostic  
The use of carboxyfluorescein as a diagnostic agent has proved promising in recent years, 
owing to its rapid and distinctive colour change upon dilution, ease of quantification and 
biocompatibility.28 Encapsulation of carboxyfluorescein within a reservoir matrix may provide 
sufficiently high concentrations such that the fluorescence output is self-quenched. Upon 
release of the dye into the surrounding biological environment (in response to a physical or 
biological trigger), the fluorescence ‘switch on’ achieved by sudden dilution is visible to the 
naked eye, thus achieving a stimuli-responsive diagnostic system. 
Such a system has recently been developed by Thet et al.29, in which 5(6)-carboxyfluorescein 
is encapsulated within lipid vesicles and dispersed within a hydrogel matrix, to create a novel 
wound dressing prototype (Figure 2.3).  
 
 
Since the composition of the vesicle loosely resembles a cellular membrane, cytotoxins 
released by pathogenic bacteria associated with skin wounds (e.g. Staphylococcus aureus (S. 
aureus)) are able to cause rapid lysis and subsequent fluorescent output as a result of 
carboxyfluorescein dilution within the hydrogel dressing (Figure 2.4). 
Figure 2.3: Schematic showing the diagnostic wound dressing concept. A lipid vesicle 
containing self-quenched dye 5(6)-carboxyfluorescein is lysed by secreted toxins from 
pathogenic bacteria. The resultant dye release manifests as a fluorescence ‘switch on’ following 
carboxyfluorescein dilution within the hydrogel matrix. Reproduced with permission from 
Zhou et al.30 © 2011, with permission from Elsevier.  
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The use of carboxyfluorescein’s fluorescent properties in their own right as ‘smart’ diagnostic 
agents, provides an interesting development in the field of POC diagnostics.  The identification 
of novel infection stimuli, alongside the advent of increasingly sensitive smart release 
technology reveals the potential to construct multiple new diagnostic systems, able to alert 
patients to bacterial colonisation via a clear and unambiguous colour change. Consequently, 
this may help to alleviate the pressure currently placed on chemical antibiotics by reducing or 
removing the need for prophylactic treatment. 
2.2.4. pH-Responsive Polymeric Systems 
All pH-sensitive polymers consist of either pendant acidic or basic groups, which may either 
accept or donate protons in response to changes in environmental pH. As basicity of the 
surrounding medium increases, pendant groups such as as methacrylic acid and acrylic acid 
undergo deprotonation and subsequent change in the net charge of the attached group, thus 
introducing repulsive forces within the polymer network. To offset such forces, counter ions 
from the surrounding medium enter the matrix, resulting in an alteration of the molecular 
structure of the gel to an expanded state. This phenomenon has been widely exploited within 
the field of pH-dependent drug release, particularly within the gastrointestinal system.31 
pH-responsive systems have also shown significant promise in the fields of cancer therapy 
(since the extracellular space of cancer tissues has a slightly acidic pH, ranging from 6.5-7.2, 
compared to the healthy 7.4)32,33, and chronic wound treatment (which exhibit alkaline pH 
Figure 2.4: Response of prototype wound dressings to colony wound biofilm models of 
pathogenic bacteria (Enterococcus Faecalis, P. aeruginosa and S. aureus), and non-pathogenic 
bacteria (E. coli). HEPES buffer was used as a negative control, and  the non-ionic surfactant 
Triton as a positive lysis control. (A) Quantitative fluorescence output. (B) Visual results 
(dressing fluorescence under UV light). Reproduced with permission from Thet et al.29 © 
2016 American Chemical Society. 
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values ranging from 5.4-7.4,34 compared to the healthy acidic value of 4.7-5.0)35. Futhermore, 
pH has provided a useful trigger in the field of drug release from urinary biomaterials. Irwin et 
al.36 have investigated a novel drug delivery system for urinary catheters, which exploits the 
poor-solubility and pH-dependent physicochemical properties of the antimicrobial agent 
nalidixic acid within a hydrogel system. With a pKa of 6.0 ± 0.5,37 nalidixic acid exists entirely 
in its ionised form at alkaline pH, thus displaying a higher affinity for aqueous media.38 Release 
of nalidixic acid was almost instantaneous at pH 9,36 effectively resulting in a pH-triggered 
‘burst’ response from the hydrogel in response to infection by P. mirabilis.  
2.2.4.1. Eudragit S100® 
Eudragit S100® is a widely used functional copolymer poly(methyl methacrylate-co-
methacrylic acid), containing a ratio of carboxyl groups to ester groups of 1:2. The polymeric 
structure of Eudragit is shown in Scheme 2.2. 
Eudragit polymers are considered the ‘gold standard’ for functional coatings on oral solid 
dosage forms, and are widely used as enteric coating formulations for drug delivery. The use 
of Eudragit in early-stage research provides significant advantages in later scale-up, since all 
commercially available polymers have gained EXCiPACT™ certification, meaning that Good 
Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards are met.39 
The pH-gradient existing in the bladder as a result of pathological conditions of P. mirabilis is 
sufficient to cause a change in the morphological structure of Eudragit. Such copolymers are of 
particular relevance to biomedical application as, beyond their biocompatibility, they remain 
neutral below pH 7, but become charged at alkaline pH. Thus, below pH 7, low permeability is 
displayed by the Eudragit polymer, owing to the uncharged hydroxyl groups, which may form 
hydrogen bonds with the carbonyl oxygen of the ester moiety. As the pH of the surrounding 
Scheme 2.2: Chemical structure of poly(methyl methacrylate-co-methacrylic acid) (Eudragit 
S100®). 
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medium rises above pH 7, the carboxylic acid groups become chaged and the polymer network 
begins to swell as a consequence of repulsion. This facilitates penetration of liquid media and 
subsequent liberation of any encapsulated species.40,41 
The use of Eudragit polymers for pH-responsive delivery of biomolecules is ubiquitous 
throughout the literature. In addition to proving location-specific release within the colon,42 
Eudragit may also be used to protect sensitive biological cargos following oral delivery. A 
recent study by Vinner et al.43 has utilised Eudragit S100 microspheres, formed using 
microfluidic glass capillary devices, to deliver Clostridium difficile bacteriophage to the colon 
via oral administration. In contrast to free bacteriophage, those encapsulated within the 
microparticles could withstand a 3 hour exposure to simulated gastric fluid (pH 2), before 
undergoing a pH-triggered burst response at within the colon (pH 7). 
Eudragit S100 microspheres have also proved promising as an oral carrier for peptide drugs 
such as insulin.44,45 Among all of the administratrative routes of human insulin, the oral route 
offers the maximum advantage in terms of patient compliance. Limitations of insulin delivered 
via this route however, include low oral bioavailability owing to degradation in the stomach, 
inactivation and digestion by proteolytic enzymes in the luminal cavity, and poor permeability 
across the intestinal epithelium. Entrapment of insulin within Eudragit microspheres 
facilitates its protection from gastric fluids, and subsequent release in the region of the 
gastrointestinal tract where the pH >7, that is, within the large intestine (where proteolytic 
enzyme concentration is lower). Early-stage in vivo studies using insulin-loaded Eudragit 
microspheres have demonstrated a prominent hypoglycaemic effect, suggesting that the 
polymer successfully protects the sensitive cargo from proteolytic degradation.46
 Chapter 2  
45 
 
2.3. Materials and Methods 
2.3.1. Materials  
Uropathogenic bacterial isolates P. mirabilis B4 and E. coli NSM59 were kindly contributed 
from a previously acquired collection (Dr Brian Jones, University of Bath). 
Triethyl citrate, Luria-Bertani broth (LB), tryptic soy broth (TSB), yeast extract, tryptone, 
sodium chloride, magnesium sulphate, magnesium chloride hexahydrate, tri-sodium citrate, 
sodium oxalate, potassium di-hydrogen orthophosphate (potassium phosphate monobasic), 
potassium chloride, ammonium chloride, calcium chloride, urea, talc, 5(6)-carboxyfluorescein, 
PVA (14,600-18,600 gmol-1), sodium phosphate monobasic, sodium phosphate dibasic, HEPES 
buffer and (3-aminopropyl)triethylsilane (APTES) were purchased from Sigma-Aldrich (Poole, 
Dorset, UK). Bacteriological agar was purchased from Oxoid (Basingstoke, Hampshire, UK). 
Eudragit S100 was kindly donated by Evonik Industries (Darmstadt, Germany). Uncoated all-
silicone foley catheters and drainage bags (2 L capacity) were obtained from Bard Medical 
Devision (Covington, GA). 
2.3.2. Methods 
2.3.2.1. Microbiological Methods 
Strict aseptic technique was employed when handling bacterial cultures and sterilised culture 
media. Assays requiring sterility were undertaken in Grade II flow laminar flow hoods.  
I. Principles of Bacterial Growth  
For the study and quantification of bacterial growth, cells are first cultured in liquid medium, 
which provides optimum growth conditions and all nutrients required for cell proliferation. 
Aliquots of liquid growth culture are then plated onto solid agar medium, in order to quantify 
bacterial cell numbers. During cultivation in liquid media, bacteria exhibit four distinct phases 
of growth, which may be monitored according to the change in measurable cell density over 
time. The first is the initial lag phase, whereby the cells are preparing for replication  (e.g. via 
DNA synthesis and production of various inducible enzymes). Cells then enter the log or 
exponential growth phase, within which cell division occurs at maximal rate, thereby 
increasing the total bacterial population exponentially. Following exponential growth, the cells 
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enter a stationary phase, as the population becomes nutrient limited or depleted by the 
accumulation of inhibitory metabolic products. During this period, the rate of cell division is 
equalled by that of cell death, thus there is no net population growth. Finally, upon the onset of 
conditions which are beyond the tolerance of the species, the cells enter the death phase, where 
the bacterial cell count begins to decline. Cell density may be assessed photometrically using 
optical density (OD) measurements (which correlate the degree of light scattering to the cell 
densitiy via quantification of solution turbidity). The generalised bacterial growth curve as a 
function of both viable cell count and OD is shown in Figure 2.5.  
 
II. Bacterial Culture Conditions  
LB media was prepared by dissolution of LB powder (20 g) in deionised water (1 L). LB agar 
was prepared by dissolution of LB agar powder (35 g) in deionised water (1 L). Non-swarming 
LB (NSLB) was used to allow the growth of single colonies of P. mirabilis on a solid agar surface. 
Tryptone (10 g), yeast extract (5 g) and bacteriological agar (15 g) were dissolved in deionised 
water (1 L). All media was autoclaved via subjection to high-pressure saturated steam at 121 
°C for 20 minutes to ensure sterility.  
Figure 2.5: Bacterial growth curve showing changing viable cell count wih time in liquid 
media (solid line), and corresponding change in OD at 600 nm (dotted line). Bacterial growth 
occurs in four distinct phases. (A) lag phase. (B) Exponential growth phase. (C) Stationary 
phase. (E) Death phase. No significant reduction in OD is observed during the death phase, as 
dead cells still exhibit turbidity in liquid culture. 
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Bacterial cultures were grown from freezer stocks via straking on an agar plate (LB/NSLB for 
E. coli/P. mirabilis respectively), followed by overnight static incubation at 37 °C. Liquid 
cultures were obtained via the addition of a single bacterial colony to LB broth (10 mL), 
followed by further overnight incubation with shaking (200 rpm). 
III. Bacterial Quantification  
Colony-forming units (CFU) are used to estimate the number of viable bacterial cells in a 
culture. Since one viable cell is able to give rise to one colony via replication by binary fission, 
CFU may be calculated by the plate counting method. Single colonies were obtained by plating 
onto nutrient agar, following serial dilution in liquid media. Briefly, test bacterial solution (100 
μL) was added to sterile PBS (900 μL) and vortexed to mix. This solution was serial diluted 10-
fold to a final dilution of 10-8. Triplicate aliquots of each dilution (10 μL) were streaked on to 
LB/NSLB agar medium, and incubated statically overnight at 37 °C. Plates displaying 30-300 
colonies were used to quantify CFU per unit volume (CFU/mL) according to Equation 1. 
 
CFU mL =  




Where d is the dilution factor (from original culture), and V is the volume of inoculum (mL). 
2.3.2.2. Analysis of 5(6)-Carboxyfluorescein Properties 
I. pH-Dependency 
The pH-dependent response of carboxyfluorescein was assessed via pH-adjustment of 
carboxyfluorescein solution (0.5 M in HEPES buffer) within the pH range of 2-10 in 0.5 
increments. Fluorescence endpoints were measured using SPECTROstar Omega microplate 
reader (BMG Labtech, UK), using excitation and emission wavelengths of 485 ± 12 and 520 nm, 
respectively.  
II. Concentration Quenching 
Dilutions from carboxyfluorescein stock solution ( 50 mM) in HEPES buffer were undertaken 
to achieve a concentration range of 10 mM to 10 nM. Dilutions were adjusted to pH 6, 7 and 8 
accordingly via the dropwise additions of NaOH/HCl (1 M). Fluorescence endpoint 
measurements were recorded on a microplate reader as above.  
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2.3.2.3. Materials Preparation 
I. PVA Hydrogel Preparation 
PVA (14,600-18,600 gmol-1, 20% w/v) was added to deionised water and heated to 97 °C with 
constant stirring to facilitate dissolution. The cooled solution was stored at room temperature 
until required. Once cast, gels were stored overnight at -20 °C to promote cryogenic gelation. 
Prior to experimental use, gels were thawed at room temperature for 4 hours.  
II. Swelling Ratios 
Swelling behaviour of PVA hydrogels was investigated by comparing the mass of the 
dehydrated gels to that of the rehydrated form. PVA solutions (10% and 5% w/v, 500 μL) were 
cast into the wells of a 24-well microplate. After freeze thawing, gels were transferred to a 12-
well microplate and coated with deionised water (1 mL). Plates were incubated at room 
temperature overnight to allow the gels to swell to their maximum mass, which was recorded. 
Gel specimens were then removed from the liquid media and incubated overnight at 37 °C to 
dehydrate. The dry mass was recorded, and the swelling ratio calculated according to Equation 
2. 
 





Where WR is the mass of the rehydrated disk, and WD is the mass of the dehydrated disk (g).  
III. SEM of PVA Hydrogels 
The internal porous structure of the PVA hydrogels was analysed by scanning electron 
microscopy (SEM) to assess the size and abundance of pores. Gels were freeze-dried (6 hours) 
and stored under vacuum overnight to ensure complete dehydration. Gels were sputter-coated 
with gold (Edwards S150B, 60 s) to reduce charging effects and thermal damage, and images 
obtained using a scanning electron microscope (JEOL SEM6480LV) operated at 10 kV. 
IV. Preparation of Eudragit S100 Solution 
The organic dip coating solution of Eudragit S100 was prepared according to the Eudragit 
technical information.39 The formaulation was scaled for a 300 g suspension (Table 2.1). 
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Table 2.1: Componencts of Eudragit S100 organic dip coating solution  
Compound Mass (g) Volume (mL) 
Eudragit S100 15.6 - 
Triethyl Citrate (plasticiser) 1.6 1.3 
Talc (anti-tacking) 7.8 - 
Acetone - 108.5 
Isopropanol - 163.6 
Deionised water - 10.8 
 
Eudragit powder was added gradually to half the diluent mixture, and stirred for 60 minutes 
until completely dissolved. To the remaining diluent mixture was added talc and triethyl 
citrate, and the resultant suspension stirred for 10 minutes with a high shear mixer. The 
excipient suspension was poured slowly into the Eudragit solution with constant stirring, 
before removing the talc via filtration under vaccum. The solution was stored at room 
temperature until required.  
V. Dip Coating Optimisation  
Sterile plastic rods were coated with PVA/carboxyfluorescein hydrogel according to Section 
2.2.2.3.VIII, and dip coated with 10, 15 or 20 coats of Eudragit S100 solution to assess dye 
retention with different coating thicknesses. Release was assessed in phosphate buffer (10 mL) 
at pH 6, 7 and 8 to mimic healthy, and infected urine respectively. Sodium phosphate 
monobasic stock solution (0.1 M) and sodium phosphate dibasic stock solution (0.1 M) were 
mixed in the proportions indicated in Table 2.2. Final pH values were adjusted using a pH 
meter. 
Table 2.2: Components of phosphate buffer (pH 6, 7 and 8) 
pH 6 7 8 
NaH2PO4 /mL 81.5 39.0 5.3 
Na2HPO4 / mL 18.5 61.0 94.7 
 
Observed fluorescence response was monitored using a microplate reader as above. Test 
solutions were returned to the bulk liquid after testing to maintain a constant volume. 
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VI. Silanisation of Urinary Catheters 
The method for hydrophilisation of catheter surfaces via silanisation of the silicone surface was 
modified from Gencer et al.47 Catheters were activated in 1:1 mixture of ammonia (33% v/v) 
and hydrogen peroxide (30% v/v) for 10 minutes with constant agitation, then rinsed with 
deionised water and dried under nitrogen. Catheters were then placed in APTES (1% v/v) 
dissolved in dry N,N-dimethylformamide (DMF) for 16 hours. The surface-modified catheters 
were subsequently washed with DMF and deionised water (x3), and dried under nitrogen. 
Water contact angle measurements were made to ensure the hydrophilic nature of the surface.  
VII. Contact Angle Analysis of Modified Urinary Catheter Surfaces 
Wettability of silanised and untreated PDMS catheter surfaces was assessed using water 
contact angle analysis. A sessile water droplet (5 μL) was placed onto the surface of a PDMS 
Foley catheter, and the contact angle measured immediately using a Dataphysics OCA20 
goniometer. The results reported represent the average of five meaurements taken on different 
areas of the specimen. The contact angle was defined as the angle formed between the 
substrate surface and the tangent to the droplet surface. 
VIII. Coating of Foley Catheters 
To cooled PVA solution was added 5(6)-carboxyfluorescein solution (500 mM, adjusted to pH 
6) at a 1:1 ratio. The resultant hydrogel solution (10 % w/v) containing carboxyfluorescein dye 
(250 mM) was stored in the dark at room temperature. Catheters were coated with the gel/dye 
solution (100 μL) between the retention balloon and the distal tip, and stored at -20 °C to 
promote cryogenic gelation. Catheters were thawed at room temperature (4 hours) before 
manually dip coating with the pH-responsive trigger layer. Catheters were coated 20 times in 
Eudragit S100 solution, with a 5 minutes solvent evaporation period at room temperature 
between each coating. Coated catheters were stored at 4 °C until required.  
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2.3.2.4. Physiological Representation 
I. Artificial Urine Preparation 
Streile artificial urine was prepared according to Stickler et al.,48 and was used as a growth 
medium for P. mirabilis when clinically relevant conditions were required. Artifical urine stock 
solution at 5x concentration was composed according to Table 2.3. 
Table 2.3: Components of 5x concentrated artificial urine stock solution  
Compound Mass (g) 
Anhydrous sodium sulphate 11.50 
Magnesium chloride hexahydrate 3.25 
Sodium chloride 23.00 
Tri-sodium citrate 3.25 
Sodium oxalate 0.10 
Potassium di-hydrogen orthophosphate 14.00 
Potassium chloride 8.00 




Components of 5x artificial urine stock were dissolved in deionised water (850 mL). The pH of 
the resultant solution was adjusted to pH 5.7 via dropwise addition of sodium hydroxide 
solution (1 M). The solution was made up to 1 L with deionised water, and autoclaved to 
sterilise.  
Calcium/urea stock solution at 5x concentration was prepared according to Table 2.4. 
Table 2.4: Components of 5x concentrated calcium/urea solution 
Compound Mass (g) 
Urea 125.00 
Calcium chloride 3.25 
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Compounds were dissolved in sterile deionised water (350 mL ) on a gently warming hotplate 
to counteract the endothermic solvation. The solution was made up to 400 mL, and filter 
sterilised through a 0.45 μm syringe filter (Sartorius, UK). 
Final working concentration aritificial urine (5 L) was prepared according to Table 2.5. 
Table 2.5: Components of working concentration artificial urine 
Component Volume (L) 
5x Concentrated artificial urine stock 1.0 
5x Concentration calcium/urea stock 0.4 
Sterile deionised water 3.6 
 
The final pH of working concentration artificial urine was adjusted to 6.1 before use. 
II. In Vitro Bladder Models 
Setup and operation of in vitro bladder models was followed according to Stickler et al.48 The 
model consists of a double-chambered glass vessel maintained at 37 °C by an external water 
jacket. The model and associated tubing was first sterilised by autoclaving, and coated 
catheters inserted into the base via silicone tubing attached to a glass outlet at the base. The 
catheter retention balloon was inflated using sterile water (10 mL), achieving the sealing of the 
bladder outlet (Figure 2.6).  
The catheter was attached to a sterile drainage bag to complete the full sterile closed drainage 
system. Sterile artificial urine was supplied to the bladder model via a peristaltic pump 
(Ismatec ISM1077A) at a flow rate of 0.75 mL/min. This allows a reservoir (~40 mL) of urine 
to collect in the bladder below the level of the catheter eyehole. As the volume of supplied urine 
increases, the overflow drains through the catheter to the collection bag.  
For bladder models simulating infection, residual urine in the models was inoculated directly 
with P. mirabilis B4 or E. coli NSM59 bacteria (1010 CFU/mL). Clinical isolates were obtained 
from urinary tract infections from the Royal Sussex County Hospital or from University 
Hospitals Bristol for P. mirabilis and E. coli, respectively. Bacterial cultures were allowed to 
incubate within the bladder model for 1 hour to establish before flow was restored.  




Figure 2.6: Schematic representation of the main components and connections in the in vitro 
bladder model system. (Left) Double-walled glass vessel representing the bladder (A). The 
Foley catheter is inserted through an outlet at the based of the vessel (B). Drainage tubing, 
mimicking the closed drainage system (C) is connected to a sterile drainage bag to collect 
urine outflow (D). Sterile artificial urine is supplied to the bladder via a peristaltic pump at a 
constant flow rate (E). Physiological temperature is maintained at 37 °C via a circulating 
water bath (F). (Right) Key features of media supply tubing, and flow of media/ water 
through the model. Media flow is governed by the peristaltic pump from the reservoir, whilst 
water flow through the bladder model’s outer chamber is driven by a circulating water bath. 
Dimensions of media supply tubing show the short section of thick walled, small bore tubing 
that passes through the peristaltic pump, allowing the pump to efficiently supply media at a 
consistent flow rate of 0.75 mL/min.   
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2.4. Results and Discussion 
2.4.1. Analysis of 5(6)-Carboxyfluorescein Properties 
The suitability of carboxyfluorescein for the in situ sensing of CAUTI, and the mechanism by 
which the fluorescent signal propagates once released from the catheter tip, were important 
considerations when designing the infection-responsive prototype coatings. 
The ability of carboxyfluorescein to self-quench (via the formation of non-fluorescent dimers) 
lends it well to this application, since the dye is released into a large volume of liquid media, 
thereby enhancing the fluorescent signal. Upon release of the dye into the urine diluent, the 
concentration is sufficiently lowered such that the self-quenching effect is inhibited and the 
fluorescence activated (Figure 2.7). 
Furthermore, higher pH of the diluent has been shown to improve the observed signal output 
(Figure 2.8). Since the pH of infected urine is highly alkaline (~pH 8), this may further enhance 
the visualisation of the resultant urinary colour change.  
 
Figure 2.7: Analysis of 5(6)-carboxyfluorescein properties. Dependence of fluorescence 
emission on dye concentration at pH 6, 7 and 8. Self-quenching of the dye is observed at 10 
mM. (Inset) Visual representation of carboxyfluorescein fluorescence at concentrations of 50 
nM- 50 mM at pH 8. 
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The properties of self-quenching and pH-dependence render carboxyfluorescein a suitable dye 
for this application. Whilst the toxicological properties of 5(6)-carboxyfluorescein have not 
been thoroughly investigated, its parent compound, fluorescein, is  approved by the FDA and 
widely used as a phthalic indicator dye for the diagnosis of corneal trauma. A broad range of 
fluorescein derivatives, including 5(6)-carboxyfluorescein, have been extensively used in the 
literature for the assessment of in vitro cell-mediated cytotoxicity, internalisation, transport, 
and cellular uptake, suggesting that the dyes themselves do not induce mammalian cell 
damage.49,50  
2.4.2. Characterisation and Development of PVA Hydrogels 
Properties of PVA at 5% and 10% w/v were investigated to assess both their physical 
characteristics and cargo encapsulation capability. The swelling behaviour and porosity were 
analysed in order to identify the concentration possessing the most suitable characteristics for 
the proposed catheter surface coating.  
PVA hydrogels have proved promising in the field of biomedical engineering owing to their 
inherent biocompatibility.51 The internal porous structure of the hydrogel also lends it to the 
encapsulation of a diagnostic or therapeutic cargo. PVA hydrogels were prepared via freeze 
thawing in order to promote inter-chain crosslinking, thus avoiding component leaching and 
subsequent toxicity issues associated with chemical crosslinking techniques.52 The freezing of 
such gels, followed by thawing at room temperature initiates the crosslinking of structures 
Figure 2.8: Dependenceof fluorescence emission on diluent pH. Measured signal is enhanced 
at alkaline pH. 
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within the gel via the process of cryogenic gelation. The physical basis of this crosslinking 
technique lies in the freeze thawing-induced crystal formation, which facilitates a network 
structure of quasi-permanent crystallites. Liquid-liquid phase separation into regions of 
polymer-rich and polymer-poor phases, along with inter- and intra-molecular hydrogen 
bonding within the amorphous phase are thought to aid the gelation of PVA, owing to the 
nucleation of PVA crystallite ‘cross-linking points’. Indeed, in-depth analysis of PVA cryogels in 
the literature53 has proven the involvement of hydrogen bonding in this process (Scheme 2.3). 
 The formation of ice crystals during conventional freezing leads to an increased polymer 
concentration in the unfrozen phase. Hydrogen bonds may then form within the polymer rich 
phase, although crystal formation may in fact be hindered by the progression of gelation. 
Hence, mechanical properties such as gel rigidity may increase with the number of freeze thaw 
cycles undertaken. During the thawing process, the ice crystals melt, resulting in a porous 
polymeric cryogel, within which a diagnostic/therapeutic cargo may be encapsulated.   
2.4.2.1. Swelling Ratios 
Swelling ratios were calculated in order to assess the degree of porosity and ability to uptake 
aqueous solution within the gel structure. Calculations were undertaken using deionised water 
as swelling agent. Average swelling ratios of 5% and 10% PVA are shown in Table 2.6. 
Table 2.6: Swelling ratios of 5% and 10% w/v PVA. (Data shown are average of triplicate 
values ± standard deviation) 
PVA Concentration (% w/v) Swelling Ratio 
5 37.1 ± 1.1 
10 13.0 ± 3.8 
Scheme 2.3: Physical crosslinking of a PVA cryogel during freeze thawing 




Both 5% and 10% w/v PVA hydrogels formed yielding, fexible structures after one freeze-thaw 
cycle. Structural rigidity of the 10% gel was significantly greater than the 5%, owing to the 
more densely packed polymer network. This was reflected in the measured swelling ratios; 
where the greatest values were observed for the lower polymer concentration. Crucially, the 
swollen state of the 10% hydrogel remained mechanically sound, whilst the 5% gel became 
loose and unstructured. These results suggest that the 10% w/v PVA hydrogel is more suitable 
for an intra-bladder catheter coating, since elastic chain networks with a high degree of 
porosity will allow effective encapsulation, and retention of a robust mechanical gel upon 
transformation to the swollen state will allow encapsulated material to move out from the 
structure, without degradation of the gel matrix itself. 
2.4.2.2. SEM Images of PVA Hydrogels  
SEM images of freeze-dried samples of 5% and 10% w/v PVA hydrogels, prepared by cryogenic 
crosslinking, were obtained to analyse the internal porous structure of each concentration. 
Owing to the inevitable collapse of the gels during sample preparation, the absolute pore sizes 
could not be accurately calculated from these images. However, the relative rigidity and 
thickness of the polymer ‘walls’, as well as the relative pore size could be estimated, thus giving 
some idea of potential encapsulation efficiency. Representative cross-sectional images of 
porous PVA hydrogels at 5% and 10% w/v are shown in Figure 2.9. 
The fibrous nature of the 5% gel can be clearly observed using SEM, where polymer-rich 
regions are sparse and seemingly frangible. By contrast, the 10% gel appears more dense and 
Figure 2.9: Comparison of cross-sectional SEM images of 5% w/v (A), and 10% w/v (B) PVA 
cryogels. (Magnification x 500, scale bar = 50 μm). 
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rigid. The stronger tensile strength and greater imperviousness to degradation upon 
incubation in liquid media , along with the greater density of polymer rich regions in the 
observed microstructure of the 10% gel, make this a more suitable candidate for the coating 
technology.  
2.4.2.3. Silanisation of Urinary Catheters 
In order to coat the hydrophobic surface of the silicone catheter with PVA hydrogel, it was 
necessary to modify the surface with a hydrophilic moiety. In this case, the silane APTES was 
used to introduce ethoxy groups onto the catheter surface. Although many attempts have thus 
far been made to improve the surface hydrophility of PDMS elastomer (for example via plasma 
treatment), these effects are often transient. Hydrophobic recovery is often observed on 
plasma-treated PDMS surfaces, and is sensitive to both time and temperature.54 Modification 
of surface chemistry via silanisation promotes stable and long-term hydrophilisation, and 
renders the surface suitable for coating with a hydrogel material.55 Silanisation of the PDMS 
surface with APTES enables the formation of self-assembled monolayers of molecules with 
reactive amino side chains, via the reaction of the APTES triethoxy group with the activated 
catheter surface.47 Modification of catheter PDMS surfaces via APTES silanisation is shown in 
Figure 2.10. 
Water contact angle measurements were made to ensure the hydrophilic nature of the surface. 
The surface wettability of the native PDMS exhibited a hydrophobic surface  property (94.38 ° 
± 0.86 °). Surface silanisation resulted in a significant reduction in the hydrophobicity of the 
surface (60.43 ° ± 2.0 °), as shown by the reduction of the observed contact angle to the 
Figure 2.10: Schematic illustration of amino-silanisation using APTES on PDMS catheter 
surfaces, following surface activation with NH3/H2O2. 
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hydrophilic region (<90 °).56  The increase in surface wettability  of  a standard all-silicone Foley 
catheter  is show in Figure 2.11. 
 
Figure 2.11: Surface modification of all-silicone Foley catheters via silanisation with APTES. 
Increase in surface hydrophilicity of PDMS elastomer was confimed via characterisation with 
water contact angle measurements. (A) Native PDMS surface, displaying a contact angle 
within the hydrophobic region (94.38 ° ± 0.86 °).  (B) Modified PDMS surface, displaying a 
contact angle within the hydrophilic region (60.43 ° ± 2.0 °). (C) Catheter sections displaying 
increased surface wettability post-silanisation. The modified section becomes rapidly 
submerged on contact with water, whereas the untreated section remains at the gas/air 
interface. (D) Average contact angle measured on chemically modified vs. unmodified urinary 
catheters. Data shown are the average of 5 different points of contact ± standard error of the 
mean (SEM) (p < 0.0001). 
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2.4.3. Eudragit S100 Dip Coating Optimisation  
The encapsulation efficiency of the Eudragit S100 trigger coating was investigated in solutions 
of phosphate buffer to simulate healthy (pH 6/7) and infected urine (pH 8). Sterile plastic rods 
imitating catheters were first coated with the 10% w/v PVA hydrogel reservoir layer 
(containing 250 mM 5(6)-carboxyfluorescein), before being manually dip coated in 10, 15 or 
20 coats of the organic Eudragit S100 solution. Since the elevation of urinary pH to highly 
alkaline levels intitiates crystalline biofilm formation, the aim of this assay was to optimise the 
number of Eudragit coats that would result in dye release and subsequent fluorescence output 
at pH 8, but not at pH 6 or 7.  The ability of the pH-responsive polymer at different film 
thicknesses  to encapsulate dye within a PVA reservoir are shown in Figures 2.12, 2.13 and 
2.14. 
Retention of the dye within the hydrogel reservoir was insufficient after 10 dips of Eudragit 
(Figure 2.12). Significant dye release was observed in the diluent at pH 7 after 3 hours 
incubation. When the film thickness was increased to 15 coats, the difference in observed 
fluorescence response between pH 7 and 8 became more conspicuous (Figure 2.13). 
Quantitative measurements of fluorescence output over 3 hours showed promising results, as 
visual dye release was observed only for buffer solution at pH 8. After 24 hours incubation, 
however, leaching of the dye was observed in solutions at both pH 6 and 7. 
Figure 2.12: Encapsulation efficiency of 10 coats of Eudragit S100 at pH 6, 7 and 8. Leaching 
of the carboxyfluorescein fluorescent dye was observed after 3 hours incubation at room 
temperature. 
 Chapter 2  
61 
 
Further increase of the Eudragit film thickness to 20 coats provided the complete 
encapsulation of dye after 24 hours incubation (Figure 2.14). Owing to increased coating 
thickness, the rate of observable dye release was slower at pH 8, although coatings appeared 
more stable to liquid penetration in buffer solutions imitating ‘healthy’ urine pHs.  
Though uninfected urine typically displays pH ranging from ~6.1-6.5, in some cases, extremes 
of pH from a lower limit of 5.5 to an upper limit of 7.0 have been reported (although these 
extremes are typically associated with other underlying disorders).57 Perhaps the more critical 
value to consider in terms of urinary catheter blockage is the pH at which crystal formation is 
initiated. This ‘nucleation’ pH is also variable between individuals, and has been reported to 
range from pH 6.75-8.95.58 Considering the range of values observed for urinary pH and 
nucleation pH, the optimisation of a system to provide dye release at pH values greater than 7 
appears to offer a good compromise between the requirement for sufficient accuracy and 
duration, and should be suitable for the majority of patients undergoing long-term indwelling 
catheterisation. 
 
Figure 2.13: Encapsulation efficiency of 15 coats of Eudragit S100 at pH 6, 7 and 8. Coatings 
appeared stable after 3 hours incubation, although leaching of the carboxyfluorescein dye 
was observed after 24 hours incubation at room temperature. 





Overall, the carboxyfluorescein release assays showed that the encapsulation of the dye 
reservoir is dependent on Eudragit film thickenss. For further prototype production, 20 dip 
coats of Eudragit was employed, as it was concluded to provide an accurate fluorescence signal 
associated with infection by P. mirabilis and subsequent crystalline biofilm formation.  
Figure 2.14: Encapsulation efficiency of 20 coats of Eudragit S100 at pH 6, 7 and 8. 
Coatings remained stable at pH 6 and 7 for 24 hours. No observable leaching of the dye 
was observed at simulated ‘healthy’ urine pHs. At pH 8, the rate of dye release was 
slower than for thinner film thicknesses, although maximum fluorescence output was 
observed after 6 hours incubation. 
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2.4.4. Sensor Coating Prototypes: In Vitro Evaluation  
2.4.4.1. Bladder Infection Models  
To evaluate the ability of the dual-layered diagnostic system to provide warning of impending 
catheter blockage following infection by P. mirabilis, the performance of coated catheters was 
assessed using the in vitro bladder model system, originally described by Stickler et al.48 This 
model represents a full sterile closed-drainage system, as used in clinical practice, and provides 
a good representation of the in vivo catheterised urinary tract. Although studies on biofilms in 
models such as the modified Robbins device,59 the constant film fermenter60 and the flow cell,48 
have provided valuable fundamental information about the properties and developments on 
different types of materials in various conditions, the in vitro bladder model allows the study 
of biofilm formation under conditions in which the design features of the catheter, and the 
hydrodynamics of the catheterised bladder are considered. 
Triggered release coatings containing carboxyfluorescein were applied directly to the top 1 cm 
of the distal tip of the catheter, above the retention balloon. Since the coating resides below the 
level of the catheter eyeholes, once the catheter is fitted the coated region sits within the pool 
of residual urine that forms within the bladder. Dye released from the sensor coatings may 
then travel to the collection bag, where its fluorescent signal may be detected by eye in advance 
of catheter blockage. Blockage can be readily identified in the bladder model system by 
monitoring the flow of urine. The flow of artificial urine supplied by the peristaltic pump is 
maintained at a constant flow rate of 0.75 mL/min, thus the running time of the model can be 
accurately determined by the volume of accumulated urine within the drainage bag. The mean 
natural filling rate of the bladder in a group of patients with an average age of 62.5 years, was 
found to be 0.76 mL/min.61 Hence, this flow rate was used for all bladder model assays, in order 
to accurately mimic physiological conditions.  
Since changes to the catheter surface may influence the rate of bacterial biofilm formation, it 
was first confimed that the coated catheters did not alter the ability of P. mirabilis to form 
crystalline biofilms and cause catheter blockage in this model system. In models containing 
coated catheters, P. mirabilis was able to rapidly infect and encrust catheters, causing complete 
catheter blockage in an average time of 16 hours. This is comparable to the time taken for the 
same bacterial strain to cause blockage in uncoated catheters under the same experimental 
conditions. In congruity with previous studies,62,63 the encrustation and blockage of catheters 
was associated with an increase in urinary pH to an average value of 8.55. No significant 
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differences were observed in the ability of P. mirabilis to elevate urinary pH or grow and persist 
in the system in models fitted with coated catheters, in comparison to uncoated controls. 
(Figure 2.15) 
Artificial urine was deemed the most suitable medium for prototype testing, as the composition 
may be tightly controlled, meaning that batch-to-batch variation is eliminated. However, the 
model may also utilise pooled human urine, which suffers primarily from patient-dependent 
variability of composition (both inter- and intra-subject variability). Nevertheless, pooled 
human urine may provide certain advantages in later-stage prototype development since it is 
more representative of the in vivo conditions within the urinary tract.64 
Figure 2.15: Assessment of coating impact on behaviour of P. mirabilis within the in vitro 
bladder model system. (A) Time taken for the catheter to block in models fitted with coated 
or uncoated Foley catheters. (B) Urinary pH elevation in models inoculated with P. mirabilis 
fitted with coated or uncoated catheters. The pH of uninoculated artitifical urine media was 
6.10. Data shows the average number of pH units by which the pH rose between model 
activation and catheter blockage time. (C) Number of viable cells present in residual bladder 
model urine at model start, and at the time of catheter blockage. Data shown are the mean of 
triplicate repeats. Error bars represent SEM. 
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The limitations of this model are primarily related to the quantification of biofilm growth. Since 
the catheter is contained within the bladder, it is impossible to constitute a system in which 
fine differences in the abilities of different biomaterials to support bacterial growth can be 
quantitifed and resolved. Nevertheless, this model has proven instrumental in providing 
information regarding the formation, physiology and control of catheter biofilms. In this work 
in particular, these models have proven invaluable in assessing the variance in blockage times, 
as well as the degree of advanced warning achieved from the diagnostic coatings.  
2.4.4.2. Activation of Catheter Coating and Advance Warning 
of Blockage  
The duration of early warning provided by the triggered-release coatings was assessed using 
the in vitro bladder model system as described. Dye release and subsequent urine colour 
change was monitored throughout the course of the experiment, and the time between visual 
urinary colour change and catheter blockage was calculated. The blockage of catheters in 
models infected with P. mirabilis was deemed the experimental end-point. 
Since the application of this technology will often be in alerting patients and/or carers in the 
ambulatory care environment, the visual signal is required to be easily visible without the use 
of specialist equipment. Therefore, the sensor coating deployment was based on direct, 
subjective assessment of colour change by eye, under ambient lighting. Visual observation of 
carboxyfluorescein release was used to prompt associated quantitative analysis of urinary 
fluorescence, viable cell count and pH of residual urine. The response of coatings to models 
infected with E. coli was also evaluated, as this species is unable to express urease, and thus 
unable to cause catheter encrustation and blockage. The ability of the coatings to discriminate 
between urease-producing P. mirabilis and non-urease producing E. coli was vital for 
preventing false positive results, therefore allowing for accurate warning of impending 
blockage. 
In models devoid of of P. mirabilis, no visible colour change was observed in the collected urine. 
In uninoculated models, or those infected with E. coli, coatings remained intact, hence no dye 
release was noted at any point during the experiment (Figure 2.16). This demonstrates the 
stability of the coatings in the absence of urease. In models infected with P. mirabilis, a distinct 
colour change was observed within urine contained within the bladder models at an average 
of 4.2 hours after the model start. Despite being clearly visible within the residual bladder 
 Chapter 2  
66 
 
urine, the signal was not visible with in the drainage bag until 6.2 hours after the start of the 
experiment (Figure 2.17). 
 
Average catheter blockage time of models inoculated with P. mirabilis was 16 hours. The 
intensity of urine colouration was slightly reduced over the course of the experiment, although 
remained visible within the drainage bag for the duration. Removal of Foley catheters from the 
control and P. mirabilis models 24 hours after the experimental start (8 hours post-blockage) 
confimed that whilst encapsulated dye had been released in response to the urease-positive 
species, the coating in the control models had remained intact, despite constant contact with a 
continuously flowing liquid culture.  
Dye release and urinary color change observed visually were correlated with changes in pH of 
residual bladder urine (Figure 2.18a). A rise in urine pH of 1.2 pH units (from 6.1 to 7.3) was 
recorded at the point of initial colour change (4.2 hours). This further increased to a maximum 
of pH 8.6 at time of blockage. 
Figure 2.16: Representative images showing coating activation during the course of 
prototype testing in an in vitro bladder model system. Columns show models infected with 
urease-positive P. mirabilis, or urease-negative E. coli species, or control models devoid of 
bacteria. Rows show bladder models at key time points related to observed coating 
activation. For initial and strong colour change, values in parentheses indicate the average 
time after model start at which the colour change was observed ± SEM. 
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The measured fluorescence of bladder urine (Figure 2.18b) within P. mirabilis models also 
corresponded with the observed response. A significant increase in fluorescence (ca. 20-fold) 
at the point of initial colour change (4.2 hours), which increased 5-fold at the point of maximum 
visual response. The reduction in visual fluorescence at the time of blockage is primarily owing 
to dilution effects of the continuous urine flow, and the exhaustion of the dye reservoir within 
the catheter coating.  
Overall, when considered in the context of catheter blockage, the infection-responsive coating 
gives a urinary colour change approximately 10-12 hours in advance of blockage, which is 
sufficient to permit intervention before the onset of any serious clinical complications. In 
comparison to the bromothymol blue sensor previously described (Section 2.1.2), the 
performace of the catheter coatings compares well to the sensor in early-scale laboratory trials. 
Moreover, the incorporation of pH-sensing functionality into a catheter surface coating has 
numerous advantages over systems that require fabrication and use of additional components. 
The use of an additive system component introduces additional cost and complexity for 
patients and carers, as well as adding junctures at which the sterility of the system may be 
compromised. Such issues were highlighted in pilot-scale clinical trials of the bromothymol 
blue-based sensor, where some patients reported issues with leakage, ease of use, and the 
ability to conceal the catheter drainage system.12 
Figure 2.17: Visual colour change within urine collection bag in response to uninoculated 
standard catheter control (A), and P. miraiblis-infected coated catheter. Images are 
representative of triplicate repeats at 6.2 hours after model start. 




Figure 2.18: Analysis of in vitro bladder model conditions. (A) pH of residual urine within the 
bladder model at model start (0 hours), initial colour change (average 4.2 hours), maximum 
colour change (average 6.2 hours), and catheter blockage (average 16.1 hours). (B) Measured 
fluorescence of bladder model urine at previously mentioned time points. **** p < 0.0001. 
Data shown are the mean of triplicate repeats. Error bars represent SEM. For (B) only, ## p < 
0.01; #### p < 0.0001 P. mirabilis at 0 hours vs. P. mirabilis at 6.2 hours. 
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2.5. Conclusion  
The research presented in this chapter describes the design and optimisation of an infection-
responsive surface coating for urinary catheters, able to provide a clear and unambiguous 
colour change in response to elevated urinary pH following infection by P. mirabilis. The 
fluorescent signal observed, following triggered release of the self-quenching dye 5(6)-
carboxyfluroescein from the coating system, provides early warning of catheter blockage, 
permitting clinical intervention prior to the onset of serious clinical consequences. 
Performance was evaluated within a clinically relevant in vitro bladder model system, where a 
urinary colour change  was detected approximately 10-12 hours in advance of catheter 
occlusion. Performance was comparable to previously described sensor systems, although the 
implementation of this approach holds considerable manufacturing and practical advantages, 
since the design is compatible with the existing Foley catheter design. Coatings were able to 
successfully discriminate ureolytic pathogens from non-urease producers. Generally, urease 
activity in species other than P. mirabilis is insufficient to raise urinary pH beyond the 
nucleation point (pH ~7.4). Indeed, among these species, only Providencia rettgeri, Morganella 
morganii and Proteus vulgaris have been reported to elevate urinary pH above 7, thus causing 
catheter encrustation.65 However, as the coating is designed to respond to an elevation in 
urinary pH (rather than direct detection of urease activity or species-specific factors), the 
coating should, in principle, be able to detect impending blockage by any urease-positive 
species. 
Perhaps the  principal advantage  of the surface coating approach described in this work is the 
potential to add further functionality to the system via the incorporation of additional active 
cargos into the hydrogel reservoir. Overall, this dual-layered coating system provides sound 
proof-of-concept for the formulation of a therapeutic coating, which will  include agents to 
actively delay catheter blockage, thus extending the lifetime of the catheter and providing a 
significant positive impact on patient welfare via the reduction in blockage-associated 
complications.  The potential to release antimicrobial species directly into the bladder allows 
targeted treatment , both in terms of release location and treatment time.  The employment of 
location-specific triggered release may bypass complications traditionally associated with 
systemic drug administration, such as unfavourable pharmacokinetic or pharmacodynamic 
effects.  
The limitations of this system lie within the regulatory differences between classes of medical 
device, and in vitro diagnostic devices. Since the catheter coating described in this chapter has 
been designed to function within the body, it would likely be subject to more stringent 
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regulatory testing in later clinical trials. By contrast, in vitro diagnostic devices function outside 
the body. Thus, the risk associated is purely regarding the information they reveal (i.e. the 
occurance of false positive/negative results), rather than a direct effect of the device with the 
patient.66 If this system can be modified such that it does not come into direct contact  with the 
patient, yet is still able to deliver the same information within a similar time frame,  the 
regulatory issues surrounding this medical device will be significantly eased.  Futhermore, the 
relocation of the diagnostic system described to an  ex vivo diagnostic , may allow the 
perceptible fluorescence response to have greater visual strength and longevity, since the 
release of carboxyfluorescein will be external to the bladder and will not rely on elusion to 
enable visualisation. The externalisation of the diagnostic system may also allow the distal tip 
of the catheter to remain free for a pH-responsive coating containing a therapeutic agent, thus 
allowing the potential construction of a theranostic system within the catheterised urinary 
tract. 
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Chapter 3: Development of an Ex-Vivo ‘Lozenge’ 
Sensor for the Early Detection of Urinary Catheter 
Blockage 
3.1. Abstract  
This research is presented as an extension of the previous study reported in Chapter 2; the 
exploitation of pH as a proxy indicator of infection by P. mirabilis. In this case, the pH-
responsive sensor is a dual-layered polymeric ‘lozenge’, able to release a fluorescent dye 
directly into the catheter drainage bag in response to alkaline urine (generated by the 
expression of bacterial urease). The system comprises a cylindrical hydrogel reservoir (PVA), 
containing the dye (5(6)-carboxyfluorescein), completely capped and sealed by the pH-
sensitive polymer Eudragit S100. The sensors are placed directly into the urine drainage bag, 
thereby allowing a greater concentration of dye to be released into the visual portion of the 
catheterised urinary tract, providing an explicit urinary colour change signalling imminent 
catheter blockage (Figure 3.1). 
Unlike the previously reported system, the lozenge sensor design avoids potential adverse in 
vivo effects such as urethral inflammation or promotion of microbial adhesion via deposition 
of a conditioning film on the luminal and external catheter surfaces. Furthermore, localised dye 
release within the catheter drainage bag enables the technology to bypass many of the 
stringent regulations surrounding indwelling medical devices, and leaves the distal tip of the 
catheter available for the incoportation of a therapeutic coating (Chapter 4). Since many 
patients suffering from recurrent catheter blockage are in community care, the system 
described here provides a means of alerting the patient themselves to catheter blockage, 
without the need for acquisition and analysis of urine samples.  
Figure 3.1: Schematic representation of the dual-layered polymeric lozenge sensor. 
Generation of an in situ fluorescent signal provides ‘early warning’of catheter blockage 
following degradation of the sensor and release of 5(6)-carboxyfluorescein. Sensor activation 
is triggered in response to alkalinsation of urine upon infection by P. mirabilis. 




3.2.1. Medical Technology: Innovation to Commercialisation  
As medical devices play an ever-growing role in the diagnosis and management of disease, the 
global medical device industry has surpassed US $350 billion in annual revenue. The UK is the 
third largest market for medical technology in Europe, consisting of 3,000 companies with a 
combined turnover of £15 billion, employing in the region of 115,000 highly-skilled personell.1  
Whilst innovation lies in the heart of academia, commercial translation of intellectual property 
is often poor, particularly within the healthcare sector. Conversion of research from lab to clinic 
traditionally lacks success and efficiency. Only half of recommended healthcare practices are 
implemented, and the process of translation often takes upwards of 15 years to effectuate.2 The 
barriers to translation are various and interrelated, and include inadequate research program 
design, insufficient marketing, or regulatory issues arising from the inherent differences 
between the academic and clinical setting.3 In healthcare technology, the NHS have identified 
a need for the encouragement of universities to commercialise research. The National Institute 
for Health Research (NIHR) was established in 2006 to improve patient and service outcomes 
via creating and nurturing relationships between universities and industry. The NIHR also 
have the ability to fund collaborative research projects, whereby the migratory pathway to 
success is significantly increased. One such example is the Invention for Innovation (i4i) 
programme, which has been successfully applied to research and development of medical, 
active implantable, and in vitro diagnostic (IVD) devices.4 
Medical device regulation (MDR) and in vitro diagnostic regulation (IVDR) are independently 
vast and rapidly growing fields, that are often complicated by legal technicalities. The design 
of novel medical devices that conform to regulations such that they may proceed through pre-
market surveillance without hinderance is rare in academia. Hence, any potentially 
commercialisable product developed within a university setting may benefit from undergoing 
subsequent design iterations which prepare it for the long and arduous journey to market. In 
particular, the ability to identify the class of the device (i.e. as medial device or IVD, as well as 
the subclass of these fields) at the conceptual stage may aid the design in undergoing a defined 
route to market.2 
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3.2.1.1. Medical Devices  
The European MDR (Article 2(1))5 defines the term ‘medical device’ as any instrument, 
apparatus, appliance, implant, reagent, software, material or similar article, intended to be 
used, alone or in combination, for human beings for one or more of the following medical 
purposes:6 
 Diagnosis, prevention, monitoring, treatment or alleviation of disease, disability or 
injury; 
 Investigation, replacement, modification or support of the anatomy or of an anatomical, 
physiological or pathological process; 
 Supporting or sustaining life; 
 Control of conception ; 
 Disinfection of medical devices; 
 Providing information for medical purposes by means of in vitro examination of 
specimens derived from the human body.  
Manufacturers of medical devices are required to determine the classification of their product, 
in order to determine the route to compliance. The four classes of medical device are shown in 
in Figure 3.2. 
Figure 3.2: The four classes of medical device. Device manufacturers may use the 
classification rules in annex VIII of the MDR to accurately categorise novel products. 
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Devices which incorporate or administer a drug (e.g. medicated urinary catheters) often fall 
within a ‘grey area’ between medical device and medicinal product. Specifically, devices 
incorporating a medicinal product which may act upon the body with action ancillary to that 
of the device, are not only subject to MDR, but also must be verified with regards to the safety, 
quality and usefulness of the proprietary medical substance. Such a device would fall into Class 
III of the medical device directive, owing to the increased complexity and risk of the secondary 
function.7  
3.2.1.2. In Vitro Diagnostic Devices 
An IVD device is defined within the IVDR (Article 2(2))8 as any reagent, product, control 
material, kit, instrument, apparatus, software or system, intended to be used for the in vitro 
examination of specimens derived from the human body, for the purpose of providing 
information on one or more of the following: 
 A physiological or pathological process or state; 
 A congenital physical or mental impairment; 
 Predisposition to a medical condition or disease; 
 Determination of safety and compatibility with potential recipients; 
 Prediction of treatment response or reaction; 
 Monitoring of therapeutic measures.  
The original IVD Directive,9 created in 1993, was generated for a fledgling industry, without 
broad scope or scalability. Changes in the regulatory landscape were thus introduced in 2017 
to account for its inevitable evolution. The new legistalation requires up to 90% of IVDs to be 
approved by notified bodies, compared to the old IVD Directive, in which 90% of the industry 
could self-certify. In addition to increased pre-market scrutiny, a new rule-based classification 
system is to come into effect, superceeding the current list-based approach.10  
IVDs are catergorised in order of increasing perceived risk according to Figure 3.3. If devices 
are intended to be used in combination, classification rules apply separately to each device.  




Innovation in diagnostics has become a major focal point of the NHS and NHIR within recent 
years. Approximately three quarters of all clinical decisions are made based on the results of 
standard diagnostic tests, many of which were previously only available in laboratory or 
hospital settings, but are now readily available as bedside POC or self-tests. Hence, recent 
regulatory changes aim to improve clarity regarding approval ,adoption and reimbursement of 
novel IVDs.11 
3.2.1.3. CE Certification 
A medical device may not be marketed or sold in Europe without a Conformité Européene (CE) 
mark, which is affixed by the manufacturer and indicates that the device meets the essential 
requirements of, and is compliant with, all relevant EU legislation. In order to apply for a CE 
mark, a conformity assessment procedure must be undertaken, the level of which reflects the 
perceived risk associated with the device (depending on its classification). For class I/A 
devices, the declaration of conformity is made by the manufacturer themselves. For higher 
classifications, conformity must be assessed by a notified body.  
Figure 3.3: Classes of in vitro diagnostic device. Device manufacturers may use the 
classification rules in annex VII of the IVDR to accurately categorise novel products. 
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Recent changes in the legislational landscape are also reflected in the Clinical Trial Regulation 
(CTR),12 which, after implementation in 2019, will replace the exisiting EU Clinical Trial 
Directive (EC) No. 2001/20/EC,13 thus altering the way that clinical trials are conducted and 
recorded. The regulation harmonises the assessment and supervision processes for clinical 
trials throughout the EU, to both avoid unnecessary duplication of successful trials, or 
repetition of unsuccessful trials.  
3.2.1.4. The Future of Medical Technology 
In 2017, changes to MDR were made in response to concerns that medical devices and in vitro 
diagnostics, especially those that pose a high risk to the human body (e.g. breast implants), are 
not currently subject to sufficiently rigorous pre-clinical testing. To combat this, recently 
introduced legislational changes aim to strengthen regulation surrounding clinical 
investigation, promote control and monitoring of European medical device manufacturing and 
marketing, and encourage greater transparency and traceability throughout the product 
marketing process. Though these changes are likely to have a major impact on the medical 
technology industry, affected companies have only until 2020 (MDR) or 2022 (IVDR) to fully 
implement these changes, many of which are transformative.  
Since EU directives are currently transitioning to a new MDR and  IVDR, the withdrawal of the 
UK from the EU, universally referred to as ‘Brexit’, is causing a double transitional headache 
for the medical device industry in the UK, as the pathway to regulatory change remains 
uncertain. Previously, many low-risk medical devices that could formerly be marketed within 
the EU by obtaining CE Certification via self auditing (aided by notified bodies), will now be 
subject for far more stringent enforcement. New regulation expands the requirement for 
clinical trials to include low-risk IVD tests, which have never previously undergone clinical 
testing in Europe. Indeed, the German notified body Technischer Überwachungsverein (TUV) 
estimates that over 500,000 medical devices will require recertification in 2019 in order to 
comply with regulations. 
3.2.1.5. Emerging Technologies for CAUTI 
The current clinical need for efficient diagnosis of CAUTI and subsequent catheter blockage is 
considerable. The ability to initiate evidence-based treatment or preventative measures, 
following rapid profiling of bacterial pathogens may significantly improve patient care and 
stem the emergence of multi-drug resistant uropathogens.  
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Current screening assays for bacteriuria include dipstick tests for detecting nitrites, 
microscopic urinalysis, and urine Gram staining. Urine dipticks, whilst readily available and 
simple to use, are inadequately sensitive.14 A meta-analysis of 34 studies assessing the accuracy 
of the nitrite dipstick test in a variety of clinical settings found a mean sensitivity of 48% for 
the detection of clinically significant bacteriuria (>105 CFU/mL).15 
Recent developments in the POC detection of CAUTI generally revolves around rapid 
microbiological quantification and antibiotic susceptibility testing, as a development from 
traditional culturing methods (which are both time consuming and lacking in clinical 
accuracy). Novel diagnostic platforms, such as nucleic acid tests,16 mass spectrometry,17 
electrochemical biosensors,18,19 microfluidics20 and lab-on-a-chip technology21 have largely 
been approved for clinical use and thus improved the speed and accuracy of pathogen 
identification from primary cultures.22 So called ‘electronic noses’ have been developed as a 
screening tool for bacteriuria, able to minic the olfactory system to detect a specific signature 
of volatile organic compounds (VOCs) produced by bacteria. The eNose (Specific Technologies) 
utilises ion mobility spectrometry to assess a VOC profile in just 15 minutes. Cultured 
uropathogens isolated from patient samples were detected with 95% sensitivity and 97% 
specificity,23 although testing with unaltered urine sampes may cause inaccurate results owing 
to the variability of VOCs in urine. Nevertheless, the simplicity of VOC-based label-free 
biosensing renders it a promising approach for low-resource settings.22 
The majority of developments in this field have been targeted towards decreasing turnaround 
time and enhancing throughput for batch processing. Thus far, very few attempts have been 
made to diagnose relevant clinical outcomes of CAUTI (e.g. catheter blockage) specifically, 
often resulting in common recurring catheter blockage and subsequent patient ill-health.24,25 
Despite substantial improvements in sensitivity and specificity in CAUTI biosensors in recent 
years, the commercialisation of such products is still in its infancy. Translation from lab to clinic 
appears to present significant challenges, owing to the differences between in vitro and in vivo 
samples. Whilst most biosensors appear to perform well with pristine samples in early stage 
testing (e.g. pure bacterial cultures, supernatants and artificial simulation fluids), unprocessed 
sampes, particularly urine, can be highly varied. Differences in salt concentration, pH and 
viscosity can interefere with analyte detection and may cause a high proportion of false 
positive/negative results in the clinical setting.22
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3.3. Materials and Methods 
3.3.1. Materials  
Materials for the development and in vitro analysis of polymeric lozenge sensors were 
purchased according to Chapter 2. 
3.3.2. Methods  
3.3.2.1. Microbiological Methods 
Bacterial culture and quantification protocols were followed according to Chapter 2. 
I. Preparation of Bacterial Supernatants 
Bacterial overnight cultures (grown from a single bacterial colony), were centrifuged (4,000 
rpm, 20 minutes) to pellet whole cells. The liquid phase of each sample was collected, sterilised 
by filtration (0.22 μm pore size) to remove any residual cells, and used immediately. 
Sedimented cells were discarded.  
II. Preparation of Bacterial Subcultures 
Bacterial overnight culture (10 μL  in LB media) was added to artificial urine media (10 mL). 
1:1000 subcultures were grown at 37 °C with agitation to assess sensor response.  
III. Correlation of Viable Cell Count with Urinary pH 
The point at which sensor ‘switch on’ was achieved was evaluated using 1:1000 subcultures of 
P. mirabilis B4 and E. coli NSM59. Cultures were grown into the exponential phase over 3 hours. 
Samples (100 μL) were removed at 10 minute intervals for analysis of bacterial bioburden (via 
serial dilution and plating on NSLB agar). Plates were incubated overnight and viable cell 
numbers quantified via colony counting. Measurements of subculture pH and fluorescence 
were also recorded at 10 minute intervals using an electronic pH meter (Jenway 3540), and 
microplate reader, respectively. 
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3.3.2.2. Materials Preparation  
Solutions of 5(6)-carboxyfluorescein, phosphate buffer (pH 6, 7 and 8), PVA and Eudragit S100 
were prepared according to Chapter 2. 
I. Dip Coating Optimisation  
Lozenge sensors were prepared according to Section 3.2.2.2.II, and dip coated with 30, 40 or 
50 coats of Eudragit S100 solution to assess dye retention with varying coating thickness. 
Release was assessed via overnight incubation at room temperature in phosphate buffer (10 
mL) at pH 6 and 8. Fluorescence output was monitored using a microplate reader according to 
Chapter 2. 
II. Preparation of pH-Sensitive Lozenge Sensors 
To carboxyfluorescein solution (250 mM, adjusted to pH 6) was added PVA (14,000-18,000 
g/mol, 15% w/v) and heated to 97 °C with constant stirring to facilitate diffusion. The resultant 
hydrogel (1 mL) was cast into a 24-well microplate containg a 2 cm length of sterilised cotton 
thread (Figure 3.4), and stored at -20 °C overnight to promote cryogenic crosslinking.  
Figure 3.4: Dimensions of the pH-responsive polymeric lozenge sensors (containing self-
quenched 5(6)-carboxyfluorescein), showing the positioning of the sterile thread. 
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Sensors were thawed at room temperature (4 hours) before dip coating with Eudragit S100 
trigger layer via suspension from the thread. Sensors were manually dip-coated 50 times, with 
a 5 minute solvent evaporation period at room temperature between each coating. Coated 
sensors were stored at 4 °C until required. 
3.3.2.3. Evaluation of Sensor Performance 
I. Bacterial Subcultures 
Protoype sensors were evaluated for species selectivity using live cultures of P. mirabilis B4 
and E. coli NSM59 clinical isolates (~105 CFU/mL). Lozenge sensors were added to 1:1000 
bacterial subcultures in artificial urine, and changes in pH and fluorescence response as a 
function of dye release were measured via sequential sampling.  
II. Physiological Representation  
Evaluation of prototype sensors under physiologically representive conditions was performed 
in order to assess duration of ‘early warning’ provided. In vitro bladder models were assembled 
and run according to Chapter 2. Models simulating late-stage infection were inoculated with P. 
mirabilis or E. coli (108 CFU/ml) and supplied with artificial urine media at a flow rate of 0.75 
mL/min. Individual lozenge sensors were added aseptically to each drainage bag, and changes 
in visual urine color change were correlated with measured fluorescence output. Quantitative 
assessment of fluorescence response was undertaken using a microplate reader as above.  
III. Kinetics of Carboxyfluorescein Release  
To evaluate the quantity of, and rate at which the carboxyfluorescein dye is released from the 
sensors, the kinetics of dye release was analysed at pH 6, 7 and 8 (37 °C, phosphate buffer). Dye 
release from the lozenge sensors was monitored at regular time intervals, and subsequent 
graphs of initial release (first 15 minutes) were created. Standard curves of fluorescence 
intensity as a function of carboxyfluorescein concentration were also produced at pH 6, 7 and 
8 (linear portion only). Values of dye concentration were calculated from the standard curves 
in order to achieve graphs of carboxyfluorescein concentration vs. time from the original 
sensor release. Kinetic evaluation was not completed for pH 6, as release of dye was negligible. 
The gradient of the resultant graphs at pH 7 and 8 shows the rate (mol dm-3 min-1) of 
carboxyfluorescein release within the first 15 minutes of contact.
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3.4. Results and Discussion 
The optimisation of an infection-detecting polymeric lozenge for the early warning of catheter 
blockage, offers numerous advantages over the catheter coating concept described in Chapter 
2. Primarily, the design discussed in this chapter transforms the aforementioned technology 
from a Class IIb medical device, to a Class B in vitro diagnostic device. Hence, the regulatory 
pathway to CE marking and subsequent use within a clinical setting is significantly less 
onerous, owing to the lower level of perceived risk associated with such a device.   
3.4.1. Eudragit S100 Dip Coating Optimisation 
Since the lozenge sensor design incorporates a significantly larger volume of PVA reservoir 
than the original catheter coating, it was predicted that a considerably thicker film of the 
Eudragit S100 trigger layer would be required to provide sufficient entrapment efficiency of 
the dye within the hydrogel. Encapsulation of 5(6)-carboxyfluorescein was investigated in 
solutions of phosphate buffer at pH 6 and 8 to simulate healthy and infected urine, respectively. 
Film thickness (30, 40 or 50 dip coats) was deemed sufficient when a visible fluorescence 
output was obtained at pH 8, but not at pH 6.  
Figure 3.5: Encapsulation efficiency of 30 coats of Eudragit S100 at pH 6 and 8. Leaching of 
the fluorescent dye was observed upon room-temperature incubation of the lozenge sensor 
within phosphate buffer simulating healthy urine pH. 
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Dye retention within the hydrogel reservoir was insufficient after 30 coats of the polymeric 
trigger (Figure 3.5). Significant dye release was observed within the first hour of incubation in 
buffer solution mimicking healthy urine pH. When the film thickness was increased to 40 coats, 
carboxyfluorescein dye was more successfully retained within the central hydrogel region of 
the lozenge sensor (Figure 3.6). 
Lozenge sensors appeared stable at pH 6 after 3 hours incubation, as dye release and 
subsequent fluorescence ‘switch on’ was insufficient to cause a visual response. However, after 
overnight incubation, the structural integrity of the Eudragit shell was compromised, resulting 
in leaching of the loaded dye into the bulk solution. Dye release at pH 6 was less efficient than 
pH 8, yet sufficient to cause a visual colour change within the recipient medium. 
Analysis of dye retention within lozenge sensors coated with 50 dip coats of Eudragit S100 
showed effective encapsulation for the duration of the assay (Figure 3.7). Loaded dye was 
effectively maintained within the hydrogel reservoir in the presence of buffer mimicking 
healthy urine pH, but underwent a rapid and visually unambiguous fluorescence ‘switch on’ at 
pH representing urine infected with urease-positive species. As with the coating optimisation 
observed in Chapter 2, the rate of dye release appeared slower with increasing coating 
thickness, although still resulted in visual fluorescence within the first hour of incubation.  
Figure 3.6: Encapsulation efficiency of 40 coats of Eudragit S100. Visual dye release was 
observed after 23 hours incubation in phosphate buffer at pH 6 and 8. 
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Overall, analysis of carboxyfluorescein retention showed that dye encapsulation within the 
hydrogel matrix is dependent on Eudragit film thickness. Protoype production will henceforth 
be completed with 50 coats of Eudragit polymer, as this provides the optimum compromise 
between sensor stability and production time. 
3.4.2. Kinetics of 5(6)-Carboxyfluorescein Release 
The rate at which loaded dye was released from the lozenge sensors was evaluated at pH 6 
(healthy urine pH), pH 7 (Eudragit dissolution threshold), and pH 8 (infected urine pH) (Figure 
3.8). Fluorescence response from sensors was monitored over a 2 hour period, until the release 
at pH 8 had reached a steady state (Figure 3.8A). Initial rate was estimated within the first 15 
minutes of exposure of lozenge sensors to phosphate buffer at relevant pHs, as  this was the 
region in which a visual response was obtained (Figure 3.8B). Values of carboxyfluorescein 
concentration were read from a standard curve at the appropriate pH  (Figure 3.8C/D) in order 
to obtain graphs detailing increasing carboxyfluorescein as a function of time (Figure 3.8 E/F). 
The gradient of the resultant graph is equal to the initial rate of dye release in units of mol dm-
3 min-1. Cumulative release from the polymer matrix at pH 6 was negligible, hence calculation 
of release rate was not possible with this method. 
Figure 3.7: Encapsulation efficiency of 50 coats of Eudragit S100 at pH 6 and 8. Coatings 
remained stable for the duration of the 24 hours incubation at healthy urine pH. Rate of dye 
release into the recipient medium  




Figure 3.8: Determination of 5(6)-carboxyfluorescien release from pH-sensitive lozenge 
sensors at pH 7 and 8. Empirical dye release was monitored over the course of 120 minutes at 
physiological pHs (pH 6, 7 and 8) (A). Initial release was defined as the first 15 minutes of 
release, within which the fluorescence output was linear (B). Standard curves of fluorescence 
intensity as a function of [carboxyfluorescein] at pH 7 (C) and pH 8 (D) were used to evaluate 
the kinetic release of dye from the sensors at each pH (E, F for pH 7 and 8 respectively). Rate 
of release could not be analysed at pH 6, owing to negligible dye release. Data shown are the 
mean of triplicate repeats. Error bars represent SEM. 
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Rate of initial release of carboxyfluorescein at pH 7 and 8 are shown in Table 3.1. Observed 
release was seen to vary with pH as predicted, with the greater rate of release observed for the 
more highly alkaline buffer pH. 
Table 3.1: Initial release of 5(6)-carboxyfluorescein from lozenge sensors at pHs 
representing healthy (pH 6) and infected (pH 8) urine 
 pH 7 (±SEM) pH 8 (±SEM) 
Initial release (mol dm-3 min-1) 5.3x10-8 ± 8.4 x10-9 1.5x10-7 ± 1.9 x10-8 
 
Maximum release of carboxyfluorescein was estimated to be 3.5 mM after 2 hours exposure to 
phosphate buffer at pH 8. Thus, despite only approximately 14% of the total encapsulated dye 
being released from the PVA reservoir, the resultant fluorescence output lies within the most 
strongly luminescent region of the fluorescent chromophore, according to Chapter 2.3.1. 
(Figure 7).  In effect, the conservation of the majority of the dye within the hydrogel reservoir 
may serve to retain signal strength over longer time periods.  
Kinetic release of a dye or other model drug from a multicomponent material system (i.e. 
integration of multiple materials with differing physicochemical properties) is known to be 
complex, and highly dependent on parameters such as delivery device size and shape. Such 
systems cannot be described using a single mathetmatical model, as release is driven by 
multiple factors (often working simultaneously to facilitate transport into the release 
matrix).26 Thus, the rate of dye release described in this work is primarily aimed to give a 
simple, semi-empirical estimate of relative dye release from the lozenge sensor. A simple 
model to describe the kinetics of drug/dye release from polymeric matrices can be described 
using the Korsmeyer-Peppas model as follows (Equation 1).27 
 
Where Mt and M∞ denote cumulative release at time t and at infinite time, respectively. k is the 
release rate constant and n is the release index, indicative of the release mechanism. For a slab 
structure, when n = 0.5, Fickian diffusion is observed, whilst 0.5 < n < 1.0 indicates non-Fickian 
diffusion (n > 1.0 for mass-transfer following a non-Fickian model).28 In the case of a cylinder 
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carboxyfluorescein release kinetics using the Korsmeyer Peppas model was fitted according to 
Equation 2. The resultant graph is shown in Figure 3.9. 
 Mt
M∞
= ktn → ln (
Mt
M∞
) = ln(k) + n ln(t) 
(2) 
Where ln(k) is the intercept and n is the slope of the fitted straight line ln(Mt/M∞) vs ln(time). 
The exponent n was calculated to be 0.48 ± 0.025, confirming that dye release is governed by 
Fickian diffusion. The process of diffusion-controlled drug release via an aqueous stimulus has 
distinct advantages in terms of the timing and control of the system’s response. For example, 
the rate at which water may swell the matrix of a crosslinked system is greater for diffusive 
systems than those governed by degradation or dissolution. In the lozenge reservoir system, 
the swelling effect is seen as a nonuniform volume expansion, whereupon swelling of the 
barrier coating results in rapid aqueous diffusion from the internal components of the system. 
3.4.3. Evaluation of Sensor Performance: Artificial Urine Supernatant 
The ability of the sensors to release their fluorescent cargo in response to elevated artificial 
urine pH was evaluated using supernatant solutions of P. mirabilis B4 (average pH = 8.98) and 
E. coli NSM59 (average pH = 6.10). Sensor stability in sterile artificial urine was also evaluated, 
to ensure that no fluorescence output was obtained as a result of interactions between the 
Figure 3.9: Korsmeyer-Peppas release plot for kinetic evaluation of 5(6)-carboxyfluorescein 
release at pH 8 (r2 = 0.99). 
 Chapter 3  
91 
 
Eudragit S100 ‘shell’, and the high ionic-strength artificial urine. Measured fluorescence 
intensity of artificial urine supernatants is shown in Figure 3.10.  
Since E. coli species are unable to express urease, the pH of the supernatant remained 
equivalent to that of the uninoculated artificial urine. Visual dye release was only observed for 
the urease-positive P. mirabilis supernatant, where the average urinary pH surpassed that of 
the Eudragit S100 swelling threshold.  
3.4.4. Evaluation of Sensor Performance: Artificial Urine Subcultures 
3.4.4.1. Correlation of Bacterial Bioburden with Urinary pH 
The point at which sensor ‘switch on’ was achieved was evaluated using 1:1000 subcultures of 
P. mirabilis in artificial urine media. Urinary pH elevation to to pH 8 was achieved in 150 
minutes of incubation, owing to the expression of urease and subsequent urea hydrolysis 
within the media. The threshold pH at which the Eudragit ‘trigger’ layer undergoes swelling as 
a consequence of repulsion (pH 7) was achieved at approximately 135 minutes. This 
corresponded to the transition period of bacterial replication from lag phase to exponential 
Figure 3.10: Analysis of sensor performance in artificial urine supernatants of P. mirabilis 
and E. coli species. Average pH of supernatants was 8.98  for urease-positive and 6.10 for 
urease–negative species, thus mimicking the urine of infected and healthy patients, 
respectively.  
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growth phase (Figure 3.11). Approximate bacterial concentration at this point was 7.45 x106 
CFU/mL. 
 
These findings agree with previous observations made by Dattelbaum et al,30 who reported 
that expression of urease with cultures of P. mirabilis was greatest at the mid-exponential 
phase. Moreover, since a substantial increase in urease production is associated with swarmer 
cell differentiation and expression of virulence factors, it is likely that P. mirabilis undergoes a 
coordinated virulence ‘switch on’ upon entering the exponential phase of growth.31 Indeed, 
previous investigation into the effects of the known anti-swarming agent p-
nitrophenylglycerol (PNPG) revealed that the expression of virulence factors such as protease, 
urease, haemolysin and flagellin were inhibited in addition to the transformation to 
hyperflaggerlate swarmer cell structure, upon incubation with PNPG.32 
Figure 3.11: Evaluation of sensor ‘switch on’ using 1:1000 subculture of P. mirabilis in 
artificial urine. Urinary pH elevation owing to urease-mediated urea hydrolysis, and 
corresponding increase in bacterial bioburden during transition from lag phase to 
exponential growth.  
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3.4.4.2. Species Selectivity  
Elevation in urinary pH was found to correspond to a rapid and observable increase in 
fluorescence response as function of carboxyfluorescein release from lozenge sensors (Figure 
3.12). 
Fluorescence emission was observed only in the presence of P. mirabilis, owing to expression 
of urease and subsequent accumulation of NH3 within the artificial urine medium. E. coli was 
used as a control species, since it is unable to elevate urinary pH to alkaline values.  
Figure 3.12: Analysis of sensor performance in artificial urine subcultures, modelling the 
onset of CAUTI. A) pH-elevation of P. mirabilis (urease-positive) and E. coli (urease-negative) 
cultures. B) Corresponding fluorescence emission of prototype sensors upon release of 
carboxyfluorescein. 
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Limitations of this model, however, prevent speculation as to the performance of sensors in 
vivo. The absence of a continuously replenishing culture renders the cells nutrient-limited after 
a finite time period, thus such a system is not indicative of the catheterised bladder. 
Furthermore, the volume limitations (10 mL) imposed on such cultures limit the information 
gained on the strength of the visual colour change obtained within a full-sized catheter 
drainage bag (2 L capacity). Overall, this model proved the species-specific capabilities of the 
lozenge sensors in the presence of live bacterial cultures, but gave no information on the nature 
of the colour change or duration of early warning in a clinically relevant setting.  
3.4.5. Evaluation of Sensor Performance: In Vitro Bladder 
Models 
Capability of the lozenge sensor prototypes to provide advance warning of impending catheter 
blockage was evaluated in a clinically relevant in vitro model of the catheterised urinary tract. 
This model replicates the closed drainage system in its entirety, thus providing an accurate 
represenatation of conditions within the catheter drainage bag. Sensor ‘switch on’ was defined 
as the point at which a visual color change was observed in residual urine within the collection 
bag. Fluorescence output was judged by eye under ambient lighting, in order to mimic 
conditions in which a patient may undergo self-evaluation of their proximity to catheter 
blockage.  
Observation of visual dye release prompted quantitative anaylsis of urinary fluorescence 
(Figure 3.13), so that the concentration of carboxyfluorescein in residual urine may be 
estimated at different time points. The response of lozenge sensors to E. coli was also assessed 
to determine the selectivity of the sensors towards urease-positive species under physiological 
conditions. Inoculation of infected bladders with large bacterial bioburdens (108 CFU/mL) 
endevours to replicate conditions within the catheterised urinary tract of patients suffering 
form recurring blockage, where the blocked catheter is removed and immediately replaced, 
directly into the existing cultures of P. mirabilis (where residual urine may already exist at 
highly alkaline pHs, and contain aggregates of microcrystalline material).33 This situation 
occurs in up to 50% of long-term catheterised patients,34 who may experience recurring 
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blockage as soon as 2 days post catheter reinsertion. Thus, the conditions used within the in 
vitro model aim to test sensor performance under ‘worst case scenario’ circumstances. 
Dye release and consequent visual colour change within the drainage bag was observed 
approximately 3 hours after model start. This corresponded to an average urinary pH of 7.2, 
and an approximate carboxyfluorescein concentration of 2 mM within the drainage bag. 
Average blockage time of models inoculated with P. mirabilis occurred at 17.5 hours, 
corresponding to a urinary pH of 8.6. Hence, the bag sensors acheived an average early warning 
of blockage of 14.5 hours, with a range of 12.5-18 hours. The duration of warning was deemed 
sufficient to allow clinical intervention before the manifestation of serious clinical 
consequences.  
The appearance and progression of sensor activation within the bladder infection model is 
shown in Figure 3.14. Control bladders inoculated with E. coli exhibited negligible fluorescence 
emission throughout the duration (23 hours) of the experiment. 
 
 
Figure 3.13: Quantitative analysis of 5(6)-carboxyfluorescein release into residual artificial 
urine of P. mirabilis-infected models. Samples were removed from the drainage bag in 
response to subjective visual prompts. Time points represent average time of consequential 
events throughout the course of the experiment:  model start (0 hours), point of visual colour 
change (3 hours), and catheter blockage (17.5 hours). 




Since many patients undergoing long-term indwelling catheterisation are within the 
community care setting, the collection and analysis of urine samples may prove both complex 
and time-consuming. Using the lozenge sensor system, a clear and unambiguous visual color 
change is observed within the catheter drainage bag approximately 14 hours in advance of 
blockage following infection by P. mirabilis. Thus, the patient or carer may be informed of 
imminent catheter complications, facilitating timely intervention.  
Figure 3.14: Progression of lozenge sensor activation within an in vitro model of the 
catheterised urinary tract. A) Appearance of drainage bag at experiment start (0 hours). B) 
Point of visual colour change (3 hours) within model inoculated with P. mirabilis. C, D) Colour 
change of residual drainage bag urine at point of catheter blockage (17.5 hours): C) in 
bladder model inoculated with P. mirabilis (urease-positive), and D) in models infected with 
E. coli (urease-negative) species. Images are representative of triplicate repeats. 
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Sensor performance was comparable to other reported sensors,24,25,35,36 although the 
implementation of this approach provides significant advantages. The specific dissolution 
threshold of Eudragit S100 at pH 7 allows this system to be more sensitive to catheters 
progressing towards encrustation and blockage specifically, rather than asymptomatic 
bacteriuria. By comparison, the previously described bromothymol blue sensor responded to 
an increasing urinary pH over a broad range (pH 6-8),24 making it highly susceptible to false 
positive results as a consenquence of activation by healthy, uninfected urine.  
However, whilst the bladder infection model described provides an accurate in vitro depiction 
of the catheterised urinary tract, it is not fully representative of the catheterised bladder in 
vivo. Futher clinical studies are thus required to analyse the sensor performance in light of the 
full complexity and variation of these conditions. Progression to pilot-stage clinical trials will 
likely be expedited by the substantial advantages of this sensor design in terms of medical 
technology classification. Since the sensor is not intented for use within the body, and gives an 
easily-interpretable signal at the POC, it would likely be classified as a Class B in vitro 
diagnostic, rather than the Class III medical device coating described in Chapter 2. 
Consequently, this system would be subject to less stringent regulatory approval, potentially 
including self-certification by the device manufacturer.




Development of simple and accurate tests for highly specific clinical outcomes would represent 
a major milestone in the field of CAUTI. As scientific  knowledge of host-pathogen interactions 
increases, the next generation of POC diagnostics may be refined to analyse speficic infection-
responsive biomarkers. Providing an early, yet refined course of treatment might not only 
benefit the patient, but also result in improved antibiotic stewardship. 
The design constraints of the Foley catheter system, and the medical technology classification 
of the sensor were important considerations in the design of the lozenge system described. 
Since the currently used Foley catheter design has remained unchanged for decades, any 
technological advances involving redesign of the current system, or fabrication of additional 
components have thus far been rejected by the clinical community, owing to the additional cost 
and  complexity. Indeed, some of these issues were emphasised in the pilot scale clinical trials 
of the bromothymol  blue sensor,36 where some patients were unable or unwilling to accept an 
additional accessory to the existing layout. In constrast, the sensor system described here may 
be incoporated into all existing drainage bag designs, without altering patient experience. 
However, the insertion of the sensor into the bag must be taken into consideration. This 
process must take place at the point of manufacture, such that the sterility of the system is not 
compromised at the point-of-care.  
Perhaps the most valuable aspect of the lozenge sensor system described is the potential to 
incorporate antimicrobial coatings to the catheter tip (using the infection-responsive coating 
approach described in Chapter 2). The relocation of the diagnostic system to an external 
location within the catheter drainage bag enables the internal portion of the catheter (namely 
the distal tip) to remain available for introduction of antimicrobial species, such as small-
molecule antimicrobials or bacteriophage. Ultimately, this permits the eventual formulation of 
a theranostic catheter system, whereby the onset of blockage is delayed by the therapeutic 
coating, and subsequent elution/failure of the antimicrobial agent is signalled by the diagnostic 
sensor located within the drainage bag.  
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Chapter 4: Prevention of Encrustation and Blockage 
of Urinary Catheters via pH-Responsive Release of 
Bacteriophage 
4.1. Abstract  
As medical procedures become ever-more reliant upon implanted devices for diagnosis and 
treatment of infectious disease, further emphasis is placed on safeguarding antibiotic therapy 
as the panacea of modern medicine. Therefore, recent research has focused on alternative 
antimicrobials, for example bacteriophage, in the battle against multi drug-resistant 
uropathogens. The research presented in this chapter describes the development and in vitro 
assessment of an infection-responsive therapeutic coating for urinary catheters, which 
endeavours to delay catheter encrustation and blockage following infection by P. mirabilis. The 
coating employs the dual-layered polymeric system described in Chapter 2, consisting of a 
lower PVA hydrogel reservoir layer, capped and sealed by the pH-sensitive polymer Eudragit 
S100. Morphological changes induced within the Eudragit ‘trigger layer’ in response to 
elevated urinary pH, induce the release of bacteriophage into the catheterised bladder (Figure 
4.1).  
The use of lytic bacteriophage was employed in order to evaluate the efficacy of a biological 
antimicrobial in inhibiting catheter blockage. The potential for bacteriophage to constitute an 
effective countermeasure for urinary catheter encrustation has a potentially wide-reaching 
impact, not only for improving patient welfare, but also in extending catheter lifetime, thus 
reducing associated healthcare costs. Protoype coatings were evaluated under conditions of 
established infection, prompting analysis of crystalline biofilm reduction in response to a 
‘burst-release’ of bacteriophage within the physiological infection model. 
Figure 4.1: Schematic representation of the dual-layered polymeric architecture for the 
triggered release of bacteriophage from an infection-responsive urinary catheter coating. 




4.2.1. Antibiotic Resistance 
At the turn of the twentieth century, infectious disease was the leading cause of death in 
humans.1 The subsequent  discovery and development of antibiotics within the last 100 years 
has revolutionalised modern medicine, forming the basis of contemporary infection control, 
both within the clinical and ambulatory care setting.  The serendipitous discovery of penicillin 
in 19292 propelled the initiation of the ‘golden era’ of antibiotics, in which natural scaffolds and 
analogues of pioneering drugs were harvested, yielding revolutionary results. Invasive 
surgeries became routine, immunocompromising chemotherapy became a viable treatment 
option for cancer, organ transplantation extended lifespan, and the radical replacement of 
deteriorating joints, diseased corneas and burnt skin improved quality of life for millions of 
patients worldwide. Indeed, antibiotics have proved pivotal in the increase in life expectancy 
in the USA from 47  years in 1900, to 74 years for males and over 80 years for females in the 
year 2000.3 Antibiotics remain one of the most commonly prescribed classes of drug, with the 
number of defined daily doses (DDDs) rising by 65% between 2000-2015, from 21.1 to 34.8 
billion DDDs.4  
Despite their initial success and consequent global impact, widesperead and indiscriminate use 
of antibiotics has induced and accelerated the evolution of biological countermeasures, 
whereby bacterial cells may resist destruction as a result of antibiotic exposure. Antimicrobial 
resistance (AMR) poses a serious global threat, estimated to cause 10 million annual deaths by 
2050 if the progression of AMR is not impeded.5 Factors including excessive use of antibiotics 
in commercial farming, over-the-counter sales, increased international travel, and the release 
of nonmetabolised antibiotic residues into the environment via manure spreading/poor 
sanitation programs have all contributed to the development of the global AMR crisis. In 
particular, the global consumption of antibiotics in livestock provides a significant risk, owing 
to extensive anthropogenic interaction and largely unregulated use of antibiotics at sub-lethal 
dosages.6 In the USA alone,  livestock receive over 13 million kilograms (approximately 80%) 
of antiobiotics annually,7 the majority of which is administered in the form of continuous 
subtherapeutic quantitities to promote growth and prevent disease. Unsurprisingly, antibiotics 
used in this context have become associated with a high frequency of reistant bacteria in the 
gut flora of chickens, swine, and other food-producing animals. Without appropriate 
regulation, it is thought that such use will induce a large, diverse reservoir of resistance genes, 
which may facilitate the emergence of bacterial pathogens within the human population.8   
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4.2.1.1. Common Mechanisms of Antibiotic Resistance 
The microbial population has possessed the molecular tools to drive resistance for many years 
before human interference. Surveys for microorganisms in samples of ancient permafrost 
revealed that the antibiotic resistome (the global collection of antimicrobial resistance genes) 
is genetically diverse,9 widespread across all environmental niches,10 and pre-dates modern 
antimicrobial resistance by millennia.11 Antibiotic targets are generally conserved across the 
bacterial domain, and are absent or sufficiently different in eukaryotic cells. The current 
antibiotic arsenal generally attacks either the bacterial ribosome, thereby inhibiting protein 
synthesis (e.g. aminoglycosides); cell wall synthesis and lipid integrity, thus compromising 
membrane integrity or lysing cells (e.g. β-lactams); single-carbon metabolic pathways, 
inducing metabolic disruption (e.g. sulphonamides), or DNA  maintanence, thus interfering 
with bacterial replication and genomic integrity (e.g. quinolones).12–14 
Typical strategies employed by bacteria to resist antbiotic action often involve one of a few 
common pathways of modificiation.15 One such mechanism involes the inactivation of the 
antibiotic via enzymatic degradation or modification of the chemical scaffold, thus rendering it 
ineffective. Examples of this mechanism include chloramphenicol acetyltransferases,16 and, 
most notably, the widespread β-lactamases.12,17 Alternatively, the protection, alteration or 
overexpression of the antibiotic target is employed by bacteria, for example vancomycin-
resistant enterococci (which enzymatically modify peptidoglycan),18 and methicillin-resistant 
S. aureus (MRSA), which expresses a redundant insensitive variation of the native penicillin-
binding protein.19 Two addtional mechanisms rely on externalising the antibiotic, either via 
efflux activity20 or alteration of membrane permeability.21 Increasingly, bacteria will utilise 
several complimentary mechanisms to achieve high levels of resistance. For example, high-
level carbapenem resistance within clinical isolates of Enterobacter cloacae lacking in any 
known carbapenemase is achieved via a combination of porin mutations (that decrease drug 
uptake), and increased expression of a chromosomal β-lactamase.22 Common antibiotic action 
and resistance mechanisms are shown in Figure 4.2.  
Resistance can develop via two distinct pathways: vertical evolution, whereby mutations that 
enhance antibiotic tolerance are selected for and transmitted to progeny; or horizontal 
evolution, whereby antibiotic resistance genes are acquired from other bacteria via 
conjugation, transduction or transformation, and subsequently transmitted to progeny.23 The 
resultant acquisition and spread of AMR renders many major classes of antibiotics obsolete, 
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making it increasingly difficult to establish and maintain even an ephemeral lead over bacteria 
in the AMR ‘arms race’. 
 
4.2.1.2.  The Future of Antibiotic Discovery  
The majority of antibiotic classes used clinically today were discovered and introduced to 
market by the end of the 1960s. Today, only 5 out of 5,000-10,000 antibiotic candidates will 
reach Phase I studies, with only 1 of those 5 ultimately receiving FDA approval.24 Indeed, in the 
past 30 years, the approval of novel antibiotic drugs by the FDA has declined by 90%.25 If the 
decline in discovery of novel classes of drug, combined with the increase in widespread AMR 
continues on its current trajectory, infectious disease-mortality will surpass that of cancer, and 
could cost up to $100 trillion worldwide.26  
Figure 4.2: (Top) Overview of common classes of antibiotics and their mechanisms of action. 
(Bottom) Resistance mechanisms frequently employed by bacterial cells to counteract 
antibiotic therapy. Mutations may then be passed to bacterial progeny via vertical or 
horizontal evolution.  Reprinted with permission from Crofts et al.6 © Springer Nature 2017. 
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Barriers to antibiotic development, including scientific, regulatory and economic hurdles have 
proven antibiotic discovery and development to be less attractive to companies than more 
lucrative therapeutic areas. The developmental phase of a drug is a substantial investment; 
recent research suggests that a conservative estimate of bringing a single drug to market can 
be in excess of $2.5 billion. For antibitoics, the average cost of Phase III development alone can 
range from $30-50 million for acute bacterial skin structure infections, and $100-150 million 
for hospital-acquired and ventilator-associated bacterial pneumonia.27 Furthermore, 
infectious disease trials involve a long turnaround time and low percentage yield of bacterial 
culture, thus studying a specific resistance phenotype/pathogen requires large patient 
populations, thereby further prolonging and increasing the cost of development.28 Upon 
market entry, antibiotics capture a staggeringly low share of market value, accounting for only 
$1.87 billion of the total hospital expenditure ($419.4 billion) in the USA. Consequently, no 
single antibiotic drug features in the top 15 drug expenditure.29 
The stagnation of the antibiotic pipeline is driving an urgent incentive for the establishment of 
global initiatives, aimed at reviving the research and development of antibiotics. Organisations 
such as the US Centres for Disease Control and Prevention (CDC),1 the European Centre for 
Disease Prevention and Control (ECDC),30 and the World Health Organisation (WHO)31 are 
considering infections caused by multi-drug resistant bacteria as an emergent global disease 
and major public health issue. Such initiatives outline that effectively combatting AMR requires 
a multifaceted approach that facilitates sustainable and equitable use of antimicrobials, 
thwarts the spread of infectious disease, preserves existing antimicrobial therapies and fosters 
innovation of novel therapies and diagnostic tools. In the UK, research councils are responsible 
for several key antibiotic research and development initiatives including the Cross Research 
Council Initiative, the Global Challenge Fund and and the Newton Fund. AMR has been named 
as one of the key priorities for the NIHR, to direct funding and coordinate translational research 
programmes to benefit the NHS. NIHR biomedical research centres, which normally marry 
universities and Public Health England, have allocated approximately £8 million (2014-2019) 
to AMR research, and set out an AMR-themed call in 2014 allocating approximately £20 million 
to 18 focused projects.32 
In 2017, the WHO published a list of antibiotic-resistant ‘priority pathogens’- a catalogue of 12 
bacterial families that pose the greatest threat to human health. The list was drawn up in a bid 
to guide and promote research and development of novel antibiotics, highlighting in particular 
the threat of Gram-negative species (displaying high-level resistance with potential for 
horizontal transfer of resistance gene cassettes). Pathogens were stratified into three priority 
tiers: critical, high and medium. Those classified as critical were deemed to pose a significant 
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threat in hospitals, nursing homes and among patients undergoing treatment using 
implantable medical devices, and include carbapenem-resistant Acinetobacter baumannii and 
P.  aeruginosa, and carbapenem and 3rd generation cephalosporin-resistant Enterobacteriaceae 
(including Klebsiella pneumonia, E. coli, Enterobacter spp., Serratia spp., Providencia spp., 
Morganella spp., and Proteus spp.).33 Until recently, the polypeptide colistin has been used as  
a last-line antibiotic for the treatment of multi-drig resistant Gram-negative bacterial infection 
(particularly in the event of carbapenem resistance). However, the emergence of the 
transferable, plasmid-mediated resistance gene mcr-1, which causes resistance to colistin, is 
now being reported from several countries including China, the UK, USA, Denmark and 
Germany, where it has been detected in the intestinal flora of farm animals, and more recently, 
in humans (including residents of long-term care facilities).34 
4.2.2. Alternatives to Antibiotics  
The global community is now in recognition of the seriousness and growing threat of AMR. The 
current set of R&D incentive programmes are laudable and contribute to making antibiotic 
development an economically viable business model once again. However, recent efforts are 
also aimed at the development of novel, alternative treatment options to be used as single or 
ancillary therapies, in order to broaden the arsenal of antimicrobial agents available to human 
medicine. Addressing the antibiotic resistance crisis requires a multidimensional approach, 
including improved stewardship of existing antibiotics, alongside the development of novel 
compounds and preventative strategies such as vaccines and immunotherapeutic measures.35 
4.2.2.1. Drug-Based Strategies  
Recent drug-based advances focused on the ‘antivirulence paradigm’ endeavour to disarm 
pathogenic bacteria by neutralising their virulence factors. Such strategies offer the potential 
to reduce, eliminate or even reverse the selective pressures that are characteristic of 
traditional antibiotics, whilst leaving commensal bacteria unaffected. Perhaps the most 
important advantage of antivirulence strategies is the large number of putative virulent targets 
which, whilst overlooked in traditional phenotypic assays conventionally used to discover 
antibiotics, may provide a library of novel targets for exisiting chemical archives. Furthermore, 
secreted or surface-exposed virulence factors are amenable targets for cell-impenetrable 
biologics such as natural and engineered antibodies.36 However, the use of antivirulence drugs 
as alternatives to antibiotics may require combination therapy to account for multiple, 
redundant or strain-variable virulence factors. Furthermore, as such drugs are currently in 
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preclinical stages, many alleged advantages of antivirulence  strategies have yet to verified 
clinically. Indeed, many potential virulence targets, which may have proved dispensible in 
vitro, may contribute to bacterial survival in vivo. Moreover, predicting the propensity of 
bacteria to develop resistance poses additional challenges owing to complex bacterial 
transmission and colonisation dynamics.35 
Nevertheless, strategies such as quorum sensing inhibitors (QSIs) have proved promising in 
initial testing.37 Recent investigation by Younis et al.38 has assessed the QSI ability of secondary 
metabolites of the halophiles marine streptomyces to inhibit biofilm formation of 
uropathogenic P. mirabilis isolates. Sub–inhibitory concentrations of crude extracts displayed 
good biofilm inhibition on urinary catheter surfaces, and were also found to attenuate quorum 
sensing-dependent factors such as haemolysin activity, urease activity, and motility. However, 
the question of whether QSIs impact selective pressures favouring drug resistance remains 
controversial.39 QSI-resistant mutants have been derived in vitro and identified in clinical 
isolates, although these may be selected for by nonspecific, antibiotic-like effects that 
incidentally confer resistance to QSIs.40 
Antimicrobial peptides (AMPs) have proved a promising alternative treatment to conventional 
antibiotics in recent years. AMPs are chains of 5-50 amino acids displaying amphiphatic or 
cationic structures, and can be considered ‘natural antibiotics’, generally displaying a broad-
spectrum of action against Gram-positive and –negative bacterial species, fungi, viruses and 
protozoa. Whilst mutants of P. mirabilis have been identified with increased sensitivity to 
AMPs,41 the 54 kDa metalloprotease ZapA, expressed by P. mirabilis has been found to degrade 
a large spectrum of AMPs, as well as many proteins found within the urinary tract. Indeed, ZapA 
was the first reported bacterial protease capable of cleaving human β-defensin (a component 
of the human renal tubule innate immune response).42 
Other strategies involve the disarming of known resistance mechanisms, such as cellular 
antibiotic expulsion, via the repurposing of drugs already used in human medicine such as 
efflux pump inhibitors (EPIs). Such drugs have been shown to be capable of restoring antibiotic 
potency in both Gram-positive and –negative species,43 including uropathogenic E. coli 
strains.44 The existing EPI drugs  fluoxetine and thioridazine have recently been found to 
inhibit efflux in P. mirabilis, and control crystalline biofilm formation, swimming and swarming 
motilities via strong interaction with the Bcr/CflA efflux system. Both EPIs were able to 
increase time to catheter blockage within an in vitro model of the catheterised urinary tract, 
thus proving that licensed drugs exhibiting EPI activity provide a promising strategy for 
controlling biofilm formation and subsequent urinary catheter blockage.45 
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4.2.2.2. Biological Strategies 
Nature provides an infinitely complex and inexhaustible source of bioactive molecules, which 
may be used to a competitive advantage in the AMR arms race. One such solution is to use 
natural predatory bacteria, which constitute an unconventional yet promising alternative to 
chemical antibiotics. Of the abundant predatory species found in nature, Bdellovibrio spp. and 
Micavibrio spp. are among the better studied for potential treatment of Gram-negative 
infection. Bdellovibrio bacteriovorus (B. bacteriovorus) is the Gram-negative 
Deltaproteobacterium that expresses a single polar flagellum, rendering it one of the fastest 
moving organisms in nature.46 Upon encountering a prospective prey cell, B. bacteriovorus is 
believed to use a type IV pilus to attach itself to the outer membrane, where it modifies the 
prey’s peptidoglycan membrane in order to create a two-cell complex known as a bdelloplast. 
Hydrolytic enzymes are expressed to break down the host cell molecules, which allow the 
complex to grow filmanetously. Once the nutrient source is exhausted, B. bacteriovorus 
undergoes separation, lysis of the bdelloplast and subsequent release of bacterial progeny. The 
process is both quick and efficient, as it takes just 2-3 hours for a prey cell to be completely 
digested.47 Multiple studies have demonstrated the ability of predatory bacteria to prey on a 
broad range of Gram-negative species in vitro, including key human pathogens such as 
Acinetobacter, Enterobacter, Escherichia, Klebsiella, and Pseudomonas spp.48,49 
Within bacteria and archaea, the prokaryotic immune system able to confer resistance to 
foreign genetic elements consists of  clustered regularly interspaced short palindromic repeats 
(CRISPR), paired with Cas9, an RNA-guided endonuclease that uses CRISPR DNA sequences in 
order to edit specific genes within invasive organisms via double-strand DNA breaks.50   One 
key feature of CRISPR-Cas is its highly sequence-specific targeting capability, allowing it to 
easily distinguish between pathogenic or commensal bacterial species. Thus, the CRISPR-Cas 
machinery may be repurposed to attack, rather than defend, invasive pathogenic species. 
Induction of double-strand DNA breaks generally results in bacterial fatality if chromosomally 
targeted, thereby resulting in the potential to selectively remove individual species within a 
complex bacterial population.51  
4.2.3. Bacteriophage  
Bacteriophage (phage) are the predatory viruses of bacteria, known to be most abundant 
organisms in nature. There are an estimated 1031 phage particles on the planet,52 which 
translates to approximately one trillion phage for every grain of sand. The  prokaryotic 
virosphere is remarkably diverse, resulting a wide range of virion size, shape and complexity. 
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Furthermore, phage genomes are highly mosaic and represent the largest reservoir of 
unexplored genes anywhere in the biosphere.53 Given their ubiquity and diversity, is is 
unsurprising that phage play a pivotal role in a variety of biological and environmental 
processes . It is estimated that between 15-40% of the ocean’s bacterial flora is lysed by phage 
every day, thereby influencing the ratio of particulate to dissolved carbon, rates of 
phytoplankton productivity and oxygen output. Moreover, phage are significant drivers of 
bacterial evolution, both owing to the avoidance of killing via lysis, and  the prominence of 
horizontal gene transfer by lysogenic phage. Globally it is believed that phage-mediated gene 
transfer events  occur up to 20 million billion times per second. 54 
In 1896, Ernest Hanbury Hankin, a British bacteriologist to the government of the Central 
Provinces of India, demonstrated that waters from the Ganga and Yamuna rivers contained a 
biological principle that destroyed cultures of cholera-inducing bacteria. Published in French 
in the Annals of the Pasteur Institute,55 he detailed that the substance could pass through 
Millipore filters known to be able to retain larger organisms such as bacteria. Following this 
observation, phage were then independently discovered by Frederick Twort (1915)56 and Felix 
d’Hérelle (1917)57. D’Hérelle in particular used phage suspensions to treat infections such as 
dysentery, which at the time had no other consistently effective treatment. The success of this 
treatment led to a period of widespread enthusiasm for phage therapy in humans, although 
this became rapidly eclipsed in western medicine upon the advent of antibiotics. Nevertheless, 
the use of phage to treat human disease has persisted in various regions of the world, including 
the former countries of the Soviet Union (most notably in Georgia, where phage are often used 
as the standard of care for bacterial infection).58 
4.2.3.1. Bacteriophage Classification  
Virus taxonomy is currently the responsibility of the International Committee on the 
Taxonomy of Viruses, whose classification scheme emcompasses 1 order, 13 families and 34 
genera of phage. The families are distinguished by categorising the type of nucleic acid and 
virion morphology.59 A full description of bacteriophage classification and characterisation is 
described elsewhere.60 As well of being of greatest relevance to this thesis, tailed bacteriophage 
of the Caudovirales order are the most numerous and widely distributed group of bacterial 
viruses. The Caudovirales order consists of 3 distinct families: Myoviridae, Siphoviridae and 
Podoviridae, based on tail morphology (Figure 4.3). Virions of order Caudovirales contain 
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double stranded, linear DNA but vary in the contractile nature of the tail and adhesion 
structures.61 
Figure 4.3: Representative structures of tailed phage of the order Caudovirales, classified as 
Myoviridae (A), Siphoviridae (B), or Podoviridae (C) based on tail morphology. Myoviridae tails 
consist of a neck, contractile sheath and a central tube. Myoviruses tend to be larger than 
other families and include some of the most highly-evolved tailed phage species. Siphoviridae 
tailes are simple, noncontractile tubular structures. Siphoviruses are the most numerous of 
all the tailed phage. Podoviridae tails are short and noncontractile. Phage belonging to both 
Myoviridae and Siphoviridae families have a baseplate at the distal end of the tail to which 
receptor binding proteins (RBPs) are attached. Since members of the Podoviridae family have 
no baseplate, RBPs attach directly to the tail. Myoviridae and Siphoviridae families 
additionally have a central tail fibre that protrudes from the distal end of the tail or baseplate. 
Adapted with permission from Nobrega et al.61 © Springer Nature 2018. 
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4.2.3.2. Bacteriophage Life Cycles  
Since phage lack the machinery required to express their own genes, and replicate their own 
genomes, they are therefore reliant upon host bacterial cells to fulfil their biological 
requirements. Much like other, eukaryotic viruses, phage have two distinct life cycles: the lytic 
cycle (a productive process leading to the synthesis of new phage particles), and the lysogenic 
cycle (a ‘silent’ stage whereby the phage genome is integrated with the host chromosome). 
Following contact with a bacterial cell encoding a receptor complimentary to the phage anti-
receptor, the phage may inject its DNA via penetration of the cell membrane, before entering 
either the biosynthetic or quiescent pathways,62 as detailed in Figure 4.4. 
In conditions where susceptible hosts are abundant and actively growing, populations of lytic 
phage dominate. Upon injection of virulent phage DNA into the cell, major physiological 
changes are induced within the host cell. A cascade of finely-tuned sequential events take place, 
driven towards the production of phage progeny. The majority of host cellular process are 
interrupted, with the exception of those required for biosynthesis. Phage-encoded genes are 
orderly transcribed and translated into the regulatory and structural proteins. Thereafter, the 
structural consitituents are irreversibly assembled into precursor polymers and gradually 
processed into mature virions. The host cell wall is then disrupted by the dual action, phage-
encoded holin and endolysin system, thereby releasing phage progeny capable of subsequent 
infective cycles.63,64 
In contrast, lysogenic phage are capable of maintaining a stable relationship with the host. 
Upon infection and DNA translocation into the host cytoplasm, the phage genome becomes 
incorporated with the host chromosome. The genetic code of the integrated phage (also 
referred to as ‘prophage’) is replicated in tandem with the bacterial chromosome, and 
transmitted to daughter cells with every binary cell division. Prophages of  this quiescent 
nature are highly stable and may be maintained indefinitely. However, stress-induced 
physiological changes of the host (such as starvation, heat-shock, and UV-induced DNA 
damage) may induce the triggering of the lytic cycle via regulatory proteins that modulate the 
expression of specific genes required to establish lysogenic or lytic cycles.64  
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Transduction is a mechanism of great importance in the selection of phage for therapeutic 
purposes. Transducing phage may insert a segment of the bacterial genome into a newly 
formed viral particle which may then be transferred to other bacterial hosts. Two mechanisms 
of transduction have been described, namely generalised and specialised transduction. During 
generalised transduction, random sections of the bacterial genomes may be packaged into viral 
Figure 4.4: Viral replication cycles of bacteriophage. Following the insertion of the phage 
genetic material into the host bacterial cell, one of two life cycles may be followed: lytic 
(virulent) or lysogenic (temperate). Lytic replication involves hijacking the host’s 
biosynthetic machinery to make new phage components. Lysis of the cell releases phage 
progeny which may then go on to perform further infection. Lysogenic phage incorporate 
their nucleic acid into the chromosome of the host cell and replicate quiescently without 
causing host destruction. In such cases, the closure of the newly-formed circular DNA and 
corresponding cohesive site is denoted ‘cos’. Reprinted with permission Campbell et al.62 © 
Springer Nature 2003. 
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particles owing to chromosomal and plasmid DNA degradation during infection. Upon 
subsequent infection, bacterial genes are injected into a new bacterium and may recombine 
(by homologous recombination) with the host’s genome. In this process, any single or cluster 
of bacterial genes may be transferred among genetically similar bacteria at equal frequency. 
Specialised transduction is a process restricted to lysogenic phage. Excision of the prophage 
DNA may be imprecise, resulting in the bacterial region neighbouring the insertion site to be 
packaged into viral particles and transferred between bacteria.65 Even under optimal 
laboratory conditions, transduction is a relatively rare event (occurring once every 
approximately 108 phage particles).54 However, considering the abundant nature of phage, 
transduction can be considered a major mechanism of lateral gene transfer within bacterial 
populations. 
From a biosafety point of view, the introduction and transfer of new genetic material into the 
bacterial gene pool may have significant negative impacts on the therapeutic potential of 
phage.65 Notoriously, the lysogenic conversion of non-toxigenic bacterial strains into deadly 
toxigenic pathogens via the expression of phage-encoded toxins is known to have occurred 
previously, for example Shiga toxins in E. coli O157:H7,66 and the botulinum toxin in 
Clostridium botulinum.67  
In light of the potential of transduction to improve the fitness and survival of bacteria, it is 
therefore essential that lysogenic, transducing phage are eliminated from any potential 
therapeutic formulations. Whilst the mechanism of transduction is known to occur in both lytic 
and lysogenic cycles, extensive degradation of the host genome during virulent infection 
renders this process largely inconsequential in lytic preparations.68 
4.2.3.3. Bacteriophage Therapy  
Advantages of phage therapy over the use of chemical antibiotics can be framed in terms of 
phage properties. Factors that contribute substantially to the utility of phage therapy in 
humans include:69 
  ‘Auto’ dosing and single dose potential. The pharmacokinetic profile of phage is 
such that the initial dose increases exponentially as the virus multiplies within the 
bacterial host. In vivo amplification of the phage population may potentially reduce 
costs associated with repeated treatments; 
 Minimal disruption of host flora. Owing to narrow host specificity, phage  typically 
recognise single or limited ranges of host bacterial strains. This reduces damage to the 
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commensal microbial community of the human host, unlike many chemical antibiotics, 
whose broad activity spectrums often induce superinfections (such as antibiotic-
associated Clostridium difficile colitis, or Candida albicans yeast infections; 
 Narrower propensity for induction of host resistance, as well as the absence of 
cross-resistance to antibiotics (making phage an effective ‘last resort’ solution for 
multidrug-resistant infection). The narrow host range of phage limits the number of 
related bacterial species which may select for specific resistance, whilst mutations to 
evade phage adhesion or infection may negatively impact bacterial fitness and cell 
function; 
 Low environmental impact. Phage are inherently biocompatible, since they are 
predominantly composed of nucleic acids and proteins. Owing to their narrow host 
range, discarded phage are unable to significantly impact the natural microbiome. 
Phage not adapted to degradative conditions such as UV or temperature extremes will 
be rapidly inactivated; 
 Rapid discovery. Whilst large-scale production of phage is more technically 
demanding than conventional antibiotics, they are easily discovered and isolated from 
sewage and other highly bacterial-dense waste materials. Accumulation of specific 
resistance to existing phage is offset by the tandem evolution of such virions with 
bacteria in nature; 
 Formulation and application versatility. Phage are versatile in terms of formulation 
development, and may be combined with chemical antibiotics to achieve synergistic or 
additive effects on bacterial killing. Application design may include liquids, hydrogels, 
creams and solids. Groups of phage strains may be combined into ‘cocktails’, typically 
broadening the antibacterial spectrum of activity in situations where multispecies 
infections are prevalent. 
One of the current challenges of progressing phage therapy into the clinic is the lack of 
validated and adequately controlled clinical trials. Whilst clinical trial design for phage 
therapy will inevitably share many parallels with standard drug trials, there are several 
factors that are unique to phage therapy (including pharmacological considerations such 
as dosage).70 Nevertheless, recent developments in clinical trials for phage therapy have 
proved promising, and in agreement with observational human studies. The British 
company Biocontrol (now Ampliphi; VA, USA) has performed what is to date the only Phase 
II clinical trial with a phage product (clinical trial indentifier: NCT03395769). Following 
promising results in dogs,71 a human trial for otitis was performed under the auspices of 
the Medicines and Healthcare Products Regulatory Agency in the UK. 24 patients with 
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chronic otitis, who had not responded to antibiotic therapy were recruited for a 
randomised, double-blind trial consisting of a single dose of 6 x105 virions. Differences in 
test and control groups (including complete resolution in 3 patients) were such that the 
trial was ended early so that the control group may receive treatment.72 Phagoburn, a 
Phase I/II clinical trial (clinical trial indentifier: NCT02116010)  launched in July 2015 
aimed to assess the efficacy of phage cocktail treatment on wound infections due to E. coli 
or P. aeruginosa in burn patients. This trial has paved the trail for the re-implementation of 
phage therapy into the human therapeutic arsenal, including the first Good Manufacturing 
Practice (GMP)-like production of phage drug products, and thorough assessment of shelf-
life and side effects.73 
4.2.3.4. Bacteriophage Therapy: Regulatory Hurdles 
Whilst phage therapy formulations have become embedded into the healthcare systems in 
Georgia, in other parts of the world, medical applications of phage present a unique regulatory 
agenda. Questions regarding the biological status of phage include determining whether or not 
they are regarded as living, which highlights the need for defined phage-specific terms of policy 
within regulatory structures. As it currently stands, phage therapy may in many cases 
represent the epitome of ‘personalised medicine’, as the process of treatment involves 
formulating tailor-made phage combinations specific for an individual infection. This presents 
difficulties in the regulatory pipeline, although such deviations from regulatory convention 
have already been achieved in areas such as cancer therapy.74 The FDA has recently provided 
an opportunity for the new Center for Innovatve Phage Applications and Therapeutics (IPATH) 
to utilise pahge therapy via the Emergency Investigational Drug scheme. Such initiatives are 
lilely to improve clinical understanding and acceptance, as well as supporting evidence for the 
creation of dedicated regulatory guidelines.75 
4.2.3.5. Bacteriophage Therapy for CAUTI 
Recently, a number of studies have investigated the use of lytic bacteriophage in the treatment 
and prevention of biolfilms of bacterial species commonly associated with infections of 
indwelling urological devices and CAUTI.76 Carson et al.77 revealed that lytic phage provide 
effective prevention of biofilm growth of uropathogenic P. mirabilis and E. coli on urinary 
catheter surfaces. Visual examination via confocal imaging of catheter sections treated with 
phage showed a marked reduction in biofilm formation on the surface of Bard Lubri-Sil™ Foley 
catheters after 24 hours, compared with untreated controls (Figure 4.5). Furthermore, the 
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same study showed the potential of phage not only in the prophylactic prevention of biofilm 
formation (via pretreatment of the catheter surface), but also in the destruction/eradication of 
established biofilms. Established biofilm populations of P. mirabilis and E. coli were reduced by 
3-4 log cycles (99.9-99.99% removal) upon treatment with lytic bacteriophage. 
 
Bacteriophage cocktails for treatment and prevention of CAUTI have been recently 
investigated by Nzakizwanayo et al.78 Models representing either an established infection or 
early colonisation of the catheterised urinary tract were treated with a single dose of a 3-phage 
cocktail. The impact on time to blockage and the formation of crystalline material was 
monitored. Established infection models (1010 CFU/mL initial inoculum) showed an 
approximately 3-fold increase in time to blockage, compared to untreated controls. Under 
conditions of early-stage infection (103 CFU/mL initial inoculum), however, phage treatment 
Figure 4.5: Confocal scanning laser microscopy images of biofilms on the surface of Bard 
Lubri-Sil™ Foley catheters, stained with Live/Dead BacLight™. Left-hand images depict 
biofilm growth of uropathogenic clinical isolates on the surface of untreated catheters. Right-
hand images shows a marked reduction in biofilm biomass on the surface of bacteriophage-
treated catheter surfaces. E. coli (A, B) and P. miraiblis (C, D)  Scale bars = 30 μm.  Reprinted 
with permission Carson et al.76 © Oxford University Press 2010. 
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eradicated blockage entirely. Models drained freely for >8 days, until medium reserves were 
exhausted. 
Evaluation of commercially available phage formulations registered in Georgia or from the 
bacteriophage collection of the George Eliava Institute of Bacteriophage, Microbiology and 
Virology have been investigated as potential treatment options for uropathogenic strains of E. 
coli and Klebsiella pneumoniae (K. pneumoniae). The lytic activity of commercial cocktails on 
41 strains of E. coli varied between 66-93%. Furthermore, one phage of the Eliava collection 
was found to lyse all 9 tested K. pneumoniae strains.79 Such studies utilising commercially-
availabe phage cocktails prove the potential of standard formulations to impact common 
illnesses. Moreover, they support the notion that phage should not be treated as chemical drugs 
in the face of regulatory legistalation, but rather like the components of the influenza vaccine, 
which is re-evaluated yearly without separate clinical trial data.80 
Numerical simulations of phage-bacterium population dynamics undertaken by Malik et al.81 
have highlighted the need for phage encapsulation to ensure that the phage titre remains stable 
and viable during storage . Thus, recent investigations into the encapsulation of phage into a 
hydrogel catheter coating have proven an important step towards the viral treatment of CAUTI 
in situ. A recent patent focuses on the controlled covalent attachment of bioactive phage to a 
hydrogel coating material for regulation of biofilm development with examples focusing on 
biofilm reduction on urinary catheters.82 Bacteriophage have been shown to remain stable and 
viable in a variety of hydrogel formulations,83 and, of particular relevance to this thesis, have 
been successfully released in response to a biochemical or physical stimulus as a direct 
consequence of infection (e.g. temperature84 or secreted bacterial enzymes85). 
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4.3. Materials and Methods 
4.3.1. Materials 
Materials for the formulation of pH-responsive catheter coatings were purchased according to 
Chapter 2. Vegetable peptone no. 1 and  tris-hydrochloride (pH 7.5) were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). 
4.3.2. Methods 
4.3.2.1. Microbiological Methods 
General bacterial culture and quantification protocols were followed according to Chapter 2. 
I. P. mirabilis Biofilm Formation  
For quantitative analysis, P. mirabilis B4 subculture (1:1000 in LB, 1 mL) was added to each 
well of a 12-well microplate, achieving a starting inoculum of 103 CFU/mL. Microplates were 
incubated statically for 24 hours (37 °C) to promote cell attachment.  
For imaging, polycarbonate membranes (GVS Poretics) were positioned on NSLB agar plates, 
and UV-sterilised (10 minutes treatment time). Bacterial growth fluid (fetal calf serum mixed 
1:1 with NaCl (0.85% w/v) and peptone (0.1% w/v) was aliquoted onto the surface of the 
membranes (20 μL). Membranes were inoculated with 1:1000 bacterial subculture (30 μL), 
and incubated statically for 24 hours (37 °C) to form confluent biofilms. 
II. Crystal Violet Biofilm Staining  
After incubation, biofilms were washed x3 with deionised water to remove planktonic cells. 
Adhered cells were stained with crystal violet solution (0.1% w/v,  500 μL),and incubated 
statically for 15 minutes (room temperature). The stain was removed via 3 exhaustive washes 
with deionised water, and dried at room temperature (30 minutes). To quantify adhered cells, 
decolourising solution (33% v/v acetic acid, 500 μL) was added to each well, and the 
absorbance measured at 595 nm to indicate the presence of a mature biofilm.  
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III. SEM Imaging of P. mirabilis Biofilms  
The hexamethyldisilazane (HMDS) drying treatment86 was used on membrane-bound biofilms 
of  P. mirabilis as an alternative to conventional critical-point drying, to prevent sample 
distortion and achieve preservation of surface details. Biofilms were cross-sectioned using a 
razor blade prior to fixation. Film fixation was performed using glutaraldehyde (1.5%), and 
paraformaldehyde (3%) in phosphate buffer (pH 7.3) for 12 hours at 4 °C. Samples were 
dehydrated in an ethanol/water mixture at concentrations of 50%, 70%, 80%, 90%, 95% and 
100% for 10 minutes each. Dehydrated samples were then submerged completely in HMDS for 
2 x 30 seconds, then air-dried (10 minutes). Samples were sputter-coated with gold (Edwards 
S150B) and images obtained using a JEOL SEM6480LV SEM operating at 10 kV for electron 
imaging. 
4.3.2.2. Bacteriophage Methods 
I. SM Buffer Preparation  
Aqueous SM phage suspension buffer was prepared according to Table 4.1. Compounds were 
dissolved in deionised water (200 mL) and sterilised via autoclaving prior to use. 
Table 4.1: Components of SM phage suspension buffer 
 
The solution was supplemented with gelatine (0.01% w/v, 20 mg) to aid the stability of phage 
during storage. 
II. Bacteriophage Isolation and Single Plaque Purification 
P. mirabilis phage were isolated from crude sewage. Bacterial enrichments with clinical isolates 
were performed to enhance phage populations. Actively growing cells from overnight liquid 
culture (5 mL) were added to LB liquid media supplemented with MgSO4 (1 mM) and CaCl2 (1 
mM), and incubated overnight (37 °C, 200 rpm) with crude sewage solution (150 mL). An 
aliquot (10 mL) was removed from the enrichment post-incubation, to which was added NaCl 
Compound Mass (g) Concentration (mM) 
Sodium chloride 1.17 100 
Magnesium chloride hexahydrate 0.42 8.5 
Tris-hydrochloride (pH 7.5) 1.58 50 
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(1 mM) and chloroform (1% v/v). The culture was centrifuged (30 minutes, 30,000 x g) and 
the supernatant filter sterilised (0.45 μm pore size). The presence of lytic phage was confirmed 
using the double agar overlay metod (see below). From each plate, isolated single plaques were 
picked using a sterile pipette tip. If present, different plaque phenotypes were picked and 
resuspended in SM buffer (300 μL). Serial dilutions (SM buffer, 10-3-10-7) and plating were 
undertaken to allow purification and isolation of a single phage. To ensure clonality of phage 
types, single plaque purification was repeated a further 5 times until homogenous plaque 
purification was observed. Finally, an individual plaque was picked and resuspended in SM 
buffer for use in subsequent methods. Purified phage were stored in glycerol (50% v/v) in LB 
at -80 °C for long-term use. Short-term stock preparations were maintained at 4 °C in SM buffer. 
III. Bacteriophage Propagation and Extraction 
Non-swarming LB-derivative soft top agar (LBDTA) was prepared according to Table 4.2.  
Table 4.2: Composition of LBDTA agar 
Compound Mass (g) 
Yeast extract 5.00 
Vegetable peptone 10.00 
Bacteriological agar 5.75 
 
Components were dissolved in deionised water (1 L), sterilised by autoclaving and stored at 
50 °C. Plates displaying confluent lysis were obtained by performing a double agar overlay 
using LBDTA, to facilitate diffusion of phage through solid media. (Figure 4.6). 
Phage lysate solution (100 μL), and host bacterial culture (100 μL) were added to molten 
LBDTA (3 mL). The resultant agar solution was poured onto an NSLB agar plate, and set at 
room temperature for 10 minutes. Plates were incubated overnight (37 °C) to result in 
confluent lysis.  
To extract phage ,the flood infected plates method was employed. SM buffer (3 mL), containing 
chloroform (2% v/v) was added to individual plates, which were incubated at room 
temperature for 4 hours with gentle rocking (30 rpm, Suart gyratory rocker SSM4). High titre 
phage lysate was removed from the plates, centrifuged to remove bacterial cell debris (4,000 
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rpm, 10 minutes), and filter sterilised (0.22 μm pore size). Lysate was stored at 4 °C until 
required. 
IV. Bacteriophage Enumeration 
To determine phage titre, the double agar overlay method (outlined above) was employed, 
following  serial dilution of viruses (10-fold dilutions in SM buffer). Zones of inhibited growth 
(plaques) were counted, and the phage titre calculated according to Equation 1. Plates 
displaying 30-300 plaques were used to quantify plaque-forming units per unit mililitre (PFU/ 
mL). 
Where d is the dilution factor (from original culture), and V is the volume of inoculum (mL). 
V. Bacteriophage Imaging 
Bacteriophage morphology was assessed using transmission electron microscopy (TEM). 
Carbon-coated glow discharge grids were firstly exposed to ozone (5 minutes) to increase 
surface hydrophilicity. Each grid was then soaked in high-titre phage lysate, rinsed with 
deionised water and soaked in uranyl acetate stain (1%). Grids were dried for 4 hours (room 
temperature), and images acquired using a JEOL JEM1200EXII with Gatan Dualvision camera. 
VI. Bacteriophage Minimum Inhibitory Concentration 
Mininmum inhibitory concentration (MIC) of lytic pahge were determined using the 
microbroth dilution method. P. mirabilis B4 (~108 CFU/ mL) was distributed in a 96-well 
microplate (100 μL, LB). Phage preparations were diluted to represent a range of 
concentrations (1010 PFU/mL – 102 PFU/mL), and added to wells containing bacterial cells 
(100 μL). Corresponding cell controls, phage controls and media controls were performed. 
 
PFU/ mL =  




Figure 4.6: Schematic representation of the double agar overlay, to achieve confluent 
bacterial lysis. 
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Microtiter plates were incubated overnight (37 °C) in a microplate reader. Optical density (600 
nm) was continuously monitored. The lowest concentration of phage at which no turbidity was 
observed was defined as the MIC. 
VII. Bacteriophage Eradication of Established Biofilms  
Biofilms were grown in 12-well microplates as above, and washed 3x with deionised water to 
remove unbound cells. Phage lysate (in LB media) at 1010 and 108 PFU/mL (1 mL) were added 
to each well in triplicate after 24 hours initial biofilm growth. Plates were incubated statically 
(37 °C), and removed at 0, 6, 24 and 48 hour time points for crystal violet staining (according 
to Section 4.2.2.1.II).  The absorbance of the decolourising solution was measured at 595 nm 
to quantify biofilm destruction by P. mirabilis phage.  
VIII. Catheter Bridge Swarming Assays 
The swarming of P. mirabilis bacteria over sections of all-silicone Foley catheter was assessed. 
The protocol was adapted from Sabbuba et al.87 in order to evaluate the efficacy of phage in 
hindering the P. mirabilis swarming motiliy. Catheter segments (1 cm length) were silanised 
according to Chapter 2, and coated in PVA hydrogel (100 μL, 10% w/v) containing 1010 
PFU/mL phage lysate. The ‘bridges’ were placed into the cut-out channels of an LB agar plate 
to permit swarming. The first channel was cut down the centre of the plate (1 cm width), to 
accommodate the catheter section. Two further channels (0.5 cm width) were cut 
perpendicular to the central channel to achieve adequate separation between experimental 
repeats (Figure 4.7). The exposed ends of the balloon-inflation line and catheter lumen were 
sealed with sterile plastic to prevent internal bacterial motility.  
Figure 4.7: Schematic representation of the catheter ‘bridge’ swarming assay experimental 
setup.  
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Aliquots of 1:1000 bacterial subculture (10 μL) was used to inoculate the agar on one side of 
the catheter ‘bridge’, and the plates incubated statically for 24 hours (37 °C) before undergoing 
visual assessment. When growth of P. mirabilis appeared on the uninoculated side of the plate, 
adjacent to the bridge, it was concluded that the test strain had migrated across the catheter 
section via engagement of the swarming motility.   
4.3.2.3. Materials Preparation 
Solutions of PVA and Eudragit S100 were prepared according to Chapter 2. 
I. Coating of Foley Catheters 
To cooled PVA solution (20% w/v, 14,600-18,600 gmol-1) was added high titre phage lysate 
(1010 PFU/mL), at a 1:1 ratio, to achieve a final PVA concentration of 10% w/v. All-silicone 
Foley catheters were coated with the hydrogel/phage solution (100 μL) between the retention 
balloon and the tip, and stored overnight at -20 °C to promote cryogenic gelation. Catheters 
were thawed at room temperature (2 hours), before coating with the pH-sensitive trigger layer 
(20 dip coats, with a 5 minute solvent evaporation period between each coating). Coated 
catheters were stored at 4 °C until required. 
4.3.2.4. Prototype Evaluation 
I. In Vitro Bladder Models 
Evaluation of prototype coatings under physiologically relevant conditions was performed in 
order to assess the degree to which phage release would increase catheter lifespan. In vitro 
bladder models were assembled and run according to Chapter 2. Models simulating late-stage 
infection were incoluated with P. mirabilis B4 or E. coli NSM59 (108 CFU/mL), and supplied 
with artificial urine media at a constant flow rate of 0.75 mL/min. Numbers of viable bacterial 
cells, as well as bacteriophage concentration were enumerated at periodic intervals 
throughout the experiments, along with pH readings of resudial urine media.  Experimental 
controls were undertaken in order to assess:  
 Time to blockage in the absence of a bacteriophage-impregnated catheter coating; 
 Bacterial health in the presence of an uncoated catheter; 
 Coating stability in the presence of a urease-negative species (E. coli); 
 Sterility of the closed-drainage system in the absence of infection. 
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II. Microbiological Quantification 
Quantitative analysis of viable bacterial cells and phage populations were performed from 
culture removed directly from the in vitro bladder models (10 mL aliquot). For bacterial 
enumeration, serial dilutions of the original culture were performed (10-1-10-8), plated in 
triplicate on NSLB agar, and incubated overnight (37 °C). Colony counting was performed as 
previously described to estimate cell numbers. For phage, the original bladder culture was 
filter sterilised (0.22 μm pore size) to remove bacteria, then serial diluted (10-1-10-8 in SM 
buffer) and plated in double agar overlay. Phage enumeration was performed to estimate 
populations of phage released from catheter coatings. 
III. Atomic Absorption Spectroscopy 
Biofilm biomass was quantified at the conclusion of each in vitro bladder model experiment via 
analysis of calcium concentration within the crystalline biofilms using atomic absorption 
spectroscopy (AAS). Catheters were removed from bladder models at the time of uncoated 
control blockage (13 hours after model start), and cut into sections (1 cm length). Catheter 
sections were soaked in nitric acid (4% v/v) for 24 hours, following sonication (44 kHz, 5 
minutes), to facilitate diffusion of crystals embedded within the catheter biofilm. The resulting 
solution was assayed for calcium using a Perkin Elmer AAnalyst 100 spectrometer (nitrous 
oxide/acetylene flame, 422.7 nm), using a combined calcium and magnesium hollow cathode 
lamp (S&J Juniper & Co). Where necessary, samples were diluted further (4% v/v HNO3) to 
ensure that the measured concentration lay within the experimental range (1-5 ppm). Linear 
calibration of the instrument was performed via dilution of standard Ca2+ solutions (BDH 
Prolabo), with 2000 ppm potassium (as KCl) as ionisation surpressant. 
IV. SEM Imaging of Catheter Cross-Sections 
Catheters were removed from bladder models at time of uncoated control blockage, and cross-
sectioned both at the eyeholes, and 1 cm below the retention balloon. Cylindrical sections were 
mounted lengthways into a split mount vice holder, and grounded to the aluminium stage using 
carbon conductive tape. Mounted catheter sections were sputter coated with gold following 
dehydration under vacuum (12 hours). Imaging of catheter cross-sections was performed 
using a scanning electron microscope (JEOL JSM6480LV) operated at 10 kV. Secondary 
electron imaging was utilised for inspection of the sample topography. 
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4.4. Results and Discussion 
Bacteriophage therapy offers an urgently required alternative to chemical antibiotics. 
However, the route to common clinical practice for phage is still frought with complication, as 
the current functional and practical legal framework does not offer the flexibility required to 
exploit and further explore the specificity of such viruses. The infection-responsive coating 
described in this chapter attempts to provide an effective countermeasure for the encrustation 
and blockage of urinary catheters. 
4.4.1. Bacteriophage Morphology  
Amongst the isolated phage, P. mirabilis B4 bacteriophage SM648 was selected as the model 
phage strain for this system, as it showed enhanced lytic activity against P. mirabilis B4. 
Bacterial strain B4 was deemed to be a suitable model P. mirabilis strain as it is widely known 
to display strong swarming and swimming characteristics, as well as high urease and flagella 
production  in both motilities.88 Phage SM648 was subjected to morphological evaluation using 
TEM (Figure 4.8). 
TEM images suggest that the P. mirabilis phage are of the classifcation Podoviridae, owing to 
the observed capsid morphology.  Observation of short, noncontractile tails with an 
icosahedral head group of diameter ~50 nm is in agreement with results observed 
previously,76,89 including 6 of the 10 complete genomes of phage specific for Proteus spp. 
available in Gen Bank.90 
Figure 4.8: Transmission electron micrographs of P. mirabilis B4 bacteriophage SM648. Scale 
bars represent A) 100 nm, B) 50 nm.  
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4.4.2. Bacteriophage Minimum Inhibitory Concentration 
The ability of phage to inhibit the growth of P. mirabilis B4 was assessed using optical density 
(OD) measurements, in order to determine the lowest concentration which, under strictly 
defined test conditions, will inhibit bacterial growth in vitro. Overnight growth curves of P. 
mirabilis B4, incubated with varying phage concentrations are shown in Figure 4.9. 
For therapeutic purposes, it is crucial to establish that bacterial lysis occurs in a phage dose-
dependent matter. Characteristic dilution-dependent killing was observed upon incubation 
with phage, although a high multiplicity of infection (MOI) was required for high killing 
efficiency. Adequate sensivity for therapeutic purposes was only observed when bacterial cells 
were challenged with 1010 PFU/mL, which corresponds to an approximate MOI of 100. Thus, 
the maximum dosage of phage was also deemed to be the MIC in this case. Whilst this dose 
appears high in comparison to therapeutic concentrations of phage described for other Gram-
negative species,91 for P. mirabilis, doses in the region of 3 x1010 PFU/mL have been deemed 
necessary for the treatment of uropathogenic species in vitro.78 Furthermore, the infective 
nature of phages still renders this concentration viable for therapeutic purposes. Slight 
Figure 4.9: Overnight growth curves of P. mirabilis B4, incubated with varying 
concentrations of bacteriophage SM648. Each data point represents the mean of three 
individual repeats. Error bars represent SEM. 
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reinitiation in bacterial growth was observed for the highest phage concentration (1010 
PFU/mL) after 18 hours incubation, although this was considered negligible in comparison to 
the untreated control. 
An increase in bacterial population was observed for the lower phage dilutions after 10 hours 
incubation, initiating regrowth of bacteria in all phage dilutions where the MOI <100. Bacteria 
can resist phage infection via a number of different mechanisms, including spontaneous 
mutation, restriction modification systems, and adaptive immunity via the CRISPR-Cas system. 
Spontaneous mutations are the most commonly employed mechanisms driving both phage 
resistance and phage-bacteria coevolution. Such mutations may confer phage resistance by 
modifying the structure of the bacterial surface components that act as phage receptors (thus 
determining specificity). These include lipopolysaccharides, outer-membrane proteins, cell 
wall teichoic acids, capsules, and other bacterial appendices such as flagella, which may 
contribute to virulence. However, phage resistance may come at a price to the defending 
bacterium. In the case of mutations to surface virulence factors, evolution of phage resistance 
may coincide with a substantial decrease in virulence or fitness, owing to generalist adaptive 
mutations.92 
To counteract phage resistance, the synergy of lytic phage with chemical antibiotics has been 
investigated and extensively reviewed elsewhere. Recently, a considerable synergistic effect 
was observed when P. mirabilis was treated with phage in combination with ampicillin, 
showing significant biofilm clearance in vitro.93 In some cases, selection of phage-resistance 
may also restore antibiotic susceptibility.94 
4.4.3. Clearance of Established Biofilms 
The ability of P. mirabilis phage to eradicate a mature biofilm was investigated, in order to more 
accurately mimic the burst release of phage in response to established infection. Concentration 
of bacteriophage deemed to be effective for planktonic cultures (1010 PFU/mL, MOI = 100), as 
well as a lower dose (108 PFU/mL, MOI = 1) to assess infectivity, were added to established 
biofilms in a simple in vitro model. Destruction of mature biofilms at time points following 
addition of phage is shown in Figure 4.10. 
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At MOI of 100 and 1, the phage eradicated 97% (p<0.0001), and 96% (p<0.0001) of biofilm 
biomass after 24 hours,  when compared to the untreated control. However, at 48 hours, these 
values became 49% and 44%, respectively. A reduction in untreated biofilm biomass was 
observed at 48 hours owing to biofilm-limiting factors such as nutrient limitations and 
accumulation of metabolic byproducts. 
With regards to phage concentration, the applied dosage required to eradicate mature biofilms 
did not appear to be higher than that required to kill cells in planktonic culture. Whilst it is 
widely accepted that phage can replicated inside biofilms, the titre required to cause significant 
cell death is expected to be greater, owing to the diffusion limitations imposed by the 
extracellular matrix.95 A possible explaination for this observation is the presence of 
polysaccharide depolymerases (specific hydrolytic enzymes which exploit polysaccharides or 
derivatives of as substrates). Expression of such enzymes confers the phage an important 
advantage, since it enhances the process of invasion and dispersion through a biofilm. 
Numerous studies have shown that polysaccharide depolymerase activity is related to tail-
spike proteins, commonly associated with phage of the classification Podoviridae.96 This 
particular advantage associated with phage treatment of biofilms provides a significant 
advantage over antibiotic therapy; the ability to express such enzymes and thus retain the 
concentration required to cause bacterial cell death when applied to biofilms is unique. When 
considering antibiotic treatement, the concentration required to successfully inhibit biofilm 
formation can be expected to increase up to 1000-fold relative to planktonic culture.97 
Figure 4.10: Evaluation of the ability of phage SM648 to eradicate mature single-species 
biofilms. Reduction in biofilm biomass was quantified using crystal violet biofilm staining at 
various time points post-phage addition (>0 hours), showing absorbance at 595 nm. Mean 
and SEM were calculated for three individual replicates. 1010 PFU/mL and 108 PFU/mL 
corresponds to an MOI of 100 and 1, respectively. 
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4.4.4. Inhibition of P. mirabilis Swarming 
Clinical studies indicate that P. mirabilis may initiate CAUTI by migration from the urethral 
meatus-catheter junction, along the luminal catheter sufaces into the bladder. The swarming 
phenomenon (discussed in Chapter 1), is known to be  cyclic, multicellular behaviour, following 
the differentiation of P. mirabilis swimmer cells (1-2 μm in length), to elongated, 
hyperflagellated swarmer cells (up to 80 μm in length), which exhibit increased expression of 
related virulence factors (Figure 4.11). 
Swarmer cell differentiation in P. mirabilis is known to be accompanied by a substantial 
increase in the production of urease.88,98 Initiation of this motility within the catheterised 
bladder may therefore expedite the generation of alkaline urine conditions that result in the 
deposition of crystalline material on the catheter surface. Furthermore, swarmer cells have 
been shown to move rapidly over all types of catheter surface, with accelerated swarming rates 
demonstrated on silicone catheters, particularly hydrogel-coated variations.87 
The ability of phage to impede swarming via inducing cell lysis from a hydrogel coating was 
investigated. Whilst hydrogel coatings are known to provide specific advantages to patients 
undergoing long-term indwelling catheterisation (e.g. increased patient comfort), it is crucial 
that additive coatings do not accelerate the pathogenesis of infection by facilitating the 
differention of P. mirabilis cells to the swarming motility. The capability of uropathogenic P. 
Figure 4.11: SEM observations of P. mirabilis B4 biofilm formation. A) Differentiation of 
bacterial cells from sparsely-flagellated swimmer cells (green arrow) into elongated, highly-
flagellated swarmer cells (red arrow) upon contact with a solid substrate. B) Entanglement of 
flagella in differentiated swarmer cells, forming a multicellular raft. Inset) Characteristic 
‘bullseye’ swarming structure of P. mirabilis, induced by multicellular cyclic swarming 
behaviour. Scale bars represent A) 5 μm, and B) 1 μm. 
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mirabilis to swarm over catheter sections, coated in PVA hydrogel containing 1010 PFU/mL 
phage SM648 is shown in Figure 4.12.  
Control hydrogel coatings (without phage) were found to permit rapid swarming of P. miraiblis 
across the catheter ‘bridges’. Characteristic concentric swarming rings were clearly visible on 
the uninoculated agar within 24 hours incubation. Hydrogel coating containing high titre phage 
lysates were able to effectively inhibit migration of bacterial cells across the catheter surface. 
Colonisation of P. mirabilis was limited to the sections of agar provided with the initial 
inoculum, whilst the impregnated phage successfully induced cell lysis of motile cells 
attempting to exapand the surface area of the established colony. Control plates that were not 
provided with a catheter bridge were also plated, to ensure that the catheter segment was the 
only pathway by which the bacterial cells migrate from one side to the other.   
These results demonstrate that phage-impregnated hydrogel coatings show significant 
promise as an anti-biofilm strategy for indwelling Foley catheters, by preventing activation of 
the swarming motility and subsequent expression of associated virulence factors (e.g. urease). 
Phage of the order Podoviridae have been suggested to be particularly suited to this application, 
as their short, noncontractile tails and smaller surface area allow for higher titre formualtions 
to be incorporated into catheter coatings with less chance of virion damage.76 
Figure 4.12: Migration of P. mirabilis B4 over 1 cm sections of all silicone catheters coated in 
10% w/v  PVA hydrogel, containing A) no phage, B) 1010 PFU/mL phage SM648. Successful 
translocational swarming was determined via the appearance of characteristic concentric 
swarming rings on the uninoculated side of the catheter ‘bridge’. A significant reduction in 
the initiation of the swarming motility was observed upon incubation with the phage-
containing hydrogel. 
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4.4.5. Evaluation of Prototype Coatings: In Vitro Bladder 
Models 
4.4.5.1. Activation of Catheter Coating: Effect on Catheter 
Blockage 
Experiments assessing the stability and efficacy of prototype phage coatings employed the in 
vitro bladder model system, mimicking late stage infection (initial inoculum of 108 CFU/mL). 
The simulation of established infection allowed for the evaluation of coatings under ‘worst case 
scenario’ conditions. Bladder model inoculums were left to establish for 1 hour before urinary 
flow was restored, allowing the initial biofilm conditioning layer to be deposited prior to model 
start. Hence, conditions were deemed to be more representative of the catheterised urinary 
tract during long-term indwelling catheterisation, particularly within patients suffering from 
recurrent blockage, where sterile catheters may be placed into an existing P. mirabilis culture.  
The blockage of the catheters and subsequent cessation of urine flow was defined as the 
experimental end point. Parallel experiments evaluating the response of coatings to infection 
by E. coli were also undertaken, in order to determine the ability of the system to distinguish 
between urease positive (P. mirabilis) and negative (E. coli) species. Since E. coli species are the 
most commonly encountered pathogens in the urinary tract (including CAB),99 differential 
switch-on of the phage-release coating system is essential, in order for the released phage to 
be of sufficient concentration during the later-stage colonisation of P. mirabilis. Further 
controls evaluating the effect of the polymeric coating (not containing phage) were also 
performed. No significant effect on urinary pH, bacterial population, or time to blockage was 
observed in the presence of the coating control in comparison to uncoated control catheters. 
Inoculation with P. mirabilis and subsequent urease expression caused a significant increase in 
residual urine pH within the two hours of the experiment start. Following the accumulation of 
ammonia within the urine, the formation of the carboxylate anion within the Eudragit trigger 
layer results in swelling of the crosslinked network, thereby exposing the PVA reservoir 
containing phage. Released phage may then diffuse out from the coating into the surrounding 
medium, where they coincide with and infect cells of P. miraiblis encased within the crystalline 
catheter biofilm (Figure 4.13). 
 





Figure 4.13: Analysis of in vitro bladder model conditions at 0, 2, 4, 6 hours after model start, 
and at time of uncoated control blockage (13 hours). A) Measured pH of residual bladder 
urine. B) Release of bacteriophage (φ) from the catheter coating. Data shown are the mean of 
triplicate biological repeats. Error bars represent SEM. *** p < 0.001, ** p < 0.005. 
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Since the threshold for Eudragit swelling occurs at pH 7, elevation of urinary pH above this 
value results in a burst release of phage from the coating (p = 0.0008). The concentration of 
phage release after 2 hours (4.3 x108 PFU/mL) (p = 0.0048) is sufficient to cause significant 
eradication of an established P. mirabilis biofilm, according to previous results. Such response 
was found to correspond to an increase in urinary pH from the healthy region (pH 6.24) to the 
infected region (pH 8.24) within the two hour period.  
A reduction of urinary pH to the healthy region (~pH 6) was observed after release in the 
phage-coated catheter. In contrast, elevated urinary pH was maintained within the uncoated 
control model throughout the duration of the experiment, leading to eventual catheter 
blockage at 13 hours. Gradual decrease of the phage population within the bladder model, and 
hence the failure of the catheter coating to completely inhibit blockage was primarily a 
consequence of elution of virions form the bladder post-release. No significant phage release 
was observed in models devoid of P. mirabilis indicating the stability of the coatings for the 
duration of the experiment, despite exposure to a continuously flowing culture system. 
As a direct consequence of phage release from catheter coatings, a significant reduction in 
bacterial biomass was observed within populations of P. mirabilis (p = 0.0016) (Figure 4.14). 
Decline in cell numbers was directly correlated to the release profile of phage. Contrarily, 
bladders containing uncoated catheters sustained cell populations in the region of 108 CFU/mL, 
leading to eventual blockage of the P. mirabilis models via formation of crystalline biofilms. 
Notably, no significant reduction in cell numbers was observed in the presence of the dual-
layered coating not containing phage, indicating that any observed cell death was as a direct 
result of phage infection. 
Phage remained stable and viable within the hydrogel coating throughout the entire 
experimental procedure, including the process of encapsulation, coating, storage and exposure  
to bladder model conditions (including both acidic, neutral and alkaline pHs, as well as the high 
ionic strength of the urine media). Phage stability within clinical formulations is considered a 
barrier to potential therapeutic applications, yet has received little attention in phage therapy 
literature.81,100 Therefore, the proof of stability within a hydrogel matrix, as well as the 
maintenance of infectivity in the face of challenging physiological conditions represents a step 
forward in this field. 
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Despite an approximately 6-log reduction in P. mirabilis concentration within 2 hours of 
coating activation, triggered release of phage was only successful in delaying catheter blockage, 
rather than preventing it completely. Restoration of bacterial populations within phage-
treated models beteen 4-13 hours after the experimental start point was expected, owing to 
the proportional elution of phage from the bladders. However, it is likely that this observation 
was multifactorial, aided by the development of reistance upon exposure of P. miraiblis to the 
released phage. Although comparable resistance has been observed within in vitro infection 
models in a similar time-frame,101 the fact that this proof-of-concept study utilises a single 
bacteria/phage combination is worth noting.  The issue of resistance may be eased via the use 
of phage ‘cocktails’; two or more species of phage used simultaneously to target bacterial 
infection for clinical applications. Treatment of uropathogenic isolates with phage cocktails has 
shown recent success in vitro,78 although formulation of an effective cocktail requires detailed 
study into host-range profiles, and binding between virus and host under relevant 
physiological conditions. In terms of stability, phage cocktails necessitate careful consideration 
Figure 4.14: Analysis of P. mirabilis population within the in vitro bladder models, containing 
phage (φ)-coated and uncoated control catheters. Measurement of bacterial biomass at 
regular intervals (0, 2, 4, and 6 hours) after model start, as well as at time of control blockage 
(13 hours) was undertaken via direct sampling of residual bladder urine. Data shown are the 
mean of triplicate biological repeats. Error bars represent SEM. ** p < 0.005. 
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of formulation conditions, as each contributing strain may require individually tailored 
formulations to ensure phage viability and stability during storage.  
In this study, burst release of phage from dual-layered coatings, and subsequent reduction in 
viable P. mirabilis population successfully doubled the time to blockage in models containing 
coated catheters, compared to the uncoated control (p = 0.0199) (Figure 4.15). 
These findings are in agreement with previous studies, which have assessed  the ability of lytic 
phage to reduce biofilms caused by common uropathogens, including E. coli and P. 
aeruginosa.102,103 Recent investigation into the effect of phage on P. miraiblis-induced CAUTI 
has shown a delay in catheter blockage of more than 8 days, when infection was modelled in 
its infancy (starting inoculum of 103 CFU/mL). Hence, the delay in catheter blockage presented 
here may translate to days, rather than hours, when assessed using an early stage infection 
model. Achieving such delay of catheter blockage has the potential to improve the health and 
welfare of millions of patients worldwide, as well as relieving some of the substantial financial 
demands that this issue places on the resources of the health service.  
Figure 4.15: Effect of bacteriophage ‘burst reslease’ on catheter blockage. Elevated urinary 
pH within in vitro bladder models induces phage (φ) release from dual-layered, infection-
responsive catheter coatings. The point at which urine flow through the catheters ceased was 
defined as the experimental end point. Data represents the mean of 3 independent biological 
replicates. Error bars represent SEM. *p < 0.05. 
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4.4.5.2. Activation of Catheter Coating: Effect on Crystalline 
Biofilm Formation 
Visual examination of crystalline biofilm formation on the luminal surfaces of the catheter 
showed a significant reduction in biomass within phage coated catheters, compared to 
uncoated controls. Models containing both coated and uncoated catheters were halted after 13 
hours (time of control blockage), and catheters from varying luminal locations were imaged 
using SEM (Figure 4.16).  
At the time of blockage of the uncoated control  catheters, which showed significant 
encrustation, the phage-coated catheters can be seen to be devoid of prominent encrustations. 
The average urinary pH within the coated catheter models 13 hours after the experiment start 
point was 6.77, which is below the nucleation pH of urine and thus insufficient to cause 
crystalline precipitation. Within the control model, the majority of crystalline material can be 
seen to have accumulated in the eyehole region of the uncoated catheter, owing to surface 
irregularitites formed by the extrusion production techniques used in catheter manufacture. 
Such surface striations are particularly prominent in the catheter eyeholes, clearly observable 
in Figure 16F. Experiments in laboratory models showed that P. mirabilis cells may be detected 
in the surface crevices of urinary catheters within 2 hours of incubation. After 4 hours, 
microcolony development was detected from pioneer cells, and, by 6 hours, corresponding to 
the rising urinary pH, crystalline deposits began to form in the developing biofilm, leaing to 
eventual blockage of the eyehole or central lumen.104 Since the release of phage from the 
triggered-release coating prevented the elevation of urinary pH via facilitating bacterial cell 
lysis, eyehole and luminal surfaces of catheters in these models can be seen to be devoid of 
microcrystal aggregates at the time of control blockage. 
The ability of phage to mitigate the growth of uropathogenic biofilms has been explored 
previously, although has shown more efficacy in speacies of E. coli (3-4 log reduction) and P. 
aeruginosa (4 log reduction) than P. mirabilis (1-2 log reduction).77,105 The 6-log reduction 
observed in this study is likely owing to the initiation of a burst response from the polymeric 
coating, resulting in exposure of viable phage to exponential-phase bacterial cells and 
subsequent rapid and substantial decline in cell numbers. Such triggered release systems 
achieve delivery of a therapeutic agent to the relevant physiological location in an adequate 
dosage, at the point of critical colonisation, thus providing a more significant therapeutic 
impact than passive release systems, whose therapeutic reservoirs may be severely depleted 
at more advanced stages of infection. 




Figure 4.16: Representative SEM images of catheter cross sections, comparing levels of 
encrustation and blockage by the crystalline biofilms of P. mirabilis. (A-D) Uncoated control. 
(E-H) With bacteriophage coating. All catheters were removed from in vitro bladder models 
13 hours after model start. (A,B,E,F) Cross sections of catheter eyehole region. (C,D,G,H) Cross 
sections of catheter lumen 1 cm below retention balloon.  
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Quantification of crystalline biofilm formation at the same time point was performed using AAS 
measurements (Figure 4.17). These results revealed low levels of calcium apatite  in the 
biofilms of the phage-treated catheter. This is likely due to the distinct stages of  complex 
crystalline biofilm formation by  P. mirabilis , whereby the accumulation of loose crystalline 
material gathers within the bladder before defined crystals precipitate into the biofilm 
matrix.106 
Limitations of this proof-of-concept model of phage delivery into the catheterised urinary tract 
include the use of a single phage strain on a single species biofilm of P. mirabilis. It is widely 
acknowledged that P. mirabilis is commonly found in mixed communities with other urinary 
tract pathogens. Thus this model does not take in to consideration the potential impact of other 
species on the biofilm structure, phage treatment kinetics and, ultimately, the time taken to 
reach catheter blockage. Indeed, the co-habitaiton of Enterococcus cloacae, Morganella 
morganii, P. aeruginosa and E. coli within catheter biofilms has shown to significantly increase 
the time to blockage within in vitro models of the catheterised urinary tract, owing to active 
exclusion and a degree of antagonism between P. mirabilis and other organisms.107 
Furthermore, the use of only a single phage strain, whilst providing sound proof-of-concept of 
the stability and release capacity in this setting, has a potentially limited therapeutic impact on 
eliminating P. mirabilis crystalline biofilms, and subsequently extending catheter lifetime. 
Figure 4.17: Quantitative analysis of crystalline biofilm biomass on catheter surfaces by 
atomic absorption spectroscopy.  Comparison of phage(φ)-coated and uncoated catheters 13 
hours post-incoluation of in vitro bladder models with P. mirabilis. Data shown are the mean 
of triplicate repeats. Error bars represent SEM. *** p < 0.001.  
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Whilst it is logical to assume that the use of a phage cocktail may successfully increase time to 
blockage, in reality, increasing phage productivity requires careful consideration of a number 
of potential limiting factors. Phage therapy with cocktails results in complex pharmacology, 
potentially resulting in reduced infection robustness or interference by one or more of the 
participating phage types.108 Moreover, treatment via phage cocktail may not effectively 
prevent the development of phage-resistant mutant populations. Such populations may not be 
present in sufficiently high concentration to support phage amplification to control population 
growth, resulting in cocktail populations ultimately equivalent to primary treatment. 
Successful secondary treatment via administration of phage cocktails may only be possible if 
phage types are supplied in sequential doses or as a continuous, high titre formulations.58




There is no doubt that phage therapy is an attractive solution for combatting the escalating 
antibiotic crisis. Numerous studies have highlighted the in vitro and in vivo potential of lytic 
phage, resulting in a number of clinical trials over the last decade . Nevertheless, there remains 
obvious challenges ahead for phage therapy, particularly in terms of regulatory policy. Fuelled 
by the ever-increasing need for antibiotic alternatives, regulatory processes must be refined 
and approached from a novel phage-based perspective, based on knowledge of phage 
applications for specific implementation. 
This study  demonstrates the potential of phage therapy  for the control of CAUTI, in particular 
the delay of encrustation and blockage following infection and device colonisation by P. 
mirabilis.  Local delivery of lytic phage was achieved via the employment of a dual-layered 
polymeric architecture, and manifested in an approximately 6-log reduction in viable bacterial 
cells within an in vitro model of the catheterised urinary tract. Reduction in bacterial 
population and consequent prevention of crystal aggregation was successful in doubling the 
time to catheter blockage, thus extending catheter lifetime and potentially reducing the 
likelihood of serious symptomatic episodes associated with catheter occlusion. Phage release 
was achieved in situ, in direct response to elevation of urinary pH and without external 
interference or treatment administration. Phage were found to remain stable and viable 
throughout production and degradation of the polymeric coating, representing a novel 
encapsulation and delivery mechanism for lytic bacteriophage within the body. 
Further development of the proof-of-concept system described here involves the  formulation 
of a multiphage ‘cocktail’, to improve the broad-spectrum capabiltiies and therapeutic 
potential of phage.  However, an in-depth understanding of phage kinetics, interference, 
competition and synergy is required to optimise the compatibility of contributing strains. 
Furthermore in vitro evaluation of this system on multispecies biofilms would provide a more 
accurate representation of the pathogenic spectrum in vivo. 
Whilst phage has undoubtedly shown potential for the prevention and treatment of CAUTI, 
fulfilment of the potential of phage within the clinical setting requires a paradigm shift  
throughout human medicine.  Additionally, the issue of phage resistance remains problematic 
in the design of generalised medical products such as phage-impregnated urinary catheters. 
Ultimately, the success of phage therapy will reply upon the acquisition of detailed information 
on the properties and behaviour of  the specific-bacterial system, both in vitro and in vivo.




1. E. Martens and A. L. Demain, Journal of Antibiotics, 2017, 70, 520–526. 
2. A. Fleming, British Journal of Experimental Pathology, 1929, 10, 226–236. 
3. J. Lederberg, Science, 2000, 288, 287–293. 
4. E. Y. Klein, T. P. Van Boeckel, E. M. Martinez, S. Pant, S. Gundra, S. A. Levin, H. Goossens 
and R. Laxminarayan, Proceedings of the National Academy of Sciences, 2018, 115, 
E3463–E3470. 
5. The Review on Antimicrobial Resistance, Antimicrobial Resistance: Tackling a crisis for the 
health and wealth of nations, 2014. 
6. T. S. Crofts, A. J. Gasparrini and G. Dantas, Nature Reviews Microbiology, 2017, 15, 422–
434. 
7. A. Hollis and Z. Ahmed, New England Journal of Medicine, 2013, 369, 2474–2476. 
8. Q. Chang, W. Wang, G. Regev-Yochay, M. Lipsitch and W. P. Hanage, Evolutionary 
Applications, 2015, 8, 240–247. 
9. J. A. Perry, E. L. Westman and G. D. Wright, Current Opinion in Microbiology, 2014, 21, 
45–50. 
10. K. J. Forsberg, S. Patel, M. K. Gibson, C. L. Lauber, R. Knight, N. Fierer and G. Dantas, 
Nature, 2014, 509, 612–616. 
11. V. M. Dcosta, C. E. King, L. Kalan, M. Morar, W. W. L. Sung, C. Schwarz, D. Froese, G. Zazula, 
F. Calmels, R. Debruyne, G. B. Golding, H. N. Poinar and G. D. Wright, Nature, 2011, 477, 
457–461. 
12. H. C. Neu, Applied microbiology, 1969, 17, 783–786. 
13. R. I. Aminov, M. Otto and A. Sommer, Frontiers in Microbiology, 2010, 1, 1–7. 
14. K. Lewis, Nature Reviews Drug Discovery, 2013, 12, 371–387. 
15. C. Walsh, Nature, 2000, 406, 775–781. 
16. W. V. Shaw, L. C. Packman, B. D. Burleigh, A. Dell, H. R. Morris and B. S. Hartley, Nature, 
1979, 282, 870–872. 
17. K. Bush, Critical Care, 2010, 14, 224. 
18. P. Courvalin, Clinical Infectious Diseases, 2006, 42, S25–S34. 
19. Y. Katayama, T. Ito and K. Hiramatsu, Antimicrobial Agents and Chemotherapy, 2000, 44, 
1549–1555. 
20. P. Ruggerone, S. Murakami, K. M. Pos and A. Vargiu, Current Topics in Medicinal 
Chemistry, 2013, 13, 3079–3100. 
21. A. Poulou, E. Voulgari, G. Vrioni, V. Koumaki, G. Xidopoulos, V. Chatzipantazi, F. Markou 
and A. Tsakris, Journal of Clinical Microbiology, 2013, 51, 3176–3182. 
 Chapter 4  
144 
 
22. B. B. Flury, M. J. Ellington, K. L. Hopkins, J. F. Turton, M. Doumith, R. Loy, P. Staves, V. 
Hinic, R. Frei and N. Woodford, Antimicrobial Agents and Chemotherapy, 2016, 60, 2383–
2390. 
23. M. O. A. Sommer, C. Munck, R. V. Toft-Kehler and D. I. Andersson, Nature Reviews 
Microbiology, 2017, 15, 689–696. 
24. K. H. Luepke and J. F. Mohr, Expert Review of Anti-Infective Therapy, 2017, 15, 425–433. 
25. B. Spellberg, Critical Care, 2014, 18, 288. 
26. J. O’Neil, Securing New Drugs for Future Generations: The Pipeline of Antibiotics, 2015. 
27. A. Sertkaya, J. Eyraud, A. Birkenbach, C. Franz, N. Ackerley, V. Overton and E. R. Group, 
ERG, 2014, 14–25, 1–107. 
28. K. H. Luepke, K. J. Suda, H. Boucher, R. L. Russo, M. W. Bonney, T. D. Hunt and J. F. Mohr, 
Pharmacotherapy, 2017, 37, 71–84. 
29. G. T. Schumock, J. A. Stubbings, M. D. Wiest, E. C. Li, K. J. Suda, L. M. Matusiak, R. J. Hunkler 
and L. C. Vermeulen, American Journal of Health-System Pharmacy, 2018, 73, 1058–
1075. 
30. ECDC, ECDC Country Visit to Belgium to Discuss Antimicrobial Resistance Issues, 2018. 
31. World Health Organisation, Global Action Plan on Antimicrobial Resistance, 2015. 
32. V. L. Simpkin, M. J. Renwick, R. Kelly and E. Mossialos, Journal of Antibiotics, 2017, 70, 
1087–1096. 
33. World Health Organisation, Global Priority List of Antibiotic-Resistant Bacteria to Guide 
Research, Discovery and Development of New Antibiotics, 2017. 
34. J. A. Al-Tawfiq, R. Laxminarayan and M. Mendelson, International Journal of Infectious 
Diseases, 2017, 54, 77–84. 
35. S. W. Dickey, G. Y. C. Cheung and M. Otto, Nature Reviews Drug Discovery, 2017, 16, 457–
471. 
36. A. DiGiandomenico and B. R. Sellmna, Current Opinion in Microbiology, 2015, 27, 78–85. 
37. S. Yu, X. Zhu, J. Zhou and Z. Cai, Royal Society Open Science, , DOI:10.1098/rsos.170702. 
38. K. M. Younis, G. Usup and A. Ahmad, Environmental Science and Pollution Research, 2016, 
23, 4756–4767. 
39. R. C. Allen, R. Popat, S. P. Diggle and S. P. Brown, Nature Reviews Microbiology, 2014, 12, 
300–308. 
40. T. Maeda, R. García-Contreras, M. Pu, L. Sheng, L. R. Garcia, M. Tomás and T. K. Wood, 
ISME Journal, 2012, 6, 493–501. 
41. A. J. McCoy, H. Liu, T. J. Falla and J. S. Gunn, Antimicrobial Agents and Chemotherapy, 
2001, 45, 2030–2037. 
42. R. Belas, J. Manos and R. Suvanasuthi, Infection and Immunity, 2004, 72, 5159–5167. 
 Chapter 4  
145 
 
43. Y. Wang, H. Venter and S. Ma, Current drug targets, 2016, 17, 702–719. 
44. A. Pantel, C. Dunyach-Remy, C. N. Essebe, J. Mesureur, A. Sotto, J. M. Pagès, M. H. Nicolas-
Chanoine and J. P. Lavigne, Antimicrobial Agents and Chemotherapy, 2016, 60, 2901–
2911. 
45. J. Nzakizwanayo, P. Scavone, S. Jamshidi, J. A. Hawthorne, H. Pelling, C. Dedi, J. P. Salvage, 
C. K. Hind, F. M. Guppy, L. M. Barnes, B. A. Patel, K. M. Rahman, M. J. Sutton and B. V. Jones, 
Scientific Reports, , DOI:10.1038/s41598-017-12445-w. 
46. H. Stolp and M. P. Starr, Antonie van Leeuwenhoek, 1963, 29, 217–248. 
47. R. E. Sockett, Annual Review of Microbiology, 2009, 63, 523–539. 
48. R. M. Q. Shanks, V. R. Davra, E. G. Romanowski, K. M. Brothers, N. A. Stella, D. Godboley 
and D. E. Kadouri, PLoS ONE, 2013, 8, e66723. 
49. K. Harini, V. Ajila and S. Hegde, Journal of Indian Society of Periodontology, 2013, 17, 
823–825. 
50. A. C. Greene, Trends in Biotechnology, 2017, 36, 127. 
51. A. A. Gomaa, H. E. Klumpe, M. L. Luo, K. Selle, R. Barrangou and C. L. Beisel, mBio, 2014, 
5, e00928-13. 
52. A. M. Comeau, G. F. Hatfull, H. M. Krisch, D. Lindell, N. H. Mann and D. Prangishvili, 
Research in Microbiology, 2008, 159, 306–313. 
53. E. C. Keen, BioEssays, 2015, 37, 6–9. 
54. S. Chibani-Chennoufi, A. Bruttin, M. L. Dillmann and H. Brüssow, Journal of Bacteriology, 
2004, 186, 3677–3686. 
55. E. H. Hankin, Annales De l’Institut Pasteur, 1896, 10, 511–523. 
56. F. Twort, Lancet, 1915, 186, 1241–1243. 
57. F. D’Herelle, L’academie des Sciences Paris, 1917, 165, 373–375. 
58. B. K. Chan, S. T. Abedon and C. Loc-Carrillo, Future microbiology, 2013, 8, 769–83. 
59. G. F. Hatfull and R. W. Hendrix, Current Opinion in Virology, 2011, 4, 298–303. 
60. H. W. Ackermann, in Bacteriophages. Methods in Molecular Biology, eds. M. R. J. Clokie 
and A. M. Kropinski, Humana Press, 501st edn., 2009, pp. 127–141. 
61. F. L. Nobrega, M. Vlot, P. A. de Jonge, L. L. Dreesens, H. J. E. Beaumont, R. Lavigne, B. E. 
Dutilh and S. J. J. Brouns, Nature Reviews Microbiology, , DOI:10.1038/s41579-018-
0070-8. 
62. A. Campbell, Nature Reviews Genetics, 2003, 4, 471–477. 
63. S. Gandon, Trends in Microbiology, 2016, 24, 356–365. 
64. E. Emond and S. Moineau, in Bacteriophage: Genetics and Molecular Biology, eds. S. 
McGrath and D. van Sinderen, Caister Academic Press, Norfolk, UK, 2007, pp. 93–125. 
65. C. Verheust, K. Pauwels, J. Mahillon, D. R. Helinski and P. Herman, Applied Biosafety, 
 Chapter 4  
146 
 
2010, 15, 32–44. 
66. T. Hayashi, K. Makino, M. Ohnishi, K. Kurokawa, K. Ishii, K. Yokoyama, C. G. Han, E. 
Ohtsubo, K. Nakayama, T. Murata, M. Tanaka, T. Tobe, T. Iida, H. Takami, T. Honda, C. 
Sasakawa, N. Ogasawara, T. Yasunaga, S. Kuhara, T. Shiba, M. Hattori and H. Shinagawa, 
DNA Research, 2001, 8, 11–12. 
67. M. W. Eklund, F. T. Poysky and S. M. Reed, Nature New Biology, 1972, 172, 480–482. 
68. O. Sekulovic and L.-C. Fortier, in Clostridium difficile: Methods and Protocols, Methods in 
Molecular Biology, eds. A. P. Roberts and P. Mullany, Springer, 2106, pp. 143–145. 
69. C. Loc-Carrillo and S. T. Abedon, Bacteriophage, 2011, 1, 111–114. 
70. J. R. Clark, Future Virology, 2015, 10, 449–461. 
71. C. Hawkins, D. Harper, D. Burch, E. Änggård and J. Soothill, Veterinary Microbiology, 
2010, 146, 309–313. 
72. A. Wright, C. H. Hawkins, E. E. Änggård and D. R. Harper, Clinical Otolaryngology, 2009, 
34, 349–357. 
73. P. Jault, T. Leclerc, S. Jennes, J. P. Pirnay, Y.-A. Que, G. Resch, A. F. Rousseau, F. Ravat, H. 
Carsin, R. Le Floch, J. V. Schaal, C. Soler, C. Fevre, I. Arnaud, L. Bretaudeau and J. Gabard, 
The Lancet Infectious Diseases, , DOI:10.1016/S1473-3099(18)30482-1. 
74. A. K. Daly, Current Opinion in Drug Discovery and Development, 2007, 10, 29–36. 
75. L. F. Furfaro, M. S. Payne and B. J. Chang, Frontiers in Cellular Infection and Microbiology, 
2018, 8, 1–7. 
76. L. D. R. Melo, P. Veiga, N. Cerca, A. M. Kropinski, C. Almeida, J. Azeredo and S. Sillankorva, 
Frontiers in Microbiology, 2016, 7, 1–12. 
77. L. Carson, S. P. Gorman and B. F. Gilmore, FEMS Immunology and Medical Microbiology, 
2010, 59, 447–455. 
78. J. Nzakizwanayo, A. Hanin, D. R. Alves, B. McCutcheon, C. Dedi, J. Salvage, K. Knox, B. 
Stewart, A. Metcalfe, J. Clark, B. F. Gilmore, C. G. M. Gahan, A. T. A. Jenkins and B. V. Jones, 
Antimicrobial Agents and Chemotherapy, 2016, 60, 1530–1536. 
79. W. Sybesma, R. Zbinden, N. Chanishvili, M. Kutateladze, A. Chkhotua, A. Ujmajuridze, U. 
Mehnert and T. M. Kessler, Frontiers in Microbiology, 2016, 7, 1–9. 
80. J. P. Pirnay, D. De Vos, G. Verbeken, M. Merabishvili, N. Chanishvili, M. Vaneechoutte, M. 
Zizi, G. Laire, R. Lavigne, I. Huys, G. Van Den Mooter, A. Buckling, L. Debarbieux, F. 
Pouillot, J. Azeredo, E. Kutter, A. Dublanchet, A. Górski and R. Adamia, Pharmaceutical 
Research, 2011, 28, 934–937. 
81. D. J. Malik, I. J. Sokolov, G. K. Vinner, F. Mancuso, S. Cinquerrui, G. T. Vladisavljevic, M. R. 
J. Clokie, N. J. Garton, A. G. F. Stapley and A. Kirpichnikova, Advances in Colloid and 
Interface Science, 2017, 249, 100–133. 
 Chapter 4  
147 
 
82. US9457132B2, 2016. 
83. A. M. Brown, Iowa State University, 2014. 
84. H. Hathaway, D. R. Alves, J. Bean, P. P. Esteban, K. Ouadi, J. Mark Sutton and A. T. A. 
Jenkins, European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 437–441. 
85. J. E. Bean, D. R. Alves, M. Laabei, P. P. Esteban, N. T. Thet, M. C. Enright and A. T. A. Jenkins, 
Chemistry of Materials, 2014, 26, 7201–7208. 
86. D. Bray, J. Bagu and P. Koegler, Microscopy Research and Technique, 1993, 6, 489–495. 
87. N. Sabbuba, G. Hughes and D. J. Stickler, BJU International, 2002, 89, 55–60. 
88. B. V. Jones, E. Mahenthiralingam, N. A. Sabbuba and D. J. Stickler, Journal of Medical 
Microbiology, 2005, 54, 807–813. 
89. V. Morozova, Y. Kozlova, E. Shedko, I. Babkin, A. Kurilshikov, O. Bokovaya, A. Bardashova, 
A. Yunusova, A. Tikunov, A. Tupikin, E. Ryabchikova and N. Tikunova, Archives of 
Virology, 2018, 163, 2189–2197. 
90. GenBank, National Center for Biotechnology Information, Nucleotide, EST, and GSS 
Databases. 
91. P. Manohar, R. Nachimuthu and B. S. Lopes, BMC Microbiology, 2018, 18, 1–11. 
92. F. Oechslin, Viruses, 2018, 10, 1–23. 
93. M. Yazdi, M. Bouzari and E. A. Ghaemi, Journal of Molecular Microbiology and 
Biotechnology, 2018, 28, 37–46. 
94. B. K. Chan, M. Sistrom, J. E. Wertz, K. E. Kortright, D. Narayan and P. E. Turner, Scientific 
Reports, , DOI:10.1038/srep26717. 
95. S. González, L. Fernández, A. B. Campelo, D. Gutiérrez, B. Martínez, A. Rodríguez and P. 
García, Applied and Environmental Microbiology, 2017, 83, e1-16. 
96. D. Gutiérrez, L. Rodríguez-Rubio, B. Martínez, A. Rodríguez and P. García, Frontiers in 
Microbiology, 2016, 7, 1–15. 
97. S. M. Jacobsen, D. J. Stickler, H. L. T. Mobley and M. E. Shirtliff, Clinical Microbiology 
Reviews, 2008, 21, 26–59. 
98. C. Ariison, H. Lai and C. Hughes, Molecular Microbiology, 1992, 6, 1583–1591. 
99. S. M. Jacobsen, D. J. Stickler, H. L. T. Mobley and M. E. Shirtliff, Clinical Microbiology 
Reviews, 2008, 21, 26–59. 
100. H. Hathaway, S. Milo, J. M. Sutton and T. A. Jenkins, Therapeutic Delivery, 2017, 8, 543–
556. 
101. W. Fu, T. Forster, O. Mayer, J. J. Curtin, S. Lehman and R. M. Donlan, Antimicrobial Agents 
and Chemotherapy, 2010, 54, 397–404. 
102. A. Chibeu, E. Lingohr, L. Masson, A. Manges, J. Harel, H. W. Ackermann, A. Kropinski and 
P. Boerlin, Viruses, 2012, 4, 471–487. 
 Chapter 4  
148 
 
103. K. S. Liao, S. M. Lehman, D. J. Tweardy, R. M. Donlan and B. W. Trautner, Journal of applied 
microbiology, 2012, 1131530-, 1530–1539. 
104. D. Stickler, R. Young, G. Jones, N. Sabbuba and N. Morris, Urological Research, 2003, 31, 
306–311. 
105. S. M. Lehman and R. M. Donlan, Antimicrobial Agents and Chemotherapy, 2015, 59, 1127–
1137. 
106. S. a. Wilks, M. J. Fader and C. W. Keevil, PLoS ONE, 2015, 10, 1–13. 
107. S. M. Macleod and D. J. Stickler, Journal of Medical Microbiology, 2007, 56, 1549–1557. 
108. A. S. Nilsson, Upsala Journal of Medical Sciences, 2014, 119, 192–198. 
 Chapter 5  
149 
 
Chapter 5: Development of a Novel Small-Molecule 
Urease Inhibitor for the Control of Urinary Catheter 
Encrustation 
5.1. Abstract 
With the looming prospect of the diminishing efficacy of current chemical antibiotics, the 
world’s population faces the dawn of the ‘post-antibiotic era’, owing to the widespread and 
indiscriminate use of antibiotics in both the healthcare and agricultural setttings. Enzymes, 
particularly those vital for pathogenesis, are considered to be effective and promising targets 
for small molecule intervention in human bacterial infection.  
Urease is a nickel-dependent metalloenzyme known to play a crucial role in the pathogenesis 
and virulence of catheter-associated P. mirabilis infection. Targeting urease as a novel 
therapeutic candidate facilitates the disarming of bacterial virulence without effecting 
bacterial fitness, therefore limiting the selective pressure placed on the invading population. 
Small molecule enzyme inhibitors based on the molecular structure of the native substrate 
have proved promising in rational drug design, including those with antiureolytic inhibitory 
effects on urease. 
The research presented in this chapter decribes the design, synthesis, and in vitro evaluation 
of a novel small molecule enzyme inhibitor, able to prevent encrustation and blockage of 
urinary catheters in a physiologically representative in vitro model of the catheterised urinary 
tract. The synthesised organic thiol compound is a structural analogue of urea, showing 
promising competitive activity against urease from jack bean (Canavalia ensiformis) as well as 
cytoplasmic P. mirabilis urease (Figure 5.1). 
Figure 5.1: Schematic representation of antiureolytic effects of a competitive small molecule 
urease inhibitor. 





Biological processes depend on a well-orchestrated series of chemical reactions, many of which 
proceed too slowly on their own to sustain life. Enzymes are natural catalysts, which greatly 
accelerate the rates of such reactions, thus facilitating many biochemical processes within 
living cells. Like all catalysts, enzymes are characterised by two main properties. Firstly, they 
increase the rate of rection without themselves being consumed or permanently altered by the 
process. Secondly, they accelerate the reaction rate without altering the chemical equilibrium 
between reactants and products. The equilibrium of the reaction is determined by the final 
energy states of the substrate and product. In order for the reaction to proceed spontaneously, 
the substrate must first be converted into a higher energy transition state. The energy required 
to reach the transition state (known as the activation energy) constitutes a barrier to the 
progress of the reaction, thus limiting the rate of both the forward and backward reactions.1 
Enzymes facilitate a reduction in activation energy, thereby increasing the rate of reaction 
(Figure 5.2).  
Owing to their complex 3-dimensional proteinaceous structures, enzymes are capable of 
exhibiting remarkable specificity for their molecular substrates, including 
Figure 5.2: Energy diagram for enzyme-catalysed and uncatalysed biochemical reactions. 
Addition of a enzyme lowers the energy required to reach the transition state (activation 
energy), thus accelerating the overall rate of reaction.   
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chemo/stereoselectivity, enantiomeric and regioselectivity. To account for this speficity, a 
number of binding models have been proposed. The simplest ‘lock-and-key’ model assumes 
that the enzyme’s active site is a rigid, static structure, to which only one complementary 
substrate structure may fit. However, this model has been proven to be largely oversimplified. 
Indeed, the majority of enzyme active sites actively undergo alteration in protein geometry 
upon substrate binding. In such cases, the conformation of the substrate is altered such that it 
more closely resembles the transition state. In this ‘induced fit’ model, the substrate distortion 
may facilitate its conversion to the transition state via the weakening of critical bonds, and 
stabilisation via tight-binding to the enzyme.2 
5.2.2. Enzyme Kinetics 
The study of enzyme kinetics concerns the rate of product formation over time as a function of 
enzyme and substrate concentration under specific, predefined conditions. Such investigations 
facilitate the calculation of key parameters related to product turnover, thus allowing 
quantifiable determination of enzyme activity.  
5.2.2.1. The Michaelis Menten Model 
The binding of an enzyme [E] to a substrate [S], forms a complex [ES], which in turn releases a 
product [P], regenerating the original enzyme. The generalised reaction scheme for enzyme-
catalysed product formation may be expressed as: 
Scheme 1: General form of a single-substrate enzyme-catalysed reaction. Rate constants for 
each step are represented by k1, k-1, k2, and k-2. 
In 1913, Leonor Michaelis and Maud Menten postulated that the formation of the enzyme-
substrate complex was almost instantaneous, and the rate of reaction was proportional to the 
concentration of this complex.3 Thus, the kinetic consideration can be restricted to the initial 
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Scheme 2: Single-substrate enzyme-catalysed reaction under conditions considering initial 
rate. Since [P] = 0, k-2 is considered negligible.  





=  k2[ES] 
(1) 
The overall rate of production of ES equates to the difference between the rates of the 
elementary reactions leading to its appearance and disappearance: 
 d[ES]
dt
= k1[E][S] − k−1[ES] − k2[ES] 
(2) 
Equation 2 cannot be explicitly integrated without two simplifying assumptions: 











Where Ks is the dissociation constant of the first step of the enzymatic reaction. 
2. Assumption of the steady state. First proposed by Briggs and Haldane,4 the so called 
‘steady state’ assumption states that the concentration of [ES] remains constant, as the 





Kinetic expressions for overall reactions must be formulated in terms of experimentally 
measurable quantities. Whilst the quantities [ES] and [E] are not generally directly measurable 
(since [E] refers to active sites), the total enzyme concentration [E0] is usually readily 
determined: 
 [E0] = [E] + [ES] (5) 
The rate equation for the enzymatic reaction is then derived as follows. Combining (2) with the 
steady state assumption (4) and the conservation condition (5), yields: 
 k1([E]0 − [ES])[S] = (k−1 + k2)[ES] (6) 
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Which, on rearrangement becomes: 
 [ES](k−1 + k2 + k1[S]) = k1[E]0[S] (7) 














The initial rate (Equation 1) may then be expressed in terms of the experimentally measurable 










The use of initial velocity (experimentally defined as the measured velocity before more than 
~10% of the substrate is converted to product) minimizes complicating factors such as the 
effects of reversible reaction, inhibition of the enzyme by the product, and progressive 
inactivation of the enzyme. 
The maximal velocity of a reaction (Vmax), occurs at high substrate concentrations when the 
enzyme is saturated, thus existing purely in the form of ES: 
 Vmax = k2[E]0 (11) 







This expression, the Michaelis Menten equation, is considered the fundamental equation of 
enzyme kinetics.  
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5.2.2.2. The Significance of the Michaelis Menten Constants 
The Michaelis Menten equation is applicable to most enzymes, and is of critical importance in 
the understanding of enzyme action in biological systems. The parameters KM and Vmax are 
determined by measuring reaction velocity at varying concentrations of substrate.  
Whilst Vmax is not an intrinsic property of the enzyme, it may be obtained via various 
extrapolation techniques, and demonstrates the maximal velocity of a given enzyme under 
predefined conditions. In contrast to Vmax, the parameter KM is an intrinsic property of the 
enzyme, and has a simple operational definition. KM is the substrate concentration at which the 
reaction velocity is half-maximal (the magnitude of which is highly dependent on the nature of 
the enzyme and substrate, and behaves as a function of temperature and pH). Therefore, if an 
enzyme has a small value of KM, it achieves maximal catalytic efficiency at low substrate 
concentrations. Provided that the assumption k2 < k1 remains true, KM provides an inverse 
measure of the enzyme’s affinity for its substrate- where a high KM indicates a low affinity, and 
vice versa.5   
5.2.2.3. Sigmoidal Kinetics 
Sigmoidal kinetic profiles are the result of enzymes that demonstrate positive cooperative 
binding. The term cooperativity refers to the observation that the binding of the substrate at 
one site affects the affinity of other sites for their substrates. The resultant sigmoid saturation 
curve (unlike the rectangular hyperbola traced by the Michaelis Menten equation) is described 








Where h is the Hill coefficient, widely used as a measure of cooperativity. If an enzyme exhibits 
no cooperativity, h = 1. A value of h greater than 1 implies positive cooperativity, where initial 
binding facilitates subsequent binding . The constant K is analogous to KM of the Michaelis 
Menten model, although only represents an approximation, since neither substrate can fully 
saturate the enzyme. Since the obtained values of KM and Vmax obtained in this matter are 
approximate, they are generally referred to as ‘apparent’ KM and Vmax values.7 
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5.2.3. Enzyme Inhibition  
Substances that reduce the activity of an enzyme-catalysed reaction are known as inhibitors. 
Inhibitory action of such molecules may occur either by directly or indirectly influencing the 
catalytic properties of the active site. The design, synthesis, characterisation and exploration 
of the potency and spectrum of biologically active enzyme inhibitors has become an area of 
great interest in recent years, particularly in the fields of medicinal and pharmacological 
research. 
The activity of an enzyme may be influenced by nonspecific factors (e.g. temperature and pH), 
owing to their inherent sensitivity. Alternatively, specific molecules may reduce or inhibit the 
catalytic activity of the enzyme via binding to the active site, blocking the entry of the substrate 
to the site, or inducing a conformational change within the enzyme structure that prevents the 
admission of the substrate to the active site.8 Based on the mechanism of interaction with the 
enzyme, inhibitor binding may be classified as either reversible or irreversible (Figure 5.3). 
Generally, reversible inhibitors form non-covalent interactions with various parts of the 
enzyme surface, which may be easily reversed by dilution or dialysis. In contrast, irreversible 
inhibitors covalently interact with surface functional groups, forming strong bonds that may 
persist even during complete protein degradation.9 
Figure 5.3: General classification of enzyme inhibitors. 
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5.2.3.1. Reversible Inhibitors 
Reversible inhibitors may be classed as competitive, uncompetitive or non-competitive, 
employing non-covalent interactions such as hydrogen bonding, hydrophobic interactions and 
ionic bonding to disrupt enzyme activity. Different variations of reversible inhibition affect the 
Michaelis Menten constants differently and thus are distinguished by the relationship between 
the velocities of the inhibited and uninhibited reactions.9 General forms of the three canonical 















Figure 5.4: General forms of reversible enzyme inhibition. A) Competitive, B) uncompetitive , 
and C) non-competitive inhibition. The inhibition constant (Ki) governs transitions between 
the different binding states: free enzyme (E), enzyme-substrate complex (ES), enzyme-
inhibitor complex (EI), and enzyme-substrate-inhibitor complex (ESI). The enzyme + product 
(E + P) state represents the end of the enzymatic turnover cycle. 
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The enzyme-inhibitor dissociation constant, Ki, is analogous to KM for uninhibited reactions, 
and reflects the binding affinity of the inhibitor for a particular enzyme. Experimentally, the Ki 
may be defined as the inhibitor concentration at which half-maximal inhibition is observed. 
I. Competitive Inhibition 
Competitive inhibitors are structurally related to the substrate, and bind reversibly to the 
active site. Occupation of the active site by the inhibitor is mutually exclusive with the 
substrate, hence both inhibitor and substrate are in direct competition. Since the reaction rate 
is directly proportional to [ES], reduction in [ES] concentration to account for formation of [EI] 
lowers the catalytic efficiency. Consequently, rate reduction is directly proportional to 
inhibitor concentration; increasing substrate concentration towards saturation alleviates 
competitive inhibition. 
Kinetically, formation of the catalytically inactive [EI] reduces the availability of free enzyme 
for substrate binding. Thus, the KM of the reaction is increased, whilst the turnover number 
(Vmax) remains unchanged. This may be shown mathematically by modifying the standard 
Michaelis Menten kinetics for competitive inhibition.10 





















The total enzyme concentration in the system is the sum of the concentration of the three forms 
in which the enzyme exists: 
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 [E0] = [E] + [ES] + [EI] (18) 
Substituting terms for [ES] (Equation 16) and [EI] (Equation 17): 
 
























Substituting (20) into the rate of product formation (Equation 1) yields the modified rate 




































Hence, the effect of a competitive inhibitor is to increase the apparent value of KM by the factor 
(1+[I]/Ki), to reduce that of Vmax/KM by the same factor,  yet leave Vmax unchanged.11 
II. Uncompetitive Inhibition  
Uncompetitive inhibition occurs when the inhibitor (which need not be structurally similar to 
the substrate) is unable to bind to the free enzyme, but instead binds to the pre-formed 
enzyme-substrate complex. Such action renders the ES complex catalytically inactive, via 
inducing structural distortion of the active and allosteric sites of the complexed enzyme. 
Increasing substrate concentration towards saturation is ineffective at reversing 
uncompetitive inhibition; reversal may only be achieved via dialysis.  
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Modification of Michaelis Menten kinetics for uncompetitive inhibition may be followed 
according to the derivation in Section 5.1.3.1.I. Briefly, the total enzyme concentration in the 
system may be described as the sum of the three forms in which the enzyme exists: 
 [E0] = [E] + [ES] + [ESI] (24) 
Since the expression for the [ES] complex may be defined according to Equation 16, the inactive 













The derivation may then be completed as follows: 
 





































=  ν0 =
k2[E0][S]


















The apparent Michaelis constant for competitive inhibition is defined according to Equation 
22, yielding the overall rate equation for uncompetitive inhibition: 













Thus, a decrease in the apparent values of both KM and Vmax is observed (Vmax/KM is unchanged 
since the effect is equal on both parameters). The seeming increase in affinity of the enzyme 
for its substrate (i.e. a decrease in KMapp) is owing to unproductive substrate binding, resulting 
in a decrease in free enzyme concentration.12 
III. Non-Competitive Inhibition 
In situations of non-competitive inhibition, the binding of the inhibitor reduces enzyme 
activity, but does not affect the binding of the substrate. This is achieved via the binding of the 
inhibitor to sites other than the active site, known as allosteric sites. Hence, the degree of 
inhibition is dependent only on the concentration of the inhibitor, and the relative rates of 
substrate and inhibitor binding are independent of each other. Since binding occurs at an 
allosteric site, non-competitive inhibitors have identical affinities for both free [E] and [ES] 
complexes. The total enzyme concentration may now be expressed in as four individual 
contributing states:  
 [E0] = [E] + [ES] + [ESI] + [EI] (33) 
Thus the derivation may be completed as follows:  
 












































Thus, non-competitive inhibition reveals an unaltered KM but a reduced Vmax, since the enzyme 
is rendered enzymatically hindered, yet the binding affinity for the substrate is unaffected. 5,13 
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5.2.3.2. Irreversible Inhibition 
Compounds that interact with the enzyme in such a way to cause permanent loss of function 
are known as irreversible inhibitors. Formation of highly stable covalent bonds (generally with 
active site residues) are able to render the enzyme inactive even in trace concentrations. Thus, 
such inhibitors are often referred to as ‘catalytic poisons’.9  
Irreversible inhibitors are generally of limited use in human medicine, as many such 
compounds behave as potent toxins. For example, organophosphorus compounds including 
diisopropyl fluorophosphate (DFP) inhibit acetylcholinesterase activity via covalent 
interaction with a serine residue of the active site. The physiological manifestation of this 
inactivation is interference with the neurotransmitter activation at nerve synapses, resulting 
in the constant propagation of nerve impulses. DFP was originally evaluated by the British as 
a chemical warfare agent during World War Two, and modified versions of this compound have 
recently been widely exploited as organophosphate pesticides.14 
A subset of irreversible inhibitors, known as ‘suicide inhibitors’ provide useful information on 
the binding location and composition of the active site. Suicide inhbitors become activated by 
the first intermediary steps of the biochemical transformation upon binding with the active 
site, in the same manner as the true substrate. However, the irreversible binding process 
prevents the release of product, thus inactivating the enzyme. Kinetically, the binding of suicide 
inhibitors reduces the possible concentration of [ES] complex, although the reimaining 
unbound molecules remain functional in terms of KM and Vmax.15 
5.2.3.3. Enzyme Inhibition in Drug Discovery 
In recent years, the increased knowledge of the function of enzymes in signalling pathways has 
lead to the identification and exploitation of enzymes as medicinal targets. With the 
improvement of global healthcare and an ageing population in the developed world, the 
demand and market for novel treatments targeting complex biological malfunctions (such as 
neurodegeneration, dementia and cancer) is ever-growing. As such, enzyme inhibitory drugs 
remain prominent throughout medicine, with 47% of all current drugs inhibiting enzymatic 
targets.16 Recent multitarget-directed ligand approaches in medicinal chemistry have 
combined inhibitors of cholinesterases and monoamine oxidases to combat the loss of 
neurotransmitters in Alzheimer’s disease,17 or with properties such as antioxidant and metal 
complexation for Parkinson’s disease.18 For cancer treatment, compounds that combine kinase 
inhibitors, or include cyclooxygenase inhibition (to reduce inflammation) have been 
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suggested.19 Structure-based drug design for a single enzyme target has been rendered 
possible via the use of crystal structures, which enable the computational searches of huge 
chemical databases to identify lead compounds for refinement. With such large-scale 
computational approaches readily available, combining suitable pharmacophores for novel 
enzyme combinations is entirely feasible via high-througput screening. Such compounds may 
then be synthesised and tested experimentally to confirm predicted inhibitory effects, before 
progressing to complex systems such as cell and in vivo models.16,20 
Evaluation of novel enzyme inhibitory drugs to target bacterial virulence has been an area of 
increasing interest in recent years, since the impending antibiotic crisis has caused a 
resurgence of various alternative anti-infection approaches. Such antivirulence enzyme 
inhibitors, unlike classic antibiotics, are aimed at disarming pathogens rather than inhibiting 
growth. Since human pathogens rely on a plethora of enzymatic virulence factors, inactivation 
of specific aspects of this arsenal will attenuate pathogenicity, potentially rendering them less 
pestilential or more susceptible to host defences.21 
Enzymes associated with virulence in P. mirabilis have been extensively researched and 
targeted as an alternative to antibiotic therapy, since systemic antibiotic prophylaxis is not 
recommended for long-term indwelling catheterisation.22 Of particular importance to this 
thesis is the development of a library of N-alpha mercaptoamide dipeptide inhibitors, for the 
inhibiton of the P. mirabilis metalloprotease virulence factor ZapA. This 54-kDa secreted 
metalloprotease possesses a broad specificity and is capable of degrading a wide-range of host 
defensive proteins including immunoglobulin A (IgA) (one of the few microorganisms able to 
do so).23 ZapA is specifically upregulated during swarmer-cell differentiation , thus is known 
to play a key role in pathogenesis. Carson et al.24 described the synthesis and in vitro analysis 
of a number of inhibitor sequences which display inhibitory activity against ZapA (Figure 5.5). 
Screening of the synthesised inhibitor library revealed a preference for large aromatic residues 
in the R1 position, and aliphatic residues in the R2 position. From the library, six compounds 
were found to exhibit micromolar values of Ki. Since ZapA is known to be critical for 
colonisation and establishment of infection by P. mirabilis, effective inactivation of this enzyme 
has potential to provide protection to the cognate substances in vivo and may represent a 
putative anti-infective/anti-virulence strategy. 
 Interestingly, these trends appeared to match those observed during the profiling of the same 
focused library on the P. aeruginosa metalloprotease, LasB. Since P. aeruginosa is also a known 
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uropathogen present during CAUTI, inhibitors of this nature may present an interesting 
strategy for broad spectrum CAUTI anti-virulence treatment. 
 
5.2.4. Urease 
5.2.4.1. Biological Significance 
Urease (urea aminohydrolase) is a 250 kDa nickel-dependent metalloenzyme of great 
biological significance. Found in a wide variety of organisms (including plants, algae, fungi and 
several prokaryotes), urease catalyses the rapid hydrolytic decomposition of urea, thus playing 
a vital role in the global nitrogen cycle. Since the hydrolytic processing of urea produces 
ammonia as a byproduct, expression of urease by human pathogens such as Proteus, 
Figure 5.5: A) General structure of the N-alpha mercaptoamide dipeptide inhibitor library, 
according to the dipeptide amino acid sequences. B) Relative potency of indidivdual 
compounds, displayed as  the fractional inhibition of ZapA activity at an inhibitor 
concentration of 25 μM. Reprinted with permission from Carson et al.22 © 2011, with 
permission from Elsevier. 
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Helicobacter, Klebsiella, Pseudomonas and Mycobacterium spp. is known to have severe 
negative consequences on human health.25 
Urease holds a significant place in twentieth-century science, having played a pivotal role in 
two fundamental landmarks of biochemistry. In 1926, James Sumner succeeded in isolating 
and crystallising the urease enzyme from Canavalia ensiformis (C. ensiformis, jack bean), thus 
demonstrating for the first time that enzymes are proteinaceous structures.26 In 1975, the 
requirement for nickel in urease catalysis was established, providing the first example of the 
biological essentiality of  this metal as an enzymatic cofactor.27 
Urea is produced in large amounts by vertebrates as the catabolic byproduct of nitrogen-
containing compounds. Indeed, humans produce and excrete ca. 10 kg urea per year.25,28 
Considering the long half-life for nonenzymatic urea hydrolysis (which has never been 
observed experimentally, but is estimated to be ca. 520 years), severe physiological and 
environmental imbalances would arise in the absence of an efficient enzymatic degradation 
process. In contrast, the catalysed process has a half-life of a few microseconds, with an 
efficiency that is 3 x1015 times higher than that of the uncatalysed reaction, making urease the 
most efficient hydrolase known.29 
5.2.4.2. Structure and Mechanism  
The reaction of urea hydrolysis catalysed by urease occurs in two steps: the first, strictly 
enzymatic step, consists of the hydrolysis of urea to yield ammonia and carbamate, followed 
by the spontaneous decomposition of carbamate to give a second molecule of ammonia and 
bicarbonate (Scheme 1, Chapter 1).30 Urease exhibits typical Michaelis Menten behaviour (with 
observed values of KM in the millimolar region), and displays maximal activity in the pH region 
of 5-9.31 
The protein architecture for C. ensiformis urease is shown in Figure 5.6, which is known to be 
representative of the majority of bacterial ureases. The quaternary structure is composed of a 
trimer of trimers of the type (αβγ)3, where α, β, and γ represent different subunits. The active 
site is found in the α subunit, giving rise to three active sites per biological unit.32 An important 
feature, conserved throughout all known ureases, is the conformation of a helix-turn-helix 
motif within the α subunit, flanking the active site cleft. This motif may be found in an open or 
closed conformation, and plays an important role in modulating the afflux of substrate and 
efflux of producs to and from the active site during catalysis.30 The coordination environment 
of the Ni atoms within the active site consists of two Ni(II) ions, separated by 3.5-3.7 Å, bridged 
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by the oxygen atoms of a carbamylated lysine residue, and bound to two histidines. The 
coordination geometry is completed by a terminally bound water molecule, and a bridging 
hydroxide ion, stabilised by an extensive network of hydrogen bonds.25,32 
The reaction mechanism for the enzymatic hydrolysis of urea is shown in Figure 5.7. Upon the 
entrance of urea into the active site channel (facilitated by the opening of the helix-turn-helix 
‘flap’), the hydrated state of the enzyme (Figure 5.7A) evolves towards an initial substrate-
bound intermediate, where three water molecules bound to Ni(II) are displaced by urea. Urea 
initially binds the more electrophilic and coodinatively unsaturated metal atom (denoted Ni1) 
using the carbonyl oxygen of the urea (Figure 5.7B). Flap closure facilitates urea coordination 
to Ni2 via its amine group, stabilised by a hydrogen-bonding network which holds the 
substrate in a specific conformation, so that hydrolysis may occur (Figure 5.7C). The 
nucleophilic attack onto the bridging substrate profoundly modifies the electronic structure, 
thus increasing the pKa of the distal urea N atom (not involved in Ni-binding). Thus, the Ni-
bridging -OH group (Figure 5.7D) has a pKa sufficiently low that it may transfer a proton to the 
distal urea amine group. The stabilisation of the resultant C-NH3+ by the catalytic histidine, 
causes the breakage of the distal C-N bond, subsequently releasing ammonia. The resulting 
carbamate spontaneously decomposes into ammonia and hydrogen carbonate, and the 
opening of the active site flap facilitates product release, thus allowing bulk water to rehydrate 
the active site (Figure 5.7A), regenerating the resting state of the enzyme.25,30,33,34 
Figure 5.6: Ribbon scheme of the functional oligomer (αβγ)3 of C. ensiformis urease, through 
the ternary axis (left), and rotated by 90 ° along the horizontal axis (right). Reprinted with 
permission from Maroney et al.25 © 2014, American Chemical Society. 
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5.2.4.3. Role of Urease in CAUTI Pathogenesis 
The P. miraiblis gene cluster consists of ureABC, which encode the apoenzyme structural 
subunits, and ureDEFG, which encode proteins that facilitate insertion of the nickel atoms in to 
the active site.35 Positive upregulation of urease is moderated by the polypeptide 
transcriptional regulator UreR, and repressed by the nucleoid-associated protein H-NS. Both 
UreR and H-NS compete for the same regulatory region of upstream of ureD, resulting in tight 
control of urease expression. Successful transcriptional repression of the ure operon by H-NS 
occurs at room temperature, although a transition to physiological temperature and high 
concentrations of urea alleviate H-NS transcriptional repression, allowing UreR to activate 
urease expression.36 
During the course of infection, the production of ammonia by urease activity raises the pH 
within the local environment, thus facilitating the precipitation of the normally soluble 
polyvalent ions struvite [MgNH4PO4.6H2O] and carbonate apatite [Ca10(PO4)6CO3]. Deposition 
of these crystalline materials onto the luminal surfaces of the catheters may cause serious 
clinical consequences as a result of catheter blockage (as discussed in Chapter 1). Furthermore, 
Figure 5.7: Mechanism of the enzymatic hydrolysis of urea. Reprinted with permission from 
Maroney et al.25 © 2014, American Chemical Society. 
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ammonia liberated by urease may contribute to urothelial damage, potentially exposing niches 
for adherence or providing nutrients for bacterial replication.37 
Assessment of the contribution of urease to P. mirabilis virulence in a mouse model of 
ascending urinary tract infection using a urease-negative mutant (containing a mutation in the 
ureC structural subunit gene), showed that expression of urease is critical for bacterial 
colonisation within the urinary tract. Transurethral challenge yielded recovery rates from the 
urine, bladder and kidneys that were significantly lower for the urease-negative strain 
compared to the wild-type strain.38 Further evaluation using the same model revealed that the 
ability of the urease-negative strain to colonise  the urinary tract is approximately 100-fold less 
than the parent strain.37 Use of the urease mutants in the mouse model of ascending infection 
unambiguously places urease as a critical virulence factor in P. mirabilis infection. Indeed, 
further studies have revealed that within the catheterised urinary tract, urease is expressed 
constitutively and plays a continuously active role in pathogenesis and virulence.39 
5.2.4.4. Urease Inhibitors 
Owing to the tremendous medical importance of urease, urease inhibitors with improved 
stability and low toxicity may be an effective therapy against diseases caused by urease-
dependent pathogenic microorganisms. Several classes of molecules have thus far been tested 
for urease inhibition in medicine and agriculture. In CAUTI, the development of systemic drugs 
displaying antiureolytic activity may provide a promising prophylactic treatment, without 
placing a significant selective pressure on colonies of pathogenic P. mirabilis.  
I. Thiols 
Thiols, particularly β-mercaptoethanol, are of historic importance as urease inhibitors, since 
they helped to reveal crucial information about the active site of C. ensiformis urease in 1980.30 
Thiols inhibit urease with a competitive mechanism in their thiolate anion form RS-, which 
bridges the two Ni(II) atoms in the urease active site and chelates the metal centre with the 
alcoholic group interacting with Ni1 (further stabilised by a hydrogen bond with the carbonyl 
oxygen of the conserved αGly280). Additionally, a second molecule of β-mercaptoethanol 
forms a disulphide bond with the conserved αCys322 residue, belonging to the mobile flap. The 
subsequent formation of hydrogen bonds decreases the flexibility of the flap, preventing access 
to the active site via steric hinderance.33 This chelating mode of competitive inhibiton may be 
inferred for all cases involving thiol-containing small molecule inhibitors.25 Recent synthesis 
of a range of substituted thiourea derivatives by Khan et al.40 support the chelating ability of 
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the inhibitor within the urease active site, displaying half-maximal inhibiton values of 5.53 ± 
0.02 – 91.50 ± 0.08 μM. 
II. Hydroxamic Acids  
Hydroxamic acids have been well characterised for their urease-inhibitory activity since 
1962.41 Acetohydroxamic acid (AHA) (Figure 5.8), the most studied derivative of this group, is 
well known to act as a slow-binding inhibitor of plant, bacterial and fungal ureases. 
 X-ray crystal structures of AHA with urease from Sporosarcina pasteurii have detailed that 
AHA interacts with the two Ni atoms in the active site. The hydroxamate oxygen atom bridges 
the two Ni(II) ions, whilst the carbonyl oxygen of the AHA chelates with Ni1. Two hydrogen 
bonds, between the carbonyl of the AHA and an αHis222 residue, and between the AHA-NH 
and the αAsp363, stabilise the interaction (Figure 5.9).  
 
AHA is thus far the only urease inhibitor to be commercially available for antiureolytic therapy. 
Having gained FDA approval in 1983 (marketed under the trade name Lithostat in the USA, and 
Figure 5.8: Structure of acetohydroxamic acid (AHA). 
Figure 5.9: Crystallographic structural model of the Sporosarcina pasturii urease active site 
(showing only selected resiudes) in complex with AHA. The nickel atoms are represented in 
green, nitrogen in blue and oxygen in red. Thin blue lines represent hydrogen bonds. Adapted 
with permission from Maroney et al.23 © 2014, American Chemical Society. 
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Uronefrex in Europe),42 it has been extensively used to treat hyperammonemia in cirrhosis of 
patients infected with the urease-positive bacteria Helicobacter Pylori, as well as chronic urea 
splitting and recurrent urinary tract infection by P. miraiblis. However, this compound is 
known to induce severe side effects, including teratogenesis and haemolytic anaemia, as well 
as psychoneurological and muscular symptoms.43 Awareness of such severe mutagenic side 
effects has made AHA an undesirable therapeutic in recent years, inducing a surge of research 
into alternative urease inhibitors with less severe toxicological profiles.  
Extensive  research into alternative groups of potential urease inhibitors, including quinones, 
polyphenols, heterocyclic compounds, boronic acids, organophosphorus compounds and 
heavy metals has also been undertaken, and extensively reviewed elsewhere.25,30,44–46 It is 
evident from such reviews that the formulation and development of a novel drug to replace 
AHA as the ‘gold-standard’ in treating urease-mediated infection will require a balance to be 
struck between inhibition efficiency and toxicity. Whilst many potential candidates are 
selected purely on inhibitory performance in vitro, the pharmacokinetics and in vivo 
cytotoxicity of the compound must be taken into consideration in the early stages of drug 
design. Thus, achieving a compromise between systemic biocompatibility and activity may 
indeed require the progression of less potent candidates over their highly active, yet highly 
toxic counterparts. 
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5.3. Materials and Methods 
5.3.1. Materials  
Methyl thioglycolate, Stuart’s Broth (SB), urea, dipotassium hydrogen phosphate, potassium 
dihydrogen phosphate, phenol red, Triton™ X-100, Dulbecco’s Modified Eagle Medium 
(DMEM), trypsin, foetal calf serum, EDTA,  penicillin, streptomycin, T75 culture flasks and 
urease from C. ensiformis (Type III powder, 15,000-50,000 units/g), were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). CyQUANT™ XTT cell viability assay, methanol and ammonia 
solution (7 M in methanol) were purchased from Fisher Scientific (Loughborough, UK). 
5.3.2. Methods 
5.3.2.1. Inhibitor Synthesis  
2-Mercaptoacetamide (2-MA) was prepared according to Latli et al.47 Briefly, methyl 
thioglycolate (3.6 g, 34 mmol) was added to a solution of ammonia in methanol (7.0 M, 45 mL) 
and stirred at room temperature for 14 hours under a nitrogen atmosphere. The solution was 
concentrated under reduced pressure to give 3.1 g of a white solid in quantitative yield. 
Presence of 2-MA was confirmed using spectroscopic methods (1H and 13C nuclear magnetic 
resonance (NMR), and electrospray ionisation mass spectrometry (ESI-MS)).  
5.3.2.2. Enzyme Assays 
I. Colourimetric Urease Quantification  
The high throughput colourimetric assay for rapid urease quantification was employed for 
initial enzymatic assays, originally described by Okyay et al.48 The colour change of SB from 
yellow (absorbance at 430 nm) to pink (absorbance at 560 nm) may be observed in the 
presence of urease, owing to the presence of  urea (20 mg/mL standard) in the broth 
composition. Absorbance output (560 nm) was observed on a microplate reader (BMG 
Labtech), using the inbuilt injector system to analyse intial rate of colour change. Uninoculated 
media was employed as a negative control. All measurements were repeated in triplicate.  
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II. Enzyme Kinetic Assays 
Enzyme kinetic parameters Vmax and KM were obtained via the measurement of initial reaction 
velocities at varying urea concentrations. Since SB contains fixed urea concentration (20 
mg/mL), the colourimetric broth was prepared manually according to Table 5.1. 
Table 5.1: General components of SB 
 
Compounds were dissolved in deionised water (500 mL) and sterilised via syringe filtration 
(pore size 0.22 μm). Urea was manually added to aliquots (20 mL) of the above solution to 
result in a range of substrate concentrations (1 mM-3 M). Urease concentration was fixed (9 
mg/ml in PBS, pH 7.4). Enzyme solution (100 μL) and SB (100 μL) were added in triplicate to 
a 96-well microplate. SB containing a predefined concentration of urea was added to the 
injector system, and each triplicate was measured (560 nm) individually to achieve a cycle time 
of 6 seconds. Each well was measured for a total of 10 cycles (60 seconds), before replacing the 
SB with a different substrate concentration. The injection needle and associated tubing were 
rinsed with ethanol (70% in deionised water) between each concentration to avoid substrate 
accumulation or dilution. To determine kinetic parameters in the presence of inhibitor, the 
enzyme solution was supplemented with a predefined concentration (10 mM) of 2-MA solution 
(100 μL dissolved in SB), in place of the standard SB as previously described. 
Kinetic curves were also analysed as Dixon plots, to support kinetic models and analyse the 2-
MA inhibition mechanism. Dixon plot analysis was performed at 3 different concentrations of 
urea (1, 5 and 10 mg/mL) and at 5 different concentrations of 2-MA (1, 2.5, 5, 7.5 and 10 
mg/mL). The reciprocal of the initial reaction rate was plotted against varying inhibitor 
concentration to yield information on Ki and inhibition type. 
III. Statistical Analysis 
Curve-fitting and statistical analyses were performed using GraphPad Prism (version 7, 
GraphPad Software Inc., San Diego, CA). Kinetic constants were obtained by fitting 
Compound Mass (g) 
Dipotassium hydrogen phosphate 4.75 
Potassium dihydrogen phosphate 4.55 
Yeast extract 0.05 
Phenol red 5 x10-3 
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experimental data to kinetic models using the nonlinear regression function. The fit of the data 
for each model was assessed from the SEM, 95% confidence intervals and R2 values. Both 
Michaelis Menten and Hill equations were employed as nonlinear fitting models, and resultant 
kinetic constants were reported as the mean ± SEM of triplicate experiments.  
IV. Enzymatic IC50 Assays 
To calculate the concentration of 2-MA and AHA required to cause half maximal inhibition of 
urease, standard time-dependent IC50 protocols were employed, according to Burt et al.49 Both 
urea (20 mg/mL, standard SB) and urease (9 mg/mL in PBS) concentrations were kept 
constant, whilst inhibitor concentrations were varied (0-900 mM in PBS) to assess the degree 
of yellow-pink colour change upon incubation for a predetermined time period (10 minutes). 
Inhibitor solution (100 μL) was added to urease solution (100 μL) in a 96-well microplate, 
before the addition of SB (100 μL) using the plate reader injector system. Inhibiton of enzyme 
activity was monitored (560 nm) for 1 hour (60 second cycle time for 60 cycles). Enzyme 
response in the absence of inhibitor was defined as the 0% inhibition (MAX), and SB  in the 
absence of enzyme was defined as the maximum inhibition (MIN). Thus, % inhibition of each 
inhibitor concentration (X) was calculated according to Equation 38.  
 
% Inhibition = 100 × [




The calculation of % inhibition at the 10 minute time point was selected to give optimum 
distribution of data points both above and below the IC50. The data were fit to sigmoidal dose-
response curves, and values of IC50 extracted using nonlinear regression.  
5.3.2.3. Biological Evaluation 
General bacterial culture and quantification protocols were followed according to Chapter 2. 
I. Urease Quantification in Bacterial Culture 
The concentration of cytoplasmic urease within bacterial cultures was estimated via the 
measurement of the rate of colour change of SB upon incubation with actively growing cells of 
P. mirabilis B4 and E. coli NSM59.  
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A standard curve of rate of SB colour change with varying urease concentration was produced 
in order to quatify the rate of colour change in the live bacterial culture. Standard urease 
solutions were prepared via serial dilution from stock (20 mg/mL in PBS), to give a range of 
concentrations from 3-12 mg/mL. The plate reader injector system was used to add SB (100 
μL) to enzyme solution (100 μL), and the colourimetric response measured at 560 nm (cycle 
time 16 seconds, 450 cycles). Each urease concentration was reproduced in triplicate. 
Overnight cultures of P. mirabilis B4 and E. coli NSM59 were centrifuged (4,000 rpm, 15 
minutes) and the supernatants discarded. Pellets were resuspended in SB (5 mL) and 
incubated (37 °C) with agitation (200 rpm) throughout the course of the experiment. The rate 
of colour change of SB was recorded every minute for 20 mintues. For each measurement, test 
culture aliquots (500 μL) were syringe filtered (0.22 μm pore size) to remove bacterial cells, 
and the absorbance measured at 560 nm in triplicate. Cultures of E. coli were employed as 
urease-negative controls.  
II. Determination of In Vitro Susceptibility  
In vitro susceptibility of inhibitors 2-MA and AHA were determined using the microbroth 
dilution method. Stock solutions of the inhibitor to be evaluated were made up to twice the 
starting concentration required (200 mM), to account for for plate dilutions. Overnight 
bacterial cultures were subcultured (1:1000 in LB). To a 96-well microplate, LB (100 μL) was 
added to columns 2-12, and inhibitor stock solution to columns 1 and 2. Inhibitor solution was 
serial diluted (100 μL each time) across the plate to column 10, to create a gradient of inhibitor 
concentrations from 10-100 mM. Columns 11 and 12 were revserved for controls in the 
absence of inhibitor and bacteria, respectively. To each well (except column 12) was added 
bacterial subculture (100 μL), and the plate incubated overnight (37 °C). Affect on bacterial 
growth was assessed as a function of OD at 600 nm. 
III. Whole-Cell Evaluation 
To evaluate the ability of inhibitors to cross the bacterial cell membrane and inhibito urease in 
vivo, without altering the viability of cells, changes in culture pH and viable cell count were 
monitored in the presence of 2-MA and AHA. Overnight cultures of P. miraiblis B4 and E. coli 
NSM59 were prepared according to 5.2.2.3.I and assessed at the start (0 minutes) and end (90 
minutes) of the experiment for media pH and CFU/mL. 
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IV. In Vitro Bladder Models 
The ability of 2-MA to extend catheter lifespan via in vivo inhibition of P. mirabilis urease was 
evaluated within a physiologically representative model of the catheterised urinary tract. 
Bladder models were assembled and operated according to Chapter 2. Inhibitory drugs were 
dissolved in urine reservoirs (2 x 5 L, 10 mM per reservoir) to replicate drug excretion 
following oral administration. Models simulating late-stage infection were inoculated with P. 
miraiblis B4 and E. coli NSM59 (108 CFU/mL), and supplied with artificial urine media 
containing drug at a constant flow rate of 0.75 mL/min. Quantification of CFU/mL and residual 
urine pH was performed at periodic intervals throughout the experiments. Time to blockage of 
inoculated catheters treated with 2-MA was compared  to those treated with AHA, and those 
without treatment as a positive blockage control. 
V. Crystal Violet Biofilm Analysis 
Biofilm inhibitory activity of 2-MA and AHA was assessed using crystal violet biofilm staining, 
as described in Chapter 4. Briefly, biofilms of P. mirabilis B4 were incubated statically for 24 
hours with various concentrations of inhibitor (1, 2.5, 5, 7.5, 10 and 15 mM) to assess the 
inhibition of biofilm growth in vitro. Stained biofilms were assessed for biofilm formation via 
measurement of optical density at 595 nm. Positive and negative controls were performed, in 
the absence of inhibitor and bacteria, respectively. 
VI. Mammalian Cell Culture Conditions 
Spotaneously transformed aneuploid immortal keratinocytes (HaCaTs) were resuscitated 
from frozen stocks (liquid N2) in DMEM supplemented with foetal calf serum (10%) and 
antibiotics (1% penicillin-streptomycin), and cultured in a controlled atmosphere (5% CO2, 37 
°C). The adherent cells were routinely passaged in T75 culture flasks every 2-3 days, or when 
cells reached 70-80% confluency (low passage number cell lines were used for experimental 
analysis). HaCaT cells were detached via pre-washing with PBS containing EDTA (1 mM, 10 
mL, incubated for 12 mintues in order to chelate divalent cations), followed by trypsinisation 
(0.25%, 3-4 minutes). Cells were resuspended in fresh medium, counted using a 
haemocytometer/ inverted microscope, and the cell solution diluted appropriately (DMEM) to 
acheieve ~5 x103 cells per well. Cells were seeded in triplicate into a 96-well microplate (200 
μL) and incubated overnight to form sub-confluent monolayers. 
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VII. XTT Cell Viability Assay 
After 24 hours incubation, cells were treated with increasing concentrations of inhibitor drug 
solutions. Half of the incubated media (100 μL) was removed and replaced with filter sterilised 
drug solution (100 μL in PBS) at concentrations 80, 40, 20, 10, 5, 2.5, 1.25, and 0.625 mM to 
assess concentration-dependent cytotoxicity. After overnight incubation with the drug, cells 
were washed (3x PBS, 200 μL) to remove residual drug, and cell proliferation was assessed 
using a standard 2,3-bis[2-methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide 
inner salt (XTT) assay kit (CyQUANT™). This test is based on the cleavage of the yellow XTT 
salt by ubiquitous dehydrogenases, leading to the formation of an orange formazan dye. The 
intensity of the observed dye is commensurate to the number of metabolically active cells in 
the sample.  XTT reagent was freshly prepared according to manufacturer’s instructions: XTT-
labelling reagent and electron coupling reagent were mixed in a ratio of 50:1, and added to 
each well of the 96-well plate (50 μL), with fresh DMEM media (not containing phenol red, 100 
μL). Plates were incubated for 4 hours (37 °C, 5% CO2 in a humidified atmosphere), and 
assessed after incubation. Quantification of cell cytotoxicity was performed in a microplate 
reader (450 nm). The cytotoxic effect of treatment was expressed as the % viability compared 
to untreated cells, according to Equation 39. 
 
% Cell Viability =  
Corrected absorbance of sample cells 
Corrected absorbance of untreated cells  
 × 100 
(39) 
Where background correction was undertaken according to the blank (media only) value. Cells 
treated with Triton X-100 (20% v/v) were used as a positive control for cytotoxic effects. All 
tested concentrations and controls were reproduced in triplicate. 
VIII. Ex Vivo Haemolysis Assay 
Whole blood (25 mL) was obtained from an anonymous human donor, drawn directly into 
lithium heparin-coated Vacutainer tubes to prevent coagulation. Blood was centrifuged (2,000 
rpm, 10 minutes), and levels of haematocrit (red, lower layer), and plasma (yellow, upper 
layer) were marked on the tube. The plasma layer was carefully aspirated and discarded, whilst 
the haematocrit tube was filled to the marked line with sterile saline solution (150 mM NaCl, 
autoclaved to sterilise). Blood cells were washed a total of 3 times (centrifugation, aspiration 
of supernatant and replacement with fresh saline solution). The pellet containing red blood 
cells was resuspended in sterile PBS (pH 7.4) and divided into Eppendorf tubes (500 μL). 
Aliquots were centrifuged (2,000 rpm, 10 minutes), and the supernatant replaced with filter 
 Chapter 5  
176 
 
sterilised drug solution (pore size 0.22 μm) at varying concentrations (500 μL, 40, 20, 10, 5, 
2.5, 1.25, 0.625 mM, made up to double the required concentration to account for dilution in 
the erythrocyte solution). Cells were incubated with inhibitor drugs for 30 minutes (37 °C, with 
agitation) before being centrifuged (2,000 rpm, 10 mintues), and the supernatant removed to 
measure the absorbance of liberated haemoglobin at 410 nm. Total lysis of the erythrocyte 
suspension was obtained via treatment of cells with Triton X-100 (20% v/v). Degree of 
haemolysis was expressed as % haemolysis, relative to the spontaneous lysis controls 
(Equation 40).  
 
% Haemolysis =
Corrected absorbance of sample cells 
Corrected absorbance of lysed cells 
× 100 
(40) 
Values were background corrected according to the average blank (PBS only) value. Results 
from each concentration of tested drug were reproduced in triplicate. 
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5.4. Results and Discussion 
Conventional and alternative antimicrobial therapies which kill or impair the growth of 
bacteria exert strong selective pressure for the development and maintenance of resistance. 
By contrast, a drug that inhibits microbial virulence without inhibiting growth generates 
minimal selective pressure, whilst significantly easing the risk of virulence-based morbidity. 
Bacterial enzymes offer a potential target for the suppression of virulence, since they play a 
key role in pathogenicity and biochemical fitness. The research presented in this chapter 
describes the formulation and in vitro analysis of a novel small-molecule drug, capable of 
inhibiting urease expressed by uropathogenic P. mirabilis, thus preventing encrustation and 
blockage of urinary catheters.   
5.4.1. Inhibitor Design  
Urease as a potential target for antimicrobial drugs has received considerable attention, given 
its versatile role in microbial infection, particularly CAUTI. However, development of effective 
urease inhibitors has proved a significant challenge owing to the deeply buried active site and 
highly specific substrate preference of bacterial urease.50 
Design of the small-molecule inhibitor described in this chapter was developed following the 
N-alpha mercaptoamide dipeptide inhibitor library described in Section 5.1.3.3 by Carson et 
al.24, which showed in vitro success in inhibiting the extracellular P. mirabilis protease ZapA. 
Inhibitors containing Gly-Gly and Gly-Val in the R1 and R2 positions, respectively, showed 
negligible activity against urease (unpublished observations; data not shown), likely owing to 
the narrow and prohibitively inaccessible nature of the urease active site.51,52 Thus, a design 
was proposed whereby the bulky, peptide-containing regions of the inhibitor were eliminated, 
leaving only the thiol-containing amide ‘warhead’ of the molecule (Figure 5.10). The conserved 
thiol moiety of the inhibitor shows structural potential for the inhibiton of bacterial urease as 
it represents a structural analogue of urea. Since urease displays high substrate specificity, the 
active site is only capable of binding molecules that are chemically analogous to urea with 
binding mode that resembles that of the native enzyme-substrate complex.  
 




Furthermore, the proposed 2-MA inhibitor contains a thiol (SH) group, which are known to 
display active inhibition of the urease enzyme (as discussed in Section 5.1.4.4.I). Indeed, the 
compound diallyl thiosulphate (commonly known as allicin, the main biologically active 
component of garlic), has been shown to act as a powerful natural inhibitor of urease from both 
C. ensiformis and P. mirabilis.53,54 Inactivation of urease by allicin takes place in the active site 
of the enzyme, as a result of SH-group modification (analogous to other thiol-containing 
compounds). Modification of the active site structure interferes with flap-closure, thus 
significantly reducing the activity of the enzyme.53 
Synthesis of 2-MA yielded a highly water-soluble white powder in a quantitative yield. Details 
of synthesis and characterisation of 2-MA are shown in Appendix 1. 
Figure 5.10: General molecular structure of the original N-alpha mercaptoamide dipeptide 
inhibitor (A), designed to inhibit the extracellular metalloprotease ZapA, excreted by P. 
mirabilis. The thiol-containing ‘warhead’ of this molecule (red circle) was isolated as a 
potential inhibitor for the urease enzyme. The molecular structure of the resultant 2-
mercaptoacetamide (2-MA) inhibitor (B), shows structural similarities to the native substrate 
of the enzyme, as well as containing an enzymatically active thiol group. 
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5.4.2. Quantification of Urease Activity 
The research presented in this chapter utilises a high throughput, quantitative, colourimetric 
assay to determine the activity and inhibition of urease from both C. ensiformis and P. 
mirabilis.48 This method utilises Stuart’s broth (SB), since it is commonly used to distinguish 
urease-positive from urease-negative bacteria via a clear and unambiguous colour change. SB 
contains the pH-sensitive indicator phenol red, thus the alkalinisation of residual media 
following urea hydrolysis induces a colour change from yellow to pink in the presence of 
urease. Figure 5.11 presents a visual and graphical representation of the urease-induced colour 
change of SB. Upon incubation with exponential-phase P. mirabilis B4, the pink colour of the 
phenol red indicator is clearly visible. By contrast, equivalent incubation with the urease-
negative uropathogenic strain E. coli NSM59 does not yield a colour change, since the pH of the 
media remains within the acidic/neutral region (pH 6.8 ± 0.2 at 25 °C). 
 At time 0, a peak at OD430 was apparent, owing to the yellow colour of the broth (corresponding 
to no urease activity). During incubation, the peak at 430 nm decreased as the peak at 560 nm 
Figure 5.11: Spectral scan of Stuart’s Broth (SB) during incubation with P. mirabilis B4. At 
time 0 (red line), the absence of urease activity manifests as a yellow colour, absorbing at 430 
nm. After incubation for 70 minutes (green line), the increase pH of residual SB as a 
consequence of urea hydrolysis causes a pink colour change, with the corresponsing 
absorbance peak at 560 nm. Inset: Distinction of urease-positive and –negative 
uropathogenic species by SB. A) E. coli NSM59 (urease-negative). B) P. mirabilis B4 (urease-
positive). 
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(corresponding to urea hydrolysis by urease) appeared for the urease-positive organism. 
Quantification of urease activity is facilitated by monitoring the appearance of the absorbance 
peak at 560 nm, the rate of which corresponds directly to the concentration of active enzyme.  
Owing to the intracellular, cytoplasmic location of bacterial ureases, the isolation and 
purification of these enzymes is highly technical, time-consuming, and largely unproductive. 
Therefore, plant ureases (such as urease from C. ensiformis) are frequently used as a proof-of-
concept model for novel inhibitor compounds before assessment in pathogenic bacteria. Since 
ureases from both C. ensiformis and P. mirabilis has been found to display significant amino 
acid similarities (suggesting an evolutionary relationship),55 urease from C. ensiformis was 
used to evaluate initial inhibition by 2-MA, as well well estimation of enzyme kinetic 
parameters.  
5.4.3. Quantification of P. mirabilis Urease 
Calculation of urease concentration in live cultures of P. mirabilis B4 was undertaken, in order 
to estimate the concentration of urease to be used in initial kinetic C. ensiformis assays. This 
estimate will define the standard enzyme concentration to be used in subsequent Michaelis 
Menten and initial 2-MA inhibition studies.  
A standard curve was produced to quantify the initial rate of SB colour change in response to 
urea hydrolysis by C. ensiformis urease (Figure 5.12).  
Figure 5.12: Standard curve showing rate (relative light units (RLU)/min-1) of SB colour 
change with increasing C. ensiformis urease concentration. Rate of enzyme activity was 
monitored as a function of OD at 560 nm over a 5 minute period. 




The standard curve demonstrated a linear correlation between change in absorbance at 560 
nm, and urease concentration. From this graph, it was possible to estimate the concentration 
of bacterial urease within a P. mirabilis B4 subculture. The rate of SB colour change was 
monitored throughout the incubation period, and the linear portion of the resultant graph 
(Figure 5.13) used to estimate bacterial urease concentration. 
From the linear regression model fitted to the standard curve, the equation of the best-fitting 
line was found to be:  
 Y = 5.25 × 10−3 × X − 2.12 × 10−3 (41) 
Substituting the value of the slope from Figure 13 into the standard curve eqution and solving 
for X:  
 
X =




 X = 8.86 mg/mL  
Figure 5.13: Colour change of SB in the presence of live P. mirabilis B4 overnight culture, at 
15-20 minutes incubation. Development of the pink phenol red indicator following urease-
mediated urea hydrolysis is followed via measurement of OD560.   
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Thus, for subsequent proof-of-concept kinetic experiments involving C. ensiformis urease, the 
standard enzyme concentration was set to 9 mg/mL. Whilst this calculation serves only as an 
estimate of P. mirabilis urease concentration owing to inherent differences in structure, and 
locational restrictions within the bacterial cells, a general valuation of urease concentration in 
a live culture will assist in improving the accuracy of the initial C. ensiformis studies. 
5.4.4. C. ensiformis Urease Kinetic Parameters 
5.4.4.1. Michaelis Menten Kinetics 
In order to assess the inhibition of C. ensiformis urease by 2-MA in terms of alteration of kinetic 
parameters, it was first necessary to determine the standard Michaelis Menten parameters Vmax 
and KM in the absence of inhibitor. The determination of such parameters was undertaken via 
measurement of the initial reaction rate at various substrate concentrations. Variation of 
substrate concentration should be within the range KM/10 to 10 KM where experimentally 
possible,56 hence a wide range of concentrations of urea were evaluated for enzyme activity in 
terms of colour change of SB. Variation in rate of enzymatically catalysed urea hydrolysis by C. 
ensiformis urease at different substrate concentrations is shown in Figure 5.14. 
Figure 5.14: Absorbance (560 nm) plotted as a function of urea concentration over time. 
Rate of colour change of SB is characterised by a change in optical density (OD), representing 
the rate of the enzyme-catalysed reaction at varying substrate concentration. Data shown are 
the mean of three independent repeats. Error bars represent SEM. 




The fundamental derivation of the Michaelis Menten equation is shown in Section 5.1.2.1. 
Equation 12 requires the determination of initial rates (so that [S] = [S]0), to ensure that there 
is no effect of reaction reversibility or product inhibition which may affect the integral method. 
Thus, the initial rate of reaction from Figure 14 was defined as the first 6-24 seconds of the 
reaction. The rate of change of optical density within the defined initial rate period was 
calculated by means of tangents and plotted as a function of urea concentration (Figure 5.15). 
Fitting of the Michaelis Menten nonlinear regression analysis to the initial rate of the enzymatic 
reaction yields the kinetic parameters Vmax and KM according to Table 5.2. 
Table 5.2: Fitting values of the Michaelis Menten constants.  
Parameter Fitting Value  ± SEM  
Vmax 1.58 x10-2 M 7.70 x10-4 M 
KM 0.20 M 2.99 x10-2 M 
 
Previously described values for the kinetic parameters of C. ensiformis urease quote KM to be in 
the region of 2.7-8.81 mM (according to BRENDA enzyme database).57 Thus, the observed 
values are roughly 100-fold higher than those calculated under strict Michaelis Menten 
conditions.  This is likely owing to the employment of a non-standard assay for the 
Figure 5.15: Michaelis Menten kinetics of C. ensiformis urease, describing the relationship 
between substrate (urea) concentration and maximum velocity of reaction. Determination of 
kinetic parameters was facilitated via the fitting of the Michaelis Menten non-linear 
regression (GraphPad Prism 7). Goodness of fit (R2 = 0.9537).  
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measurement of reaction rate, leading to erroneous conditions and subsequent 
unrepresentative enzyme performance. For example, the optimum pH of urease from C. 
ensiformis is known to pH 7.4,57 yet the experimental pH at which this assay is undertaken is 
defined by the pH of the SB medium (~pH 6.8). Slight variation from optimum conditions 
described for the determinsation of kinetic parameters may manifest as a substantial alteration 
of the value of KM. Indeed, the conditions under which the Michaelis Menten equation 
accurately captures the steady-state kinetics of a simple enzyme-catalysed reaction is 
contrasted with the conditions under which the same equation can be used to estimate the 
parameters Vmax and KM from a progress data curve.58 The validity of the underlying 
assumptions are necessary for the derivation of the equation, but not experimentally sufficient 
or realistic to guarantee accurate estimation of such parameters. Indeed, the treatment of Vmax 
and KM with respect to enzyme and substrate concentrations relies on simplifying assumptions 
relating to the quasi-steady state of the intermediate ES complex. Since this is often not the 
case in real systems, using values of Vmax and KM measured in vitro (particularly to predict the 
activity of an enzyme in a living organism) can prove unreliable.59 Nevertheless, the 
measurement of kinetic constants in this case provides parameters that may be compared to 
those in the presence of inhibitor, giving a relative comparison of enzyme activity both in the 
presence and absence of inhibitory drugs. 
5.4.4.2. The Hill Fit 
An interesting observation from the determination of the Michaelis Menten parameters is the 
Goodness of fit (R2) value of ~0.95 for the rectangular hyperbolic plot shown in Figure 15. At 
low values of substrate concentration, the data shows some exponential character, as opposed 
to the expected linear nature of the Michaelis Menten. This slightly sigmoidal nature of of the 
data is representative of a certain degree of cooperativity in a multisubstrate reaction, as 
described by the Hill equation (Section 5.1.2.3). Fitting of the initial rate tangents as a function 
of substrate concentration to the Hill equation yields an improved R2 value, indicating some 
degree of bisubstrate binding within C. ensiformis urease (Figure 5.16). 
The improved fit observed with the Hill slope (R2 = 0.9959)  is in agreement with previous 
observations for urease, where the urease active site binds both a molecule of urea, as well as 
a nucleophilic water molecule. This nucleophilic group participates in substrate modification 
during the catalytic mechanism (as described in Section 5.1.4.2).57,60 




Fitting of the Hill fit nonlinear regression analysis to the initial rate of the enzymatic reaction 
yields the apparent kinetic parameters Vmax and KM according to Table 5.3. 
Table 5.3: Fitting values of the Hill Equation. Apparent values of Vmax and KM are analogous to 
those obtained with the Michaelis Menten model. The Hill coefficient (h) represents a 
measure of cooperativity. 
Parameter Fitting Value  ± SEM  
Apparent Vmax 1.31 x10-2 M 1.59 x10-4 M 
Apparent KM 0.16 M 3.71 x10-3 M 
Hill Coefficient (h) 2.19 0.10 
 
The calculated value of the Hill coefficient (h) represents positive cooperativity within the 
urease active site. This is in agreement with previously calculated values of h for bi-nickel 
binding (h = 2.0).61 The apparent value of KM  obtained via fitting to the Hill equation is closer 
to the literature value, although still represents a significant overestimation. Whilst the Hill fit 
gives arguably more accurate values of the kinetic constants for C. ensiformis urease, 
subsequent experiments investigating the inhibition of urease will utilise standard Michaelis 
Figure 5.16: Sigmoidal kinetics displayed by C. ensiformis urease. Initial rate data were fitted 
to the Hill equation, to account for cooperativity in the bisubstrate binding model. 
Determination of kinetic parameters was facilitated via the fitting of the Hill slope. Goodness 
of fit (R2 = 0.9959).  
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Menten kinetics, to remain consistent with previous investigations undertaken in the 
literature.11,53,62 
5.4.4.3. Urease Inhibition: Alteration of Kinetic Parameters 
KM and Vmax  
Modification of Michaelis Menten constants upon addition of inhibitor yields insights into the 
mechanism of inhibition. As discussed in Section 5.1.3, different mechanisms of enzyme 
inhibition display varying effects on kinetic parameters KM and/or Vmax. Since the synthesised 
inhibitor 2-MA displays structural similarities to urea, it was predicted that competitive 
inhibiton would be observed. In this case, the inhibitor would compete directly with the 
substrate for access to the enzyme’s active site, manifesting as an increased KM value, reflecting 
the decrese in the affinity of the enzyme for the substrate (owing to the formation of the 
inactive EI complex). The observed Vmax for competitive inhibiton remains unaltered since the 
binding velocity of the enzyme is unchanged. The effect of the addition of 2-MA to C. ensiformis 
urease in comparison to the uninhibited reaction is shown in Figure 5.17.  
Comparison of Michaelis Menten parameters both in the presence and absence of the 2-MA 
inhibitor provided further evidence of competitive inhibition (Table 5.4). 
Figure 5.17: Michaelis Menten kinetics for competitive inhibition of C. ensiformis urease by 
2-MA (+I) compared to the uninhibited reaction (-I). Determination of kinetic parameters 
was facilitated via the fitting of the Michaelis Menten non-linear regression. Goodness of fit 
(R2) = 0.9537 for –I, and 0.9337 for +I. 
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Table 5.4: Calculated kinetic parameters for Michaelis Menten kinetics in the presence (+I) 
and absence (-I) of inhibitor 2-MA. 
 KM ± SEM Vmax ± SEM 
-I 0.2 ± 2.99 x10-2 M 1.58 x10-2 M ± 7.70 x10-4 M 
+I 8.27 ± 6.07 9.56 x10-3 ± 6.03x10-3 
 
Calculated values of Vmax for urease-catalysed urea hydrolysis remain unchanged within the 
calculated error. However, the values of KM for the inhibited/uninhibited reaction do not 
overlap within the error. Thus, it is likely that 2-MA behaves as a reversible competitive 
inhibitor. This observation is in agreement with other structurally analogous inhibitors of 
urease, including thiol inhibitors such as β-mercaptoethanol.63,64 
5.4.4.4. The Dixon Plot 
The mechanism of enzyme inhibition by 2-MA, as well as the dissociation constant (Ki) were 
confirmed via the linear graphical method known as the Dixon plot. The effect on the enzymatic  
intitial rate (V0) is determined at two or more substrate concentrations, over a range of 
inhibitor concentrations. For competitive inhibition, a plot of 1/ initial rate against inhibitor 
concentration will yield a series of straight lines that intersect above the x axis; the abscissa at 
which they converge represents the inhibitor constant, –Ki (Figure 5.18). 
The calculated Ki value from the Dixon plot is 2.97 mM. This value provides a quantitative 
measure of inhibitory potency that is independent of substrate concentration.65 Thus, 
determination of KI for a novel inhibitor allows for direct comparison with existing inhibitory 
compounds. Previous investigation of thiols as urease inhibitors has revealed a wide range of 
inhibitory potency for such structures, varying from 5.0 μM – 10 mM for mercaptamine and 3-
mercaptopropionate, respectively.63 Recently, Grela et al.66 have evaluated a series of 
aminophosphinic urease inhibitors, active against pure urease isolated from P. mirabilis with 
extremely high inhibitory potency (Ki = 0.20-0.62 μM). However, such effectiveness comes at a 
significant cost to cell viability; for the most potent inhibitors, a 96-98% reduction in bacterial 
cell viability was observed, compared to the untreated control, thus placing a significant 
selection pressure on treated cultures of P. mirabilis. The inhibitory constant for AHA has been 
previously stated as 5.7 ± 0.4 μM and 0.053 mM for P. mirabilis and C. ensiformis urease, 
respectively.66,67 Whilst the observed Ki value calculated for 2-MA appears approximately 100-
fold lower than that observed for the ‘gold-standard’ AHA, the use of AHA in human medicine 
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is known to be riddled with serious clinical side-effects (as previously discussed). Thus, a 
compromise must be struck between inhibitory potency and cyctotoxicity of novel inhibitory 
drugs, both for human and bacterial cells. Whilst a less potent drug may require higher dosages, 
or even be less effective at preventing urolithiasis in vivo, a more biocompatible drug will both 
reduce the onset of adverse reactions within the human patient, and the development of drug 
resistance within the bacterial population. 
5.4.5. Inhibition of C. ensiformis Urease by 2-MA 
The in vitro ability of 2-MA to inhibit urease activity was evaluated using C. ensiformis urease 
as a model system. All inhibitory studies were performed in direct comparison to AHA, so that 
drug performance may be directly comparable to the paradigmatic treatment for in vivo 
urolithiasis without being limited by variation in experimental conditions. 
Figure 5.18: Dixon plot for the competitive inhibition of C. ensiformis urease by 2-MA. The 
abscissa of line  intersection yields the dissociation constant (-Ki).    
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5.4.5.1. Determination of Inhibitor IC50 
The determination of the half-maximal inhibitory concentration (IC50) of an inhibitory 
compound provides a further measure of the antagonistic potency, in a manner depenedent on 
defined experimental conditions (e.g. substrate concentration). Dose-response curves and 
subsequent determination of IC50 for 2-MA and AHA are shown in Figure 5.19. 
 
Figure 5.19: Determination of half-maximal inhibiton (IC50) of (A) acetohydroxamic acid 
(AHA), and (B) 2-mercaptoacetamide (2-MA) against urease from C. ensiformis. The 
enzymatic inhibition was related to the activity in the absence of inhibitor (defined as 0% 
inhibition), and activity in the presence of 300 mM inhibitor (defined as 100% inhibition). 
Background measurements were obtained from the signal in the absence of enzyme. 
Inhibition dose-response curves of normalised, logarithm-transormed data were performed. 
Data shown are the mean of independent triplicate repeats. Error bars represent SEM. 
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Values of IC50 for both inhibitors were calulcated following the fitting  of the data to a four-
parameter logistic equation. The calculated parameters for both 2-MA and AHA are shown in 
Table 5.5. 
Table 5.5: Comparison of IC50 values for AHA and 2-MA using urease from C. ensiformis as a 
model system.  
  Best Fit Value 95% Confidence Interval 
AHA Log10IC50 3.684 μM 3.673 - 3.695 μM 
IC50 4.835 mM 4.714 - 4.958 mM 
R2 0.995 
2-MA Log10IC50 4.763 μM 4.742 – 4.783 μM 
IC50 57.902 mM 55.201 – 60.643 mM 
R2 0.994 
 
Whilst the IC50 provides an arguably more accurate measurement of relatively potency 
between two drugs under the same assay conditions, the IC50 for 2-MA was approximately 10-
fold greater than that for AHA, thus remaining in agreement with results determined by 
comparison of the inhibitor constant of 2-MA with the literature value for AHA. Nevertheless, 
since determination of IC50 yields no pharmakokinetic information on biocompatibility, 
cytotoxitiy, or indeed whether or not the novel drug is capable of inhibiting bacterial urease in 
vivo, further biological evaluation is required before true assessment of the drug’s therapeutic 
potential can be made.  
5.4.6. Inhibition of P. mirabilis Urease by 2-MA 
Evaluation of the ability of 2-MA to inhibit intracellular P. mirabilis urease adds a crucial, 
clinically relevant dimension to the inhibitory analysis. Progression from the C. ensiformis 
urease model to cytoplasmic bacterial urease provides a significant challenge to the novel 
inhibitory compound, since its activity depends on first traversing the bacterial cell membrane 
to gain access to the enzyme. As previously discussed, all whole-cell 2-MA inhibition studies 
were undertaken in direct comparison to AHA, providing a point of reference for archetypal 
enzyme-inhibitory treatment of chronic urea-splitting infection.  
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5.4.6.1. In Vitro Antimicrobial Susceptibility 
Prior to the assessment of 2-MA within P. mirabilis B4, it was first necessary to determine an 
appropriate dosage of drug with which to treat live bacterial cultures. In vitro susceptibility 
tests were performed via standard microbroth dilution methods for both 2-MA and AHA 
(Figure 5.20). 
Figure 5.20: Susceptibility of P. mirabilis B4 to 2-MA (A) and AHA (B). 
Determination of the maximum inhibitory concentration for both drugs was 
achieved via standard microbroth dilution methods. Inhibition of bacterial growth 
was measured as a function of OD at 600 nm. Data shown are the mean of 
quadruplicate repeats on the same bacterial isolate. Error bars represent SEM. 
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The objective of ‘maximum inhibitory concentration’ determination for both 2-MA and AHA 
was to discover the concentration of drug at which the bacterial fitness remains unaffected. 
Since the pathogenicicty of P. mirabilis is characterised by instrinsic properties such as 
virulence factors (including urease), the ability to ‘disarm’ the population via reducing or 
eliminating urease activity provides a novel strategy of treatment for CAUTI. Dose selection 
requires a compromise between inhibitory efficacy and directing bacterial evolution, since it is 
well-known that the application of an antimicrobial drug may result not only in direct selection 
of the corresponding resistance, but also in the development of cross-resistance (resistance to 
several structurally-related antimicrobials) and coresistance (resistance to several 
structurally-unrelated antimicrobials) via specific mechanisms.68  
Both 2-MA and AHA induced a decrease in observed cell viability at concentrations greater 
than 10 mM. At high concentrations (>50 mM), AHA appeared to induce a greater decrease in 
viable bacterial cells than 2-MA. For whole-cell urease evaluation, it was imperitive to employ 
a concentration of drug that will not affect the growth of bacterial populations, such that any 
reduction in urinary crystal formation may be attributed solely to urease inhibition. Thus, the 
selected dosage for futher biological evaluation was 10 mM for both 2-MA and AHA.  
5.4.6.2. Whole-Cell Studies 
The ability of 2-MA to inhibit cytoplasmic P. mirabilis urease was investigated, using urinary 
pH elevation as a proxy indicator of enzymatic activity. Permeation of the cell membrane 
provides a significant challenge in the design of small molecule drugs such as enzyme 
inhibitors, with many promising drug candidates failing to reach their cytosolic targets when 
tested in whole-cell screening assays.69 The mechanism of membrane permeation is governed 
by parameters including molecule size and polarity.  Small, uncharged, polar molecules are 
generally able to move across the lipid bilayer down the concentration gradient by means of 
simple diffusion. However, the majority of polar drug molecules may only penetrate the cell 
membrane in the presence of membrane-transport proteins (including channel and carrier 
proteins) via either passive or active transport.70  
Cytosolic uptake is frequently confirmed via measurement of a biological effect generated only 
when the payload is successfully delivered to the cytoplasm. In this system, the macroscopic 
effect of urinary pH elevation was monitored before and after a short incubation period with 
both 2-MA and AHA (Figure 5.21A), in order to assess the ability of the drugs to access their 
intracellular target. Viable cell counts of bacterial cultures were also performed at the 
beginning and conclusion of each incubation period (Figure 5.21B), to ensure that any effect 
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on residual medium pH was not as a consequence of cell death. The effect of inhibitory drugs 
were also evaluated on a uropathogenic strain of E. coli, which acts as a ureae-negative control 
(Figure 5.21C and D) 
Treatment of P. mirabilis B4 cultures with 10 mM 2-MA successfully prevented urinary pH 
elevation via urease activity. Inhibition appeared to be comparable with that of 10 mM AHA; 
both drugs achieved significant enzyme inhibition in comparison to the untreated control (p < 
0.0001). No alteration in urinary pH observed within cultures of E. coli owing to the lack of 
expressed urease, whilst the untreated P. mirabilis culture yielded a significant elevation of 
Figure 5.21: Whole cell evaluation of 2-MA and AHA. Ability to penetrate the bacterial cell 
membrane and inhibit intracellular urease activity was determined by elevation of urinary pH 
(A, C). Viable cell counts were performed to ensure the viability of cultures before (0 minutes) 
and after (90 minutes) treatement with inhibitory drugs (B, D). Evaluation was undertaken 
on both urease-positive (P. mirabilis B4) (A,B) and urease-negative (E. coli NSM59) (C,D) 
uropathogenic clinical isolates. Data shown are the mean of triplicate biological repeats. Error 
bars represent SEM. ****  p < 0.0001, ## p < 0.005. 
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urine pH even after the short incubation period (p = 0.0015). Furthermore, no statistically 
significant change in viable cell count was observed for either strain in the presence of 2-MA 
or AHA, compared to the untreated control. Thus, it was concluded that the observed alteration 
in residual urine pH was as a direct result of intracellular urease inhibition by 2-MA and AHA. 
5.4.7. In Vitro Bladder Models 
Efficacy of 2-MA in a clinically representative system was assessed using the in vitro bladder 
model mimicking late-stage infection (as previously described). In order to mimic oral 
administration of urease inhibitory drugs, 2-MA and AHA were dissolved directly into the urine 
reservoirs at 10 mM concentration.  
The blockage of urinary catheters and subsequent termination of urine flow was defined as the 
experimental end point. Performance of 2-MA was compared directly to that of AHA within 
triplicate experiments, in order to reference the extension of catheter lifetime under the same 
experimental conditions. Periodic measurements of bladder conditions (pH and CFU/mL) 
were performed throughout the experiment, to monitor the urease activity as a function of 
residual urine pH, as well as the viability of colonising bacteria. Both inhibitors achieved 
significant extension of catheter lifetime compared to the untreated control (Figure 5.22). 
Figure 5.22: Extension of catheter lifetime upone treatment (10 mM dosage) with urease 
inhibitory drugs 2-MA and AHA. Average blockage times for the untreated and AHA treated 
models were 15 and 74.3 hours, respectively. No blockage was observed for the 2-MA treated 
models within the experimental time-frame. Models were run for 5 days (120 hours) until 
media reservoirs were exhausted. Data represents the mean of 3 biological repeats. Error 
bars represent SEM. **** p < 0.0001. 
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When urease activity was uninhibited, blockage of control models (initial inoculum 108 
CFU/mL) occurred 15 hours after model start. Treatment with AHA extended average blockage 
time by 400%, to 74.3 hours (p < 0.0001). This result is in agreement with previous 
observations of catheter blockage prevention in vivo, where treatment of 5 catheterised 
patients with AHA decreased catheter encrustation by 81% and significantly reduced the need 
for frequent catheter changes.71 Surprisingly, treatment of P. mirabilis-infected models with 2-
MA further extended catheter lifetime within the in vitro model, such that blockage was not 
observed througout the 5-day duration of the experiment. Reservoirs of artificial urine media 
were exhausted 120 hours after model start, at which point catheters treated with 2-MA were 
still draining freely. 
The outperformance of AHA by 2-MA in the bladder model system was an unexpected outcome, 
since early kinetic data suggested that AHA displayed more inhibitory potency in terms of 
kinetic parameters and early evaluation using the C. ensiformis model system. Periodic 
measurement of residual bladder conditions confimed the efficacy of 2-MA at preventing 
urinary pH elevation and catheter colonisation by P. mirabilis (Figure 5.23). 
Within the untreated control models, the pH of artificial urine media within the bladder 
underwent rapid alkalinisation, owing the urease-mediated urea hydrolysis within the P. 
mirabilis population. Indeed, the pH of residual media was elevated to pH 8 within 5 hours of 
the experiment start (Figure 5.23A).  This was accompanied by an increase in viable cells 
within the bladder, since urease expression was able to facilitate rapid colonisation and biofilm 
formation. Local supersaturation and precipitation of crystalline materials within the catheter 
lumen and eyehole region therefore elicited total occlusion of the catheter within 15 hours of 
the model start. In contrast, pH elevation within treated models  was unable to surpass to 
nucleation point (~pH 7.4) until approximately 45 and 108 hours for AHA and 2-MA, 
respectively. Eventual elevation of urine to pH 8 in AHA-treated models was accompanied by 
catheter blockage via crystalline biofilm formation. In models treated with 2-MA, models were 
unable to reach pH 8 within the experimental term, thus the degree of crystalline biofilm 
formation was insufficient to result in catheter blockage.  
Both the AHA and 2-MA-treated models underwent an approximately 1-log reduction in viable 
cell count within the first 24 hours of the experiment (Figure 5.23B). Since P. mirabilis virulence 
factors (particularly urease) are known to play an extensive role in bacterial pathogenesis and 
biofilm formation,36 it is therefore unsurprising that inhibition of urease activity manifested as 
a decrease in bacterial colonisation. Since urease-negative mutants have previously been 
shown to colonise the urinary tract 100-fold less efficiently than the parent strain (Section 
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5.1.4.3), it is likely that the reduction in adherence resulted in direct elution of a large portion 
of the bacterial population from the bladder in the early stages of infection. 
Within the 2-MA-treated models, bacterial biomass was unable to recover and surpass the 
value of the intial inoculum at the point of pump activation (3.7 x108 CFU/mL at 120 hours vs 
4.7 x108 at 0 hours) . Thus, whilst the measured conditions within the 2-MA-treated bladder 
suggest that blockage was forthcoming, it was not reached within the timecourse of this 
experiment. 
Disparities in the degree of encrustation on catheter luminal surfaces at time of AHA-treated 
model blockage (~74 hours) and unblocked 2-MA-treated model (120 hours) were observed 
visually (Figure 5.24). Total occlusion of the eyehole and drainage lumen were observed in the 
Figure 5.23: Analysis of in vitro bladder model conditions at periodic intervals after model 
start (0 hours) via direct sampling of bladder model urine. A) Residual urine pH. B) Bacterial 
biomass. Data shown are the mean of triplicate biological repeats. Error bars represent SEM. 
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catheter removed from the blocked model. Significantly less crystalline material was observed 
within the catheter removed form the 2-MA-treated model.  
Whilst the degree of encrustation for the 2-MA-treated catheter is significantly lesser than its 
AHA-treated counterpart, there is evidence of encrustation around the eyehole region at 120 
hours post-inoculation. Thus, the visual results are in agreement with the measurement of 
residual pH/ CFU/mL in predicting the extrapolated blockage of this model. Nevertheless, the 
novel inhibitor 2-MA appears to outperform AHA in this model. 
5.4.7.1. 2-MA Biofilm Inhibition 
The ability of 2-MA to inhibit the formation of P. mirabilis biofilms was investigated using a 
simple in vitro crystal violet staining model. Since treatment of the in vitro catheterised bladder 
with 2-MA (10 mM, described previously) resulted in significant elution of planktonic cells 
from the bladder in the early stages of the experiment, it was hypothesised that this drug is 
preventing the early colonisation of a biofilm on the catheter’s luminal surfaces. The ability of 
both enzyme inhibitory drugs to prevent biofilm formation of P. mirabilis is shown in Figure 
5.25. 
Figure 5.24: Distal regions of catheters removed from 2-MA-treated model (left) at 
experimental end point (120 hours), and AHA-treated model (right) at time of blockage (74.3  
hours). Crystalline biofilm encrustation as a result of urease activity is observed in the 
eyehole and luminal surfaces of the AHA-treated catheter. Images are representative of three 
independent biological repeats. 
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At the therapeutic concentration of 10 mM, 2-MA showed significantly greater biofilm 
inhibitory activity than AHA (p < 0.0001), although it did not succeed in complete prevention 
of biofilm formation (p = 0.0214). Since previous investigation into the antimicrobial 
susceptibility of P. mirabilis to both 2-MA and AHA has confirmed that 10 mM concentrations 
are unable to induce bacterial cell death (Section 5.2.2.3.II), it appeared that the reduction in 
biofilm formation (and hence extension of catheter lifetime) is owing to the prevention of 
catheter colonisation and adherence to the catheter surface.  
As the observed biofilm inhibitory activity cannot have occured as a result of bacterial cell 
death, it was thus hypothesised that 2-MA behaved as a quorum sensing antagonist, thus 
interfering with cell-cell signalling processes that mediate biofilm formation within the 
catheterised bladder. Whilst confirmation of this conjecture would require testing of specific 
P. miraiblis reporter systems, similar attenuation of biofilm formation has previously been 
observed on uropathogenic strains of P. aeruginosa using garlic extract as a phophylactic 
agent.72 As discussed in Section 5.3.1, allicin, the biologically active component of garlic, is 
known to display potent urease inhibitory activity. Fresh garlic extract induced significant 
reduction in AHL production when compared to the untreated control, manifesting in lowered 
renal bacterial counts in a mouse kidney model.73 Recent investigation in to the mechanism of 
urease inhibition by allicin has theorised it to be similar in nature to that of small-molecule 
thiol inhibitors,54,74,75 thus supporting the argument for quorum sensing antagonism by 2-MA. 
Figure 5.25 : Quantitative measurement of P. mirabilis B4 static biofilm inhibition by 10 mM 
2-MA and AHA. Quantification was performed via crystal violet biofilm staining. Data shown 
are the mean of triplicate repeats. Error bars represent SEM. **** p < 0.0001. 
 Chapter 5  
199 
 
5.4.8. Cytotoxicity Testing 
5.4.8.1. Mammalian Cells  
In vitro cytotoxicity testing provides a crucial means of ranking compounds for consideration 
in drug discovery. For cell culture systems, a compound is considered cytotoxic if it interferes 
with cellular attachment, significantly alters morphology, adversely affects growth rate, or 
causes cell death.76 The XTT assay, as described in Section 5.2.2.3.VII, measures cell 
proliferation based on the metabolic activity, and is frequently used in 2D culture conditions. 
The ability of metabolically active cells to reduce the tetrazolium salt XTT to a water-soluble 
formazan product provides a quantifiable measure of dose-related compound toxicity.  
2-MA was evaluated for cytotoxicity using a HaCaT immortalised keratinocyte cell line. 
Metabolic activity of HaCaT cells in the presence of various concentrations was compared 
directly to those in the presence of the same concentrations of AHA. The results were expressed 
as a percentage viability compared to the untreated controls (Figure 5.26). 
Throughout the range of tested concentrations, 2-MA displayed significantly less cytotoxicity 
than AHA (p < 0.0001). Of particular interest is the comparison at 10 mM concentration, since 
this was the therapeutic dose employed in earlier studies (p = 0.0002). These results are in 
Figure 5.26: Viability of HaCaT keratinocytes in the presence of varying concentrations 
(0.625-80 mM) of 2-MA and AHA. Corrected values of absorbance at 450 nm are displayed as 
a percentage of untreated control, to yield % viability. **** p < 0.0001. *** p < 0.001. 
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agreement with previously observed toxicity studies for AHA, which is known to display 
significant cytotoxicity both in vitro and in vivo. Indeed, AHA has been shown to behave 
synergistically with bacterial virulence factors to increase toxicity to human cell lines. 
Evaluation of HeLa cell viability in the presence of Helicobacter pylori (H. pylori) (a known 
producer of potent bacterial urease), showed that a H. pylori cytotoxin caused damage to the 
cell membranes of HeLa cells, thus allowing AHA to accumulate intracellularly and exert 
cytotoxic effects.77 
Enchanced cytotoxicity of AHA in comparison to 2-MA at the defined therapeutic concentration 
(10 mM) were observed qualitatively, to compare the degree of cell damage induced by drug 
exposure. For the AHA treated cells, the presence of cellular debris after overnight exposure 
indicated possible necrosis and apoptosis (Figure 5.27). 
 
Figure 5.27: Visual examination of HaCaT cells both in the absence of inhibitor (A,B) and  
following (C,D) treatment with 2-MA (A,C) and AHA (B,D) (10 mM). Images are 
representative of three individual replicates. Exposure of cells to AHA appears to induce 
nectrotic and apoptotic effects. 
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The limitations of this assay lie in the reliability of in vitro assays as a model of human 
medication. Whilst drug screening in assays such as the XTT viability assay allow rapid and 
facile identification of promising compounds, favourable results do not mean an automatic 
green-light for in vivo application. Furthermore, the evaluation of 2-MA on a single 
immortalised cell line from an arguably unrelated organ may limit the scientific value of this 
study. Nevertheless, it has recently been noted within the literature that the significance of in 
vitro toxicity data may be improved by performing comparative studies between established 
and novel drugs, in preference to static IC50 values.78  
5.4.9. Haemolytic Evaluation 
In clinical practice, AHA is the only urease-inhibitory drug to have gained FDA-approval for the 
treatment of infections caused by urease-producing bacteria.79 However, significant limitations 
associated with severe side effects (such as teratogenicity, psycho-neurological and musculo-
integumentary symptoms) have resulted in limited use and clinical acceptance of this drug.80 
In particular, AHA is known to cause severe haemolytic anaemia within human patients, as well 
as direct damange to human erythrocytes as a result of toxic haemolysis. 81  
Within the healthy circulatory system, the rate of red blood cell (RBC) destruction is in a steady 
state with RBC production. Liberated iron (Fe3+) from destroyed RBCs is bound by transferrin 
with high affinity, rendering it unable to react with reactive oxygen species and other 
substances in vivo. As a result of toxic haemolysis (as observed for AHA in concentrations 
greater that 1.25 mM) the rate of iron release into circulation may surpass the rate of uptake 
by transferrin, thus producing non-transferrin-bound iron (NTBI). A fraction of NTBI, known 
as labile plasma iron (LBI), may become loosely bound to proteinaceous structures and is 
known to be highly redox active, thus causing iron-mediated oxidative stress. Both NTBI and 
LBI can also enter a variety of cell types, including liver, pancreas, endrocrine glands and 
cardiomyocytes, where cell antioxidant defences may be overcome, compromising cell 
integrity and causing organ damage or failure.82 
The degree of haemolytic anaemia induced by a drug may be evaluated ex vivo by assessing the 
dose-dependent liberation of haemoglobin from human RBCs via measurement of absorbance 
at 410 nm. Obtained values were corrected against media controls, and degree of haemolysis 
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expressed as a percetange of the positive lysis control (Triton-X 100). Percentage haemolysis 
for both 2-MA and AHA at varying concentration is shown in Figure 5.28. 
Toxic haemolytic activity was significantly lower for 2-MA than AHA (p < 0.0001). Of particular 
relevance was the result at the defined therapeutic concentration (10 mM), where % 
haemolysis was observed to be 10.7 % ± 0.8 for 2-MA; an 89% reduction from the value 
observed for AHA at the equivalent concentration. Even at the highest evaluated concentration 
of 40 mM, observed haemolysis was still 78% lower following treatment with 2-MA in 
comparison to AHA (p < 0.0001 for all comparative concentrations).  
Visual results reinforced quantitiative measurement of toxic haemolysis for the drug 
performance comparison. Liberated haemoglobin as a result of drug toxicity appears as a deep 
red colouration in the liquid media, thus displaying clear evidence of the lower toxicological 
value of  2-MA in this haematological assay (Figure 5.29). 
 
 
Figure 5.28: Percentage ex vivo haemolytic acitivity of dose-dependent 2-MA and AHA 
treatment on human erythrocytes. Drug concentration was varied from 0.625-40 mM. 
Corrected values of absorbance at 410 nm are displayed as a percentage of untreated control, 
to yield % viability. **** p < 0.0001.  




Visual similarity of AHA-treated erythrocytes with the positive surfactant control suggest 
complete destruction of RBCs. Moderate toxicity is observed at a concentration of 2.5 mM, and 
low toxicity between 0.625-1.25 mM. Conversely, 2-MA does not appear to induce RBC damage 
at any of the tested concentrations, owing to its visual resemblance to the negative buffer 
control. Thus, from a purely toxicological point of view, 2-MA appears to be the most promising 
drug following comparison with AHA, as it lacks both RBC, keratinocyte, and bacterial toxicity 
at a therapeutic concentration.  
Figure 5.29: Haemolysis observation within a 96-well microplate. Visual assessment of toxic 
haemolysis was undertaken following incubation of various concentrations of 2-MA and AHA 
(0.625-40 mM) with human red blood cells. Liberated haemoglobin released in the 
supernatant of samples can be observed via the red colouration of the PBS media. Negative 
(PBS) and positive (Triton X-100) controls are shown for comparison. 




Drugs that function as enzyme inhibitors constitute a significant portion of the orally 
bioavailable therapeutic agents that are in clinical use today. Consequently, many of the 
current drug discovery and developmental efforts are focused on the identification and 
optimisation of drug candidates that act via the inhibition of specific enzymatic targets. The 
attraction of enzymes as novel drug targets stems from the high levels of disease association 
(target validation) and target traceability that typically characterise this class of proteins. 
Furthermore, the ‘disarming’ of such potent bacterial virulence factors without placing a 
significant selective pressure on the cells themselves comprises a therapeutic approach of 
great clinical significance in light of the dawn of the post-antibiotic era.  
Whilst 2-MA has shown significant promise in vitro, further work is required to determine the  
mechanism of bacterial membrane permeation. Caco-2 cells and renal MDCK cells (allowing 
passive permeation and transporter-mediated permeation, respectively) would provide 
valuable insight into the specific mechanism of action of this drug, and its pathway of entry into 
the cytoplasmic space of the cell. In terms of cytotoxicity cell culture studies, the use of primary 
cell lines from human tissue as opposed to previously described immortalised cell lines may 
provide a more representative in vitro model of the human bladder. Furthermore, in silico 
mechanistic and molecular docking studies would provide information as to the mechanism of 
urease inhibition and binding affinity to P. miraiblis urease. Such evaluation may direct the 
synthesis of further 2-MA-based inhibitor anlogues, resulting in a library of structurally related 
molecules from which to chose a lead compound. Following candidate selection, the 
pharmacokinetic profile may be evaluated via techniques such as 3D cell culture absorption 
models and prediction of in vivo drug metabolism.  
Further development of 2-MA as a possible treatment for CAUTI will involve investigation into 
novel delivery methods of this drug into the catheterised bladder. The catheter coating concept 
described in Chapters 2 and 4 would provide the ideal platform from which to release this 
chemical cargo into the infected area at high local concentration. This would subsequently ease 
the pressure on achieving high systemic doses of drug via oral administration, as well as 
limiting any potential side effects as yet uncovered in the cytotoxic profile.  
Overall, the clear outperformance of the ‘gold standard’ treatment for chronic urea-splitting 
infection in the comparison of the two described drugs highlights the urgent need for novel 
urease inhibitors that have a less extensive portfolio of side effects than AHA.  Pharmaceutical 
development of such compounds evidently requires a compromise to be struck between 
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potency and toxicity. The results of the initial toxicity profiling of 2-MA in comparison to AHA, 
along with the performance within the in vitro catheterised bladder model clearly demonstrate 
that novel drugs with lower initial promise in terms of in vitro efficacy are perhaps overlooked 
in light of low dosage formulation, but at the cost of systemic patient health and inherent 
cytotoxicity.
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5.7. Appendix 1 




The title compound was obtained as a white solid (Scheme 5.3) (3.1 g, 98%). 1H NMR (400 MHz, 
DMSO-d6) δ: 7.35 (brs, 1H), 3.47 (s, 2H), 1.51 (brs, 1H) (Figure 5.30A). 13C NMR (DMSO-d6) δ: 
170.86, 34.68 (Figure 5.30B). 
 
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
Synthesis of 2-MA was confirmed by electrospray ionisation (ESI) mass spectrometry (MS) in 
positive ion mode m/z: [M+Na]+. Theoretical m/z 113.9984, measured m/z 113.9983 (sigma: 
0.0326).
Scheme 5.3: Synthesis of 2-Mercaptoacetamide  
A 
B 
Figure 5.30: NMR spectra of 2-mercaptoacetamide. A) 1H NMR. B) 13C NMR. 
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The overall objectives of this research endeavoured to develop diagnostic and therapeutic 
strategies for the detection and prevention of urinary catheter encrustation, following 
infection by the Gram-negative bacterium P. mirabilis. Such research is unavoidably 
multidisciplinary, combining chemical, biological and engineering advances in tandem for the 
treatment and prevention of CAUTI. All described strategies aimed to evaluate the chemical 
and biological capabilities of the modified Foley catheter system, whilst remaining sympathetic 
to the limations of the clinical requirements and patient usage.  
The diagnostic approaches described in Chapters 2 and 3 attempted to fulfill the proveb 
“prevention is better than cure”, in order to counteract the onset of serious symptomatic 
episodes as a result of catheter blockage. The purely diagnostic standpoint of these 
methodologies represents an amelioration of the intention all of medical technology; to avoid 
therapeutic usage where possible, in order to preserve efficacy. The initial iteration of the 
catheter coating design descried in Chapter 2 provided sound proof-of-concept that species 
may not only be released directly into the catheterised urinary tract in response to elevated 
urinary pH, but also that an unambiguous urinary colour change may be achieved within 
residual urine in advance of catheter blockage. Nevertheless, the shortcomings of this design 
mainly included complications regarding regulatory pathways and toxicity issues concerning 
the release of chemical species directly into the human bladder. Thus, the second design 
iteration of this diagnostic system (described in Chapter 3) aimed to externalise this system, 
removing the pH-responsive release system from in vivo to ex vivo in its entirety. The resultant 
‘lozenge’ sensor was placed directly into the catheter drainage bag, releasing the fluorescent 
dye 5(6)-carboxyfluorescein in response to an infection-induced increase in urinary pH. Early 
diagnosis of catheter blockage was achieved within a physiologically relevant model of the 
catheterised urinary tract approximately 14.5 hours in advance of urine occlusion, which was 
deemed sufficient to allow clinical intervention prior to vesicoureteral reflux. Limitations of 
this model include the lack of testing with pooled human urine in favour of artificial urine; an 
issue which will endeavour to be solved during an upcoming pilot clinical study of the sensors, 
in collaboration with the Royal United Hospital, Bath. 
The therapeutic approaches described in Chapters 4 and 5 intended to increase the lifespan of 
the catheter whilst avoiding the use of conventional antibiotics, owing to the rapid initiation 
and accumulation of antimicrobial resistance within the acute and ambulatory care settings. 
Bacteriophage offer an elegant natural system for the control of bacterial populations that has 
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been arguably underexploited in recent years. Impregnation of the catheter coating (originally 
described in Chapter 2) with P. mirabilis bacteriophage proved promising in doubling the time 
to catheter blockage (13 hours to 26 hours), thus significantly extending catheter longevity and 
potentially improving patient quality of life. However, whilst phage therapy has proved 
encouraging in the treatment of CAUTI, the regulatory challenges surrounding this treatment 
pathway are extensive and likely prohibitive. Indeed, it is likely that phage therapy will not 
undergo a revival in western medicine until even the most potent chemical antibiotics are 
rendered ineffective. The current clinical framework for conventional antibiotic approval may 
prove unsuitable for phage, which as self-replicating biological entities, are unlikely to conform 
to classical drug analysis. Nevertheless, investigation of phage products (such as phage 
endolysins) may conform more successfully to current clinical assessment, thus allowing the 
benefits of phage therapy to appear within the clinic in the near future. 
Finally, the development of a small-molecule enzyme inhibitor characterised an appealing 
approach for the incapacitation of uropathogenic bacteria. Chapter 5 described the rational 
design, synthesis and in vitro evaluation of such a drug, proving the potential of this approach 
in the field of CAUTI. Physiological models mimicking late-stage P. mirabilis infection were 
unable to reach blockage in the presence of 2-mercaptoacetamide (10 mM concentration), up 
to 120 hours post-inoculation. Drugs capable of inhibiting bacterial urease have significant 
potential in the treatment of P. mirabilis infection, since the subsequent prevention of urinary 
alkalinisation may prevent the cascade of events resulting in blockage, without placing a 
selective pressure on the bacterial cells themselves. Therefore, resistance to such drugs is 
expected to be hindered or impossible, as mutation for resistance to such a drug would likely 
result in a fatal decrease in bacterial fitness. Small molecule drugs such as that described in this 
chapter may also be substituted into the pH-responsive coating as a therapeutic cargo in order 
to delay catheter encrustation and blockage. Indeed, such therapeutic approaches may be used 
in tandem with the diagnostic lozenge sensor to provide a theranostic system capable of 
delaying catheter blockage and warning of its own impending failure. Limitations of this drug 
design may be overcome by the screening of a larger library of inhibitor analogues, as well as 
further investigation into the genetic response of P. mirabilis. Additional evaluation of drug 
cytotoxicity will also be necessary prior to clinical progression, including pharmacokinetic and 
pharmacodynamic evaluation in vitro. 
Overall, the research agenda initially presented in Chapter 1 has been largely fulfilled. The 
design, synthesis, engineering and in vitro evaluation of novel diagnostic and preventative 
strategies within physiologically representative models of the catheterised urinary tract has 
allowed the development of four novel control measures for CAUTI. All of the described 
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approaches are compatible with the current design of the Foley catheter, such that the original 
design and operation of the closed drainage system will remain unchanged for care-givers and 
patients within the clinical setting. Future evaluation of all novel strategies described will 
involve the employment of more physiologically accurate evaluation, including the use of 
multispecies biofilms and pooled human urine. Nevertheless, the research presented has 
successfully achieved both the advanced diagnosis and prevention of catheter blockage, whilst 
taking into consideration the practical implications of such systems within the clinical setting,   
Future Perspective: The Role of Biotechnology in the 
Treatment and Prevention of CAUTI 
Many clinical challenges persist in the management and treatment of catheter-associated 
urinary tract infection. Whilst applied research within the engineering sciences has proven its 
potential to directly address challenges associated with the original, flawed design of the Foley 
catheter, there has undoubtedly been a paucity of of technological innovation compared with 
major advances in other areas of healthcare for conditions of similar prevalence. Despite 
potentially significant health and economic gains, the social stigma often associated with 
incontinence has proven detrimental to engagement by researchers in academic settings. 
Nevertheless, the need for the acceleration of innovation for CAUTI is being increasingly 
recongnised, not only for the development of new technology, but also for the improvement of 
existing systems. 
For continence technologies, the research challenge emcompasses a wide-range of 
underpinning interdisciplinary knowledge. Addressing these challenges has the potential to 
bring forth incremental improvements in previously overlooked areas. In turn, this will deliver 
short- and long-term improvements to diagnosis, treatment, prevention and management of 
CAUTI to profoundly improve the lives of sufferers. 
The marriage of broad and often tenuously-linked scientific disciplines must occur in order to 
overcome the complexity of catheter encrustation and blockage. Stimulation of 
interdisciplinary research among the scientific, engineering, industrial and clinical 
communities is necessary to develop novel technologies that are sympathetic to aspects of the 
original design. Indeed, the passive release of antimicrobial cargos should not be considered a 
panacea or universally effective strategy. Rather, they should be considered part of a concerted 
effort to control known risk factors of CAUTI, and form the basis of more microbiologically 
advanced methods, such as stimuli-resposnive release. Such ‘smart’ catheter coatings provide 
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the basis of a multifaceted solution, in which the properties and local concentration of released 
species are taken into consideration, whilst limiting systemic exposure. However, several key 
challenges remain in this field in order for stimuli-responsive approaches to become a truly 
valued tool in the CAUTI-preventative arsenal (including long-term stability, maintenance of 
catheter functionality, and ease of commercial manufacture).  
Future challenges for the described technology involve progression towards clinical platforms 
in the face of a changing regulatory landscape. Translational success relies heavily upon 
objective evaluation and validation methods, such that clinical efficacy may be accurately 
extrapolated. Overcoming these challenges will require collaborative effort from those 
working in across a broad range of disciplines, though success will offer ample opportunity for 
innovation, as well as a long-overdue solution to a complex and ubiquitous clinical problem. 
 
 
